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For the effective control of African animal trypanosomiasis, there is a great need for the 
development of point of care diagnostic tests that are affordable to the end-users. 
Parasite cysteine proteases are involved in the pathogenesis of African 
trypanosomiasis, hence serve as a good target for the development of new 
chemotherapeutics and diagnostics. The aim of this study was to evaluate the potential 
of the cysteine protease TviCATL from Trypanosoma vivax as a chemotherapeutic 
agent and diagnostic target for African animal trypanosomiasis. The catalytic domain, 
TviCATL, was recombinantly expressed in Pichia pastoris, auto-catalytically activated 
by low pH removal of the proregion, purified by three phase partitioning and molecular 
exclusion chromatography to homogeneity and its identity confirmed by western blot 
analysis. Endoglycosidase H treatment of TviCATL indicated that the protease is Asn-
glycosylated. The pH optimum was determined to range between 6.5 and 7.5 
suggesting that the enzyme would be active in the host bloodstream following parasite 
lysis.  The protease was able to degrade the host proteins: bovine serum albumin, 
bovine haemoglobin, gelatin, type I collagen and the endogenous protease inhibitor, 
bovine α2-macroglobulin in vitro at neutral pH. The peptidolytic specificity of the 
protease was determined by considering the active site binding pocket S2- substrate -
P2 interaction. TviCATL showed high endopeptidase specificity for Z-Phe-Arg-AMC and 
H-D-Ala-Leu-Lys-AMC, suggesting that the hydrophobic residues Phe or Leu are 
favoured at the P2 position in the presence of basic Arg or Lys at P1 position. The 
TviCATL peptidolytic activity was inhibited by E-64, iodoacetate, leupeptin, antipain, Z-
Gly-Leu-Phe-CMK (albeit at a reduced level) and iodoacetamide inhibitors and this 
indicated that TviCATL is a cysteine protease.  
Satisfactory anti-TviCATL antibody levels were produced in chickens as evidenced by 
good signals in the ELISA and western blot analysis. The specificity and affinity of 
chicken anti-TviCATL IgY antibodies for TviCATL antigen was improved by affinity 
purification of these antibodies using a TviCATL-affinity column. The serodiagnostic 
potential of the TviCATL antigen and cross-reactivity with anti-T. congolense 
antibodies (in sera) was evaluated in an antibody inhibition ELISA format. These 
antibodies were able to discriminate between non-infected cattle sera and T. 
congolense-infected sera, thus suggesting some degree of cross-reactivity between 
TviCATL antigen and anti-T. congolense antibodies. As an alternative to animal-based 
antibody production, the Nkuku® phage library was used to select for single-chain 
variable fragment (scFvs) antibodies by panning against TviCATL antigen. As 
evaluated by polyclonal and monospecific phage enzyme-linked immunosorbent assay 
v 
  
(ELISA), after the third round of panning, the TviCATL-scFvs binders were enriched. 
However, only one clone gave a promising ELISA signal suggesting that further 
optimisation of panning conditions are required in order to obtain improved 
monospecific ELISA signals for application of TviCATL-scFvs in diagnostic assays. 
TviCATL therefore shows promise as both a chemotherapeutic and diagnostic target to 
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African human and animal trypanosomiasis (HAT and AAT) are diseases commonly 
called sleeping sickness in humans and nagana in domestic livestock. African 
trypanosomiasis is caused by unicellular flagellated protozoan parasites of the genus 
Trypanosoma (El-Sayed et al, 2000; Baral, 2010). Whereas T. brucei gambiense 
(Western Africa) and T. b. rhodesiense (Central Africa and East Africa) are the 
exclusive causative agents of human trypanosomiasis, T. vivax and T. congolense are 
the most prevalent pathogenic species for cattle in Africa while T. brucei brucei is non-
pathogenic in humans since normal human serum contains trypanosomal lytic factor 
(Pays & Vanhollebeke, 2009). T. vivax, T. congolense and T. b. brucei are mainly 
transmitted cyclically to their mammalian host by the haematophagous tsetse fly of the 
genus Glossina and to a lesser extent, T. vivax is mechanically transmitted by the 
biting flies most of which are African tabinids (horse flies) and stable flies. 
Trypanosomes can infect all domesticated animals, but cattle are highly susceptible 
due to the feeding preferences of tsetse flies. The alternative transmission of T. vivax 
by vectors other than tsetse flies allows this parasite to spread beyond the tsetse fly 
belt (Moloo et al, 2000; Fikru et al, 2012). The spread of trypanosomiasis is 
proportional to the distribution of tsetse vectors which infest more than 10 million km2 
of the continent (Figure 1.1). Consequently, it is estimated that trypanosome infections 
in livestock negatively influence agricultural-based economies with an estimated total 
loss of approximately $4.5 billion yearly in Africa (Swallow, 2000; Roditi & Lehane, 
2008; Antoine-Moussiaux et al, 2009). 
1.2 Classification of trypanosomes 
The eukaryotic genus Trypanosoma is classified as order Kinetoplastida and family 
Trypanosomatidae (Figure 1.2) (Hoare, 1972). They are called Kinetoplastida due to 
the presence of a single mitochondrial DNA within a structure called the kinetoplast 
(Bastin et al, 2000). Based on mechanisms of transmission, trypanosomes are divided 
into two groups: salivaria and stercoraria. The developmental stages of salivarian 






Figure 1.1: The proportional distribution of tsetse flies and cattle in Africa (Naessens et 
al, 2002). 
 
towards the salivary glands where the infectious form of the parasite develops. In 
contrast, stercorarian parasites develop in the intestinal tract or hind gut, and 
transmission to the mammalian host is via faeces. Whereas T. brucei, T. congolense, 
T. evansi and T. equiperdum are examples of salivarian trypanosomes found in the 
tsetse fly belt of Africa, T. cruzi, the causative agent of American Chagas disease, is 
an example of the stercoraria subgroup (Vickerman, 1985). Other than the mode of 
transmission being the main distinguishing feature of these two subgroups of 
trypanosomes, salivarian trypanosomes also differ from the stercoraria in that the 
former evade the host immune response by antigenic variation due to expression of 




parasites (Borst et al, 1996; Haag et al, 1998). 
 
Figure 1.2: Classification of trypanosomes. Adapted from Baral (2010) 
 
1.3 General morphology of trypanosomes 
Trypanosomes are single-celled parasites that are elongated (ranging from 8-50 µm) 
and tapered at both ends (Figure 1.3). Since trypanosomes are eukaryotic, they exhibit 
typical features such as a nucleus and organelles including an endoplasmic reticulum, 
Golgi apparatus, a mitochondrion as well as endocytosis and exocytosis systems 
(Clayton et al, 1995; Bastin et al, 2000). Trypanosomes have a flagellar pocket, 
flagellum and mitochondrial DNA. The flagellar pocket (FP) is a protected invagination 
of the plasma membrane. Due to the concentration of receptors responsible for 
endocytosis and immune evasion, the FP is considered to be a site for protein 
trafficking, protein and lipid sorting, and a recycling compartment (Moreira-Leite et al, 
2001; Gull, 2003; Overath & Engstler, 2004; Gadelha et al, 2009). The flagellum which 
is responsible for parasite motility extends from the flagellar pocket. The basal body at 
which the flagellum attaches is called the flagellum attachment zone, and it also 
interacts with a single elongated mitochondrial DNA which is situated within the 
structure called the kinetoplast (Bastin et al, 2000; Kohl et al, 2003; Broadhead et al, 




(1 kb). Maxicircles are responsible for encoding mitochondrial proteins whilst 
minicircles are responsible for extensive post-transcriptional modification or RNA 
editing of these regions using guide RNAs (Stuart et al, 1997; El-Sayed et al, 2000) 
  
Figure 1.3: Diagrammatic representation of the African trypanosome, T. brucei showing 
associated organelles. Accessed on 20 May 2013 from http://imgarcade.com/1/trypanosoma-
brucei-diagram/ 
 
1.4 Trypanosome lifecycle 
The trypanosome lifecycle is divided into two stages: that in the mammalian host and 
that in the insect vector (Figure 1.4) (Roditi & Lehane, 2008). In the tsetse vector, 
trypanosomes undergo preparatory developmental stages (differentiation, proliferation 
and migration). Different trypanosome species develop in different organs: T. vivax 
develops exclusively in the mouthparts of the vector, while initial infections of both T. 
brucei and T. congolense start in the fly midgut and the parasites subsequently migrate 
into the salivary glands and proboscis of the tsetse fly (Roditi & Lehane, 2008). The 
transmission cycle begins during a blood meal from a mammalian host, where an 
infected tsetse fly injects its infective metacyclic trypanosomes into mammalian skin 
tissue. The metacyclic form is transformed into blood-stage trypomastigotes. The 
parasite then becomes distributed throughout the body. Insect stages begin when 
bloodstream trypomastigotes are transformed into procyclic forms which occupy the 




slender forms that can replicate by asexual division and non-replicating stumpy forms 
(Schnaufer et al, 2002; Matthews et al, 2004; Roditi & Lehane, 2008; Baral, 2010). 
When the parasite relocates from the midgut to the salivary gland, epimastigotes 
multiply by binary fission in the bloodstream, lymph and spinal fluid. The cycle is 
repeated when susceptible tsetse feed on a new mammalian host (Baral, 2010). 
 
 
Figure 1.4: Life cycle of Trypanosoma brucei in tsetse fly vector and mammalian host. 
Adapted from Geiger et al (2011). 
 
1.5 Antigenic variation 
Salivarian trypanosomes exploit a well-documented process called antigenic variation 
as a defence mechanism against host immune responses (Donelson, 1995; Borst et al, 
1996; Barry & McCulloch, 2001). Since the trypanosome lifecycle and replication 
occurs in extracellular compartments such as host tissue fluids and bloodstream, the 
parasite is susceptible to attack by the host immune system. To circumvent this attack, 
trypanosomes make use of antigenic variation using VSGs which determine the variant 
antigen type (VAT). The parasite is coated with more than 107 copies of VSGs which 
are encoded by specific telomeric loci which contain numerous genes for surface 




antibodies against expressed parasite VSGs, the VSGs’ antigenic specificity is 
continuously changed and the parasites proliferate, resulting in a second wave of 
parasitemia (Donelson et al, 1998). Two switching mechanisms are used: the first  
involves expression of a single gene at the VSG expression site, followed by the 
subsequent silencing of that gene and activation of the next distinct gene (Morrison et 
al, 2009), while the second mechanism is called recombination involving gene 
conversion where an active silent gene is copied and transferred to an expression site 
to compensate for the deleted gene (Barry & McCulloch, 2001; San Filippo et al, 2008; 
Morrison et al, 2009). It can be concluded that successive expression of VSGs is 
critical for chronic infections by trypanosomes and onward transmission by the tsetse 
vector to a new host (Barry & McCulloch, 2001; Pays, 2006). Due to periodic switching  
of the parasite VSGs, the development of vaccines capable of preventing trypanosome 
infection in immunised animals, is unlikely (Lalmanach et al, 2002). There are no 
reports that antigenic variation contribute to the chronic phase of infection by 
stercorarian trypanosomes, but the tenacity of these parasites inside the host cells is 
due to the presence of carbohydrate-rich components (glycolipids and glycoproteins) 
which allow evasion of the host innate immune system (Takle & Snary, 1993; Almeida 
et al, 1994) 
1.6 Transmission and pathogenesis of trypanosomes 
Livestock such as cattle, pigs and other domestic animals are susceptible to AAT or 
nagana (Aksoy, 2003).  T. brucei, T. congolense and T. vivax are the most widespread 
pathogenic trypanosomes causing nagana, and are transmitted to the host by Glossina 
spp. tsetse fly vectors. T. brucei and T. evansi commonly attack tissues (humoral), 
while T. congolense and T. vivax  are restricted to the circulation and mainly invade 
blood (haematic) (Igbokwe, 1994; Mbaya & Ibrahim, 2011). T. evansi, mostly 
distributed in Asia, Africa and South America causes surra, which is transmitted 
mechanically by tabanic flies (Otto et al, 2010). Equines, camels and Asian elephants 
are more susceptible to surra (Hoare, 1972). T. equiperdum, which is closely related to 
T. evansi, causes a venereally transmitted disease called dourine and mainly targets 
equines (Hoare, 1972; Brun, 1993). 
Each trypanosome species shows unique pathogenic properties, but anaemia is the 
pre-eminent symptom of AAT, the severity of which depends on parasite strain and 
breed of targeted host (Prowse, 2005; Chamond et al, 2010). Due to concurrent 
infection and susceptibility of the host to more than one trypanosomal parasite species, 




general, injection of the infective metacyclic trypanosomes into the skin of the 
mammalian host results in inflammation and swelling called a chancre at the site of a 
fly bite. Since metacyclic trypanosomes divide and multiply rapidly in the chancre, this 
results in invasive blood forms that invade lymphatics, lymph nodes and the blood 
stream. The common clinical symptoms of livestock trypanosomiasis are 
immunosuppression, intermittent fever, anaemia, weight loss and decreased milk 
yields in cattle. During the chronic condition, which is characterised by fluctuating 
levels of parasitemia as a result of the competition between the expression of the 
parasites of the same antigenic type (homotype) and parasites of the variable antigenic 
type (heterotype), animal reproduction is affected resulting in abortions, premature 
births and testicular damage in males. Also, working capacity is reduced, cattle 
become lethargic and emaciated, and subsequently die due to heart failure   (Barrett et 
al, 2003; Baral, 2010).  
1.7 Control of animal trypanosomiasis 
1.7.1 Vector control 
The simplest approach to trypanosome control is to reduce transmission by eliminating 
tsetse vectors (Allsopp, 2001). There are many vector control strategies that have 
been undertaken including those currently considered as deplorable such as 
deforestation and slaughtering of wild animals (Dransfield et al, 1991). Ground and 
aerial spraying with residual insecticides such as dichlorophenyltrichloroethane (DDT) 
has been useful for the reduction of flies but this procedure was limited by quick 
reinfestation of sprayed areas. Persistent usage of residual insecticides had been 
associated with a number of pitfalls such as tsetse flies developing resistance to 
insecticides, imbalances in the ecosystem due to cross-eradication of non-targeted 
insects, bioaccumulation and potential toxicity of insecticides to individuals spraying 
them as a result of overexposure. Due to the high cost and environmental unfeasibility, 
residual insecticide spraying became restricted (Dransfield et al, 1991; Holmes, 1997). 
Residual insecticides were replaced with non-residual insecticides which are aerially 
sprayed at very low concentration and volume and non-targeted insects are less 
susceptible. This sequential aerosol technique (SAT) is approved by scientific 
environmental monitoring groups as an environmentally friendly tsetse control method 
when used under appropriate supervision (Grant, 2001; Alsopp & Hursey, 2004; 




Alternative control measures include odour baited traps treated with insecticides to 
which female flies are attracted over long distances and no-return cages where they 
die through starvation or heating. Baited traps aim to suppress tsetse population 
density rather than eradication of the insects (Vale, 1993; Bouyer et al, 2010). Baited 
traps led to the development of “live-bait’’ technology in which livestock are treated with 
“pour-on’’ insecticides. The effectiveness of the pour-ons is evidenced by the ability of 
deltamethrin pour-on used on Ugandan cattle to significantly reduce tsetse 
populations, thus resulting in a gradual decrease in the prevalence of cattle 
trypanosomiasis (Okiria et al, 2002). The main disadvantages of this technique are the 
need for repeat treatments, cost of insecticides and potential development of 
resistance to the insecticides (Bauer et al, 1995; Leak, 1999).   
The development of sterile insect technique was successful in eradicating populations 
of Glossina austeni from the Island of Zanzibar (Bailey, 1998; Vreysen et al, 2000). 
Sterile insect technique is a genetic suppression approach which releases irradiated 
sterile male insects over a wide area. If sterile males are dispersed in high numbers 
that outcompete wild males for wild females over a long time, the reproductive capacity 
of tsetse fly is severely minimised, thus levels of trypanosome transmission are 
controlled (Aksoy, 2003; Dyck et al, 2005; Vreysen et al, 2013). Control measures that 
utilise molecular genetics are under consideration in an attempt to improve the sterile 
insect technique. These include the use of genetically produced symbionts like 
Wolbachia with cytoplasmic incompatibility, which induces sterility in their host by 
introducing reproductive abnormality. If this male strain of tsetse is released, they 
spread Wolbachia infection when mating with wild females, thus resulting in embryonic 
lethality (Dobson, 2003; Abd-Alla et al, 2013).   
1.7.2 Trypanotolerant cattle 
The use of trypanotolerant cattle is another approach for the control of 
trypanosomiasis. Trypanotolerance is the genetic trait  that makes it possible for cattle 
to survive and remain productive after trypanosome infection (Naessens, 2006). 
N’Dama cattle, mainly found in West and Central Africa, is the cattle breed that exhibits 
this trait (Authié, 1994). However, this breed only represents approximately 6% of the 
cattle population in Africa and there is a perception that this breed is not economically 
beneficial to farmers since they are not productive due to their relatively small size. 
Genotypic analysis of quantitative trait loci of Boran-N’Dama derived F2 calves 




Boran grandparent. This led to the perception that trypanotolerance in Boran cattle can 
be improved by crossbreeding Boran and N’Dama cattle (Hanotte et al, 2003). This led 
to the development of haemopoetic  Boran/ N’Dama chimeric twins (Naessens et al, 
2003). When chimeras were experimentally challenged with T. congolense, the 
chimeras successfully controlled the levels of parasitaemia to a similar extent as 
N’Dama singletons, but anaemia was severe. Overall, this suggested that 
trypanotolerance is derived from two independent systems. These include the ability to 
control anaemia which relies on haematopoietic cells, and an ability to control 
parasitaemia which is independent of haemopoetic cells (Naessens et al, 2003; 
Naessens, 2006). 
1.7.3 Chemotherapeutic approaches  
1.7.3.1 Trypanocidal drugs 
The treatment of the livestock infected by AAT largely depends on chemotherapy and 
chemoprophylaxis using three trypanocidal drugs; isometamidium, homidium and 
diminazine. These drugs generally cease the multiplication of the parasite and this 
strengthens the capacity of the host immune system to defeat any spread of the 
ongoing trypanosomal infection (Osman et al, 1992). These drugs have been in use for 
over 50 years, and it is thus not surprising that drug resistance (multiple) has been 
reported in 18 African countries including South Africa (Delespaux et al, 2008b; 
Chitanga et al, 2011). This multiple drug resistance interferes with the idea of using a 
sanative pair system in which two trypanocidal drugs are used. The first drug is 
administered until the resistant strain appears, and then the second drug is used to 
eliminate the accumulated drug resistant strain from both the host and the vector 
(Mamoudou et al, 2008).   
A sudden reduction of the effectiveness of isometamidium in Boran cattle infected with 
T. congolense has been reported, and is thought to be associated with drug resistance 
(Sutherland et al, 1991; Codja et al, 1993). The prevalence of drug resistance was also 
reported when T. congolense infected cattle were treated with diminazine, and even 
after withdrawal of treatment with diminazine, there was no possibility of regaining 
diminazine-sensitive trypanosomal strains (Delespaux et al, 2008a; Chitanga et al, 
2011). Resistance to trypanocidal drugs has been associated with mutated nucleoside 
transporters which prevent free diffusion of trypanocidals through the parasite 
membrane (Barrett & Fairlamb, 1999; Baral, 2010). Due to a limited number of drugs 




new drugs in the near future, the prevalence of drug resistance and exhibition of 
severe toxic side effects, there is a high demand for alternative treatments (Barrett et 
al, 2005; Delespaux & de Koning, 2007). The recently synthesised commercial forms 
of isometamidium (i.e. Veridium® and Samarin®) were tested in vivo and in vitro to 
access their trypanocidal capabilities. These drugs were trypanocidal against T. 
congolense and T. b. brucei when tested in vitro. When mice were treated with 1 mg/kg 
of these compounds (one drug per mouse), the evaluation of trypanocidal activity two 
months post treatment showed that these compounds induced prophylactic activity 
against T. congolense. However, more work is needed in order to optimise drug 
dosage and identify  any drug resistant trypanosomal strains (Sahin et al, 2014). 
1.7.3.2 Targeting cysteine proteases for the development of new drugs 
It has been long established that the trypanosomal cysteine proteases, which are 
involved in parasite invasion, proliferation and differentiation during mammalian 
lifecycle stages, are involved in pathogenesis by degrading host proteins, and that 
targeting these proteases with suitable inhibitors results in trypanosomal lifecycle 
arrest in vitro (Troeberg et al, 1999; Bryant et al, 2009). Consequently, research effort 
is focussed on determining the substrate specificity of each trypanosomal protease for 
developing specific inhibitors without toxicity towards the treated host. Numerous 
irreversible inhibitors specific for cysteine proteases have been developed. These 
include diazomethane, halomethyl ketones, epoxysuccinyl derivatives and vinyl sulfone 
derivatives. These inhibitors irreversibly bind into the cysteine protease active site and 
form a covalent adduct that inactivates the enzyme (Otto & Schirmeister, 1997). There 
are several studies that can be considered as the ‘proof of concept’ that specific 
inhibitors result in parasite arrest. Vinyl sulfone inhibitors have been shown to treat 
mice experimentally infected with T. cruzi (Engel et al, 1998b; Roush et al, 2001). 
These inhibitors killed T. cruzi in culture by inducing morphological abnormalities of the 
Golgi apparatus due to the accumulation of the unprocessed enzyme as a zymogen. 
Low micro-molar concentrations of the TbbCATL inhibitors, chloro-, diazo-, and 
fluoromethyl ketones, were able to alter the growth of T. b brucei parasites in culture 
significantly (Troeberg et al, 1999). The vinyl sulfone peptide inhibitor K1117 has also 
been proven to be a potent inhibitor that rescued animals infected with T. cruzi that 
causes Chagas disease (Doyle et al, 2007). Recently, aryl thiosemicarbazone-derived 
compounds have been synthesised and characterised as anti-T. cruzi inhibitors that 




activity, therefore further studies are necessary for understanding the mechanism 
involved (Magalhaes Moreira et al, 2014).    
 
1.8 Vaccination 
There are no vaccines for one of the major animal parasites, African trypanosomes. 
The first vaccination approach was based on producing anti-VSG antibodies. This 
vaccination has been fruitless due to antigenic variation that these trypanosomal 
parasites have deceitfully  evolved  (Cornelissen et al, 1985; Magez et al, 2010). It was 
apparent that vaccination based on anti-VSG antibodies would never eliminate 
trypanosomiasis due to on-going VSG gene switching and the fact that VSGs 
predominantly elicit a short lived IgM immune response rather than the preferred long 
lived IgG isotype (Mitchell & Pearson, 1983). Besides VSGs, the survival of the 
trypanosomes also depends on the ability to express other invariant surface molecules. 
The flagellar pocket contains a variety of proteins which have been identified as 
potential targets for vaccine development (Mkunza et al, 1995). Cattle vaccinated with 
invariant antigen from the flagellar pocket prior to exposure to infection with T. 
congolense and T. vivax, were able to partially protect themselves against infection 
compared to unvaccinated cattle (Mkunza et al, 1995). Surprisingly, when mice were 
subjected to subsequent infections with a high parasite dose, the level of protection 
was indirectly proportional to parasite dosage. Due to the lack of reproducibility of FP 
vaccination, this vaccination approach shows little promise (Radwanska et al, 2000). 
The cytoplasm of the trypanosomes contains the microtubules which are made up of 
tubulins. When the trypanosome tubulin was investigated as a vaccine candidate, mice 
pre-immunised with tubulin from T. brucei were challenged with T. brucei, T. 
congolense or T. rhodesience. The mice were protected against these parasites, 
suggesting that tubulin is a promising vaccine candidate (Lubega et al, 2002). In order 
for the host immune system to produce antibodies that are different from antibodies 
produced as a result of infection, mice were pre-immunised with invariant surface 
glycoproteins (ISGs). Upon infection with T. b. brucei, partial protection was observed. 
This protection failure was as a result of the vaccinated host’s immune system being 
unable to produce an effective B cell memory response even after successive 
challenge with incoming T. b. brucei ISGs (Radwanska et al, 2008; Magez et al, 2010; 
Lança et al, 2011). Due to these pitfalls of anti-trypanosome vaccinations, it was 




This led to the development of the anti-disease vaccine approach which targets 
infection-associated pathology rather than the parasite itself (Authié, 1994). This 
approach targeted parasite cysteine proteases which are thought to play a role in 
pathogenesis. Experimental studies based on the cathepsin-like cysteine protease 
from T. congolense (TcoCATL) showed that TcoCATL plays a pathogenic role in 
trypanosomiasis by degrading host proteins (Authié, 1994). Infections of 
trypanotolerant cattle with T. congolense resulted in an increased IgG response 
against TcoCATL antigen. It was hypothesised that the levels of anti-TcoCATL 
antibodies are directly proportional to levels of resistance in trypanotolerant cattle, and 
that they lessen the extent of disease in these cattle (Authié et al, 1992; Authié, 1994; 
Authié et al, 2001). 
1.9 Diagnosis of African animal trypanosomiasis 
Successful control of trypanosomiasis depends on reliable detection of the parasites, 
which is difficult in closely related subspecies (Agbo et al, 2003). For a diagnostic  test 
to be considered adequate, it must accomplish a number of criteria such as high 
diagnostic specificity, sensitivity, simplicity, reproducibility, affordability, availability of 
expertise and ease of interpretation (Terrestrial, 2013). T. vivax, T. congolense and T. 
brucei infection exhibit similar clinical symptoms, hence diagnosis of trypanosomiasis 
cannot be reliably based only on clinical signs, but require laboratory tests (Holmes, 
2013). Diagnosis in the laboratory is achieved through parasitological, molecular and 
serological techniques. 
1.9.1 Parasitological diagnosis 
Parasitological diagnosis aims at detection and identification of trypanosome parasites 
in the infected host blood circulation. The simplest methods include direct visualisation 
of blood by wet film which identifies motile trypanosomes or by thin or thick smear 
methods which rely on the detection of trypanosomes based on their morphology using 
light microscopy. These methods are effective for detecting many animal samples, but 
are very insensitive (Nantulya, 1990). The insensitivity of these methods was improved 
by the introduction of haematocrit centrifugation, which concentrates the parasites in 
the buffy coat layer and this allows simple detection of trypanosomes by microscopy 
(Ancelle et al, 1997; Matovu et al, 2012). This method is very sensitive as it effectively 
detects blood parasites as low as 2.5 x 102 T. congolense, 5 x 102 T. vivax, and 5 x103 




depends on the availability of electricity, thus cannot be used in the field. Due to lower 
sensitivity and failure to detect parasites at earlier stages of infection, the development 
of alternative diagnostic methods such as molecular and serological diagnosis was 
necessary.    
1.9.2 Molecular diagnostic tests 
Due to the failure to differentiate two trypanosome species that develop in the same 
locations in the tsetse e.g. T. congolense and T. simiae, molecular diagnostic tests 
have been developed (Gibson, 2009). Effective identification of low parasite copy 
numbers was enhanced by the introduction of the polymerase chain reaction (PCR) 
that uses specific oligonucleotide primers to amplify DNA of trypanosome species 
(Moser et al, 1989). The PCR assay showed high sensitivity as it sufficiently identified 
the mixed genotypes of livestock trypanosomes (including T. congolense Savannah, 
Forest,  Kilifi and T. godfrey) (Masiga et al, 1992). Since the use of several specific 
primers for PCR is time consuming, a single molecular marker to distinguish different 
trypanosomal species was attempted. This advanced single PCR utilised multi-copy 
internal transcribed spacer 1 (ITS1) within ribosomal RNA genes of trypanosomes. 
This method was able to distinguish a pool of trypanosomal species in a single PCR 
run because each trypanosomal species constitutes unique sized ITS1 compared to 
other species, thus the PCR product of each species migrates at a specific size 
(Desquesnes et al, 2001). This method is preferable for diagnosis of trypanosomiasis 
since this assay is associated with reduced cost and time for conducting a series of 
species-specific assays. However, this method showed low sensitivity for detection of 
T. vivax (Desquesnes et al, 2001), but in a study conducted by Fikru et al (2012), a 
five-fold higher detection efficiency for T. vivax as compared to the haematocrit 
centrifugation technique was reported. The ITS1 PCR assay in a “touchdown’’ format 
has been identified as a good diagnostic technique for evaluating drug efficacy against 
T. congolense infection in cattle (Tran et al, 2014). 
 
A diagnostic assay called PCR-ELISA, which couples PCR for a specific species to 
ELISA was developed (Masake et al, 2002). In PCR-ELISA, nested PCR using specific 
primers is used for the amplification of DNA, after which the specificity of the PCR 
products is assessed by coating PCR products on ELISA plates. PCR-ELISA has been 
effective for the detection of T. vivax and T. brucei, but not T. congolense in peripheral 
blood of infected cattle. This technique is limited by its high cost that prevents its use in 




2009). As an alternative to PCR-based diagnostic techniques, the Loop-mediated 
isothermal amplification (LAMP) has been introduced (Kuboki et al, 2003). Although it 
is an expensive procedure, the LAMP technique amplifies parasite DNA with relatively 
high specificity, reproducibility and efficiency as compared to PCR-based techniques. 
Even though this method has been used for the diagnosis of T. congolense infections 
in livestock (Kuboki et al, 2003), this method has mainly been used for the diagnosis of 
human-infecting T. brucei parasites (Mitashi et al, 2012; Mitashi et al, 2013). 
1.9.3 Serological diagnosis 
Serological diagnosis is an immunodiagnostic technique involving antigen or antibody 
detection (Luckins, 1977; Nantulya & Lindqvist, 1989). Due to the fact that 
trypanosome lysis depends on both complement and antibody, it was found that 
complement fixation is a candidate for trypanosomiasis diagnosis. Indirect 
immunofluorescence antibody test (IFAT) is another serodiagnostic test. In the IFAT 
technique, the antigen from parasitised red blood cells is fixed with fixatives such as 
acetone followed by storage at ultra-low temperatures (Katende et al, 1987). The fixed 
slide is then incubated with antibodies (in serum from cattle with trypanosomal 
infections). For detection, a secondary antibody such as a rabbit anti-bovine IgG-
fluorescein isothiocyanate conjugate is added followed by fluorescence microscopy 
(Terrestrial, 2013). The IFAT technique is not widely used due to the requirement for 
several blood smears, ultra-low temperatures for storage and transportation of 
reagents, the possibility of cross-contamination of samples thus non-specific detection, 
as well as the need for a sophisticated fluorescence microscope (Nantulya, 1990). In 
an attempt to improve the IFAT technique, the use of light-emitting diodes (LED) 
illuminated microscopy has been suggested for replacing fluorescence microscopy. 
The LED microscope does not require UV light, uses minimal voltage, thus small 
batteries can be used for field purposes, but this idea is hindered by the need for 
extensive optimisation of labelling trypanosomal antigens with appropriate fluorophores 
(Anthony et al, 2006; Robertson et al, 2009; Mitashi et al, 2012). Card agglutination 
test for trypanosomiasis (CAAT) is a further important diagnostic test and enables 
detection of surface coat antigens, VSGs. The effectiveness of the CAAT relies on 
optimal fixing and stabilisation of the parasite using formaldehyde in order to detect the 
whole trypanosomal parasite during the agglutination test (Nantulya, 1990).  
The development of the enzyme linked immunosorbent assay (ELISA) was a major 




ELISA is that the source of antigen for the test is either whole parasites or crude 
parasite lysate. ELISA was found to be a suitable diagnostic test for the detection of 
bovine anti-trypanosome antibodies using both blood stream form and procyclic 
trypanosomes (Greiner et al, 1997). When antigen-capture ELISAs were used for 
diagnosis of T. vivax and T. congolense in experimentally infected cattle, the overall 
specificity was high whilst the sensitivity was very low (Eisler et al, 1998). Due to the 
lower sensitivity of direct ELISA, immunoassay methods for the detection of 
bovine anti-T. congolense and anti-T. vivax antibodies were developed. This assay 
with improved sensitivity and specificity, uses specific ELISA kits, I-TAB ELISA-
(TcAGd) and -(TvAGd) where plates were precoated and air-dried with denatured 
antigen (AGd) from T. congolense (TcAGd) and T. vivax (TvAGd), respectively. 
Antigens used in this indirect ELISA were detergent-denatured lysates from 
bloodstream T. congolense and epimastigote T. vivax parasites cultured in vitro 
(Rebeski et al, 2000; Lejon et al, 2003).  
To avoid the use of parasite antigens that are cultured in vitro and in vivo, standardised 
recombinant expression systems have been used for the production of antigens with 
diagnostic potential. Targeting non-variant trypanosomal molecules, which are highly 
antigenic (e.g. heat shock protein 70, HSP70) is associated with improved 
serodiagnosis (Bannai et al, 2003; Bossard et al, 2010). The immunodominant  antigen 
HSP70 that is closely related to mammalian immunoglobulin binding protein (BiP), is 
expressed in all lifecycle stages of T. congolense, T. vivax and T. brucei (Boulangé & 
Authié, 1994). In an inhibition ELISA format, recombinant HPS70/BiP was used as an 
antigen for antibody detection in sera from cattle with natural or experimental T. 
congolense infections. The secondary infections were detected at higher sensitivity 
than primary infections (Boulangé & Authié, 1994; Boulangé et al, 2002; Bossard et al, 
2010). A proteomic approach has been used for identifying trypanosomal antigens with 
diagnostic potential (Sullivan et al, 2013). A flagellar-associated protein, TvGM6 from 
T. vivax,  was recombinantly expressed in an E. coli expression system and used in an 
indirect ELISA for the detection of antibodies in sera from cattle with T. vivax infections 
(Pillay et al, 2013b). A protein, Tc38630, from T. congolense has been identified as an 
invariant surface glycoprotein with diagnostic potential. This protein was recombinantly 
expressed in E. coli and used in an indirect ELISA for the detection of T. vivax 
infections. High sensitivity and specificity was reported (Fleming et al, 2014).  
Immunodominant proteases that are involved in the pathogenesis of trypanosomes can 
serve as serodiagnostic antigens and can be produced using recombinant technology. 




bloodstream upon parasite lysis, and these proteases have diagnostic potential 
(Caffrey & Steverding, 2009). A cysteine protease TcoCATL from T. congolense is an 
example of a virulence factor with diagnostic potential (Authié et al, 1992; Authié et al, 
2001; Lalmanach et al, 2002). For effective diagnosis of T. vivax infections, it is 
necessary to evaluate the potential of TviCATL as a diagnostic antigen. 
Immunodiagnostic tests based on trypanosomal antigens either detect the antibodies 
produced in the infected host or the antigen released into the bloodstream following 
parasite lysis. Both antibody (inhibition ELISA) and antigen detection require specific 
antibodies produced in experimental animals. For the production of polyclonal 
antibodies, egg yolk immunoglobulin (IgY) technology represent a preferred method 
that offers advantages with respect to animal care, cost and antibody yield (Polson et 
al, 1980). Due to the phylogenetic distance between chickens and parasites, parasite 
antigens are highly immunogenic in chickens, and antibody production in hens is 
readily stimulated (Bizhanov et al, 2004). Recombinant trypanosomal antigens such as 
ISG65 and ISG75 (Baiyegunhi, 2013), oligopeptidase B, pyroglutamyl peptidase and 
the cysteine protease TcoCATL from T. congolense (Eyssen, 2014), have been 
reported to be very immunogenic in chickens as evidenced by antibodies with high 
signals in ELISA. The chicken anti-trypanosomal antibodies produced in the study 
conducted by Eyssen (2014) were useful for diagnosis of AAT using an antibody 
detection inhibition ELISA format as well as an indirect antibody detection ELISA. 
 
An alternative way of producing antigen detection reagents for use in 
immunodiagnostics is through identification of single chain variable fragments (scFvs) 
of antibodies that recognise the diagnostic antigen of interest. Phage display 
technology is used to this end as will be discussed in Section 1.12.  
1.10 Classification of cysteine proteases  
Proteases, also called peptidases are peptide-hydrolysing enzymes. Proteases are 
classified according to the initial position at which they cleave the peptide substrate. 
The proteases that cleave within the polypeptide chain are called endoproteases, while 
those cleaving the peptide towards the amino or carboxyl ends are called 
exoproteases (Sajid & McKerrow, 2002). Based on which reactive residues are found 
in the active site, these enzymes are further categorised into seven main groups: 
serine, cysteine, aspartic, metallo, threonine, glutamate and asparagine proteases 




Proteases are grouped into specific clans based on their evolutionary relationships. A 
number of characteristics such as sequence similarity and substrate specificity, are 
considered in order to assign proteases to a specific clan (Sajid & McKerrow, 2002). 
Cysteine proteases are divided into ten clans (CA, CD, CE, CF, CH, CL, CM, CN, CO 
and unassigned clan A-, C-, M-, S-, T-, or U- family) (Rawlings et al, 2012). Clan CA is 
the best documented clan for the parasitic cysteine proteases and belong to the papain 
superfamily of the proteases (Barrett & Rawlings, 2001; McKerrow et al, 2006). Clan 
CA is further divided into subfamily C1 [i.e. plant cysteine proteases (papain) and 
mammalian lysosomal cysteine proteases (cathepsin B-like and cathepsin L-like)] and 
subfamily C2 (calpain-like) (Sajid & McKerrow, 2002). Family C1 is the best 
characterised since it contains the plant enzyme papain, which was the first cysteine 
protease to be characterised and its structure solved. An enormous number of recently 
discovered proteases exhibit features similar to papain, and thus are called papain-like 
proteases. Trypanosomal cysteine proteases express C1 proteases related to 
mammalian cathepsin B and L, and are therefore referred to as cathepsin B- and L-like 
proteases (Mottram et al, 2003). However, a new nomenclature for naming cathepsin 
B-like and cathepsin L-like peptidases has been proposed so that they are now 
commonly called CATB and CATL, respectively (Clayton et al, 1998; Caffrey & 
Steverding, 2009). This nomenclature replaces the preceding nomenclature proposed 
by Cazzulo et al (1990) whereby the papain-like cysteine proteases were named by 
adding suffix ‘-pain’ or ‘-ain’. For example, cruzain from T. cruzi, congopain from T. 
congolense and vivapain from T. vivax. For the proposed new nomenclature, the first 
italic capital letter indicates the genus followed by two italic lower case letters indicating 
the species. For example, TcoCATL for the CATL of T. congolense and TviCATL for 
the CATL of T. vivax. 
1.11 Structural features and substrate specificity of CATL-like cysteine 
proteases 
CATL-like proteases have structural features common to most papain-like proteases 
(Lecaille et al, 2001). The structure (Figure 1.5, A) of the CATL-like proteases, 
including TcrCATL and TcoCATL homologues, fold into two domains; an α-helical L-
domain and R-domain rich in antiparallel sheets forming a β-barrel-like motif. The 
catalytic triad consisting of conserved Cys25, His159 and Asn175, is found in the cleft 
between these two domains. The active site Cys25 is located in the central helix of the 
L-domain opposite to the R-domain containing His159, and these residues are partially 




Asn175. Each domain contains two loops connected by disulfide bonds (Lecaille et al, 
2001).  
CATL-like proteases are synthesised as inactive zymogens as characterised by the 
presence of the proregion or propeptide (Figure 1.5, B). These inactive forms are 
activated to mature forms by the cleavage of the N-terminal peptide which is conferred 
through the exposure to the acid endosome. The synthesis of cysteine proteases as 
precursors is associated with many valuable benefits. These include proregions acting 
as intramolecular chaperones to enhance protein folding, regulate protease activity by 
blocking the active site, and as a signal that directs proteases to appropriate 
intracellular compartments (Lalmanach et al, 1998; Wiederanders, 2000). The 
propeptide contains a highly conserved helical ERFNIN motif found in all cathepsin L-
like cysteine proteases. This motif is thought to be crucial for transport and maturation 
of cysteine proteases (Karrer et al, 1993). The trypanosomal propeptide of cysteine 
proteases also contains a conserved inhibitory YHNGA motif, but this motif is absent in 
mammalian lysosomal cathepsins (Lalmanach et al, 1998). Trypanosomal cysteine 
proteases such as TcrCATL and TcoCATL contain a C-terminal extension which is not 
present in mammalian CATL proteases (Aslund et al, 1991; Rosenthal, 1999). The C-
terminal extension of TcrCATL contains two asparagines which are considered as 
potential Asn-glycosylation sites (Cazzulo et al, 1997; Gea et al, 2006). The C-terminal 
extension of TcoCATL is linked to a catalytic domain by a proline-rich hinge region 
while that of TcrCATL is linked by a threonine-rich hinge region (Lalmanach et al, 
2002). The presence of the C-terminal extension in most trypanosomal CATLs confers 
relatively high antigenicity and immunogenicity (Cazzulo & Frasch, 1992). The C-
terminal extension of plant cysteine proteases has been shown to play a fundamental 
role in zymogen activation, catalytic activity, folding and stability of the protease (Dutta 





Figure 1.5: A, The ribbon representation of TcrCATL active site in complex with an 
inhibitor (in ball-and-stick representation). The domains fold into an L-domain rich in α-
helices and an R-domain rich in antiparallel β-sheets. The active site Cys25 residue is found in 
the interior of these domains while His159 is found in the R-domain  (Choe et al, 2005). B, the 
schematic representation of the CATL-like protease proteins from N to C terminus. The catalytic 
domain is flanked between the pre-pro and the C-terminal domain, thus forming a zymogen 
(Rodrigues et al, 2014). 
 
The substrate specifically binds in the active site cleft which contains seven subsites 
(S) each limited to bind only one specific amino acid residue of the peptide substrate 
(P). There are more than four subsites (…S4-S3-S2-S1) towards the N-terminal side of 
the active cleavage site and three subsites towards the C-terminal site (S1ꞌ, S2ꞌ, S3ꞌ). 
The protease active N-terminal (…S4-S3-S2-S1) and primed C-terminal subsites (S1ꞌ, 
S2ꞌ, S3ꞌ) are complementary to peptide substrate amino acid residues (….P3-P2-P1) and 
primed peptide substrate residues (P1ꞌ, P2ꞌ, P3ꞌ), respectively (Schechter & Berger, 
1967; Smooker et al, 2010) (Figure 1.6). Cysteine proteases must first bind their 
specific peptide substrates in the active site in order to efficiently hydrolyse the peptide 
bond (Sajid & McKerrow, 2002). The P2 residue which is complementary to the active 
site S2 pocket, exhibits a very pronounced interaction with both L and R domains (Sajid 
& McKerrow, 2002; Turk et al, 2012). Therefore, the substrate specificity of the majority 
of CATL-like cysteine proteases is defined by the S2 pocket. The trypanosomal 
proteases including TcrCATL and TcoCATL prefer bulky hydrophobic amino acids 
such as phenylalanine in P2 (Eakin et al, 1992; Nery et al, 1997; Pillay et al, 2010). 
TcrCATL exhibits a dual specificity for both basic (Arg) and hydrophobic residues 




responsible for adjusting or rotating the conformation of the S2 pocket in such a way 
that it is flexible to accommodate both hydrophobic and basic residues (Gillmor et al, 
1997; Cazzulo, 2013). Conversely, TcoCATL exhibits restricted specificity for Phe 
residues at P2. This is ascribed to the fact that at the bottom of the S2 pocket of 
TcoCATL, there is Leu205 (instead of Glu205) which restricts the binding capacity of 
the S2 pocket (Chagas et al, 1997; Gillmor et al, 1997). It has also been reported that 
the presence of conformational constrained substrate analogs (e.g. Dansyl-Xaa-Arg-
Ala-Pro-Trp, where Xaa= nonproteogenic Phe analogs in P2 position) results in an 
incorrect binding into the S2 subsite of TcoCATL and this suggested that the 
hydrophobic Phe group is crucial for efficient binding and hydrolysis of the substrate 
(Lecaille et al, 2001). 
1.12 Mechanism of peptide hydrolysis by cysteine proteases 
The active sites of cysteine proteases contain Cys25 and His159 residues which are 
crucial for hydrolysis of the peptide substrate. The active site also contains Asn175 
which is responsible for positioning the imazidole ring of histidine so that it is properly 
orientated for optimal peptide hydrolysis. The active site cysteine residue initiates the 
peptide hydrolysis by nucleophically attacking the carbonyl carbon of a peptide bond 
(Figure 1.7). At weak to acid pH, the imazidole group of histidine deprotonates the SH 
group of cysteine, thus producing a nucleophilic intermediate referred to as a 
thiolate/imidazoium ion pair. This ion pair intermediate then attacks the carbonyl 
carbon of the susceptible peptide bond in order to form a tetrahedral intermediate 
which is stabilised by an oxyanion hole (Otto & Schirmeister, 1997; Lecaille et al, 
2001). Following the acylation of the enzyme to release RꞌNH2, an acyl-enzyme is 
produced. Then, during the deacylation step, the acyl-enzyme reacts with a water 
molecule to release a second product, thus resulting in a cleaved substrate (as a free 





Figure 1.6: The Schechter and Berger schematic representation of the interaction of the 
peptide substrate with the active site of cysteine protease. Peptide (P) substrate with its N- 
and C-terminus indicated, interacts with protease sub-sites (S). The peptide substrates are 
complementary to the sub-sites of the proteases, and this allows correct subsite fitting. The 
residue in the P2 position is strictly bulky hydrophobic in the case of TcoCATL.  Sulfhydryl (SH) 
of the active site cysteine attacks the peptide bond during hydrolysis. Accessed on 05-June-
2014 from http://www.nature.com/horizon/proteases/background/ figs/prespective_f1.html.   
 
Figure 1.7: Schematic representation of the mechanism of peptide hydrolysis by cysteine 






1.13 Phage display technology 
Phage display technology is a molecular technique whereby specific libraries 
(peptides, proteins and antibody fragments) are expressed on the surface of the 
filamentous phage particle. The specific binding properties allow specific in vitro 
screening of a target (e.g. antibody fragment that recognises a trypanosomal antigen) 
from a pool of variants (antibody fragments with different affinities or specificities) using 
a method called bio-panning (Smith, 1985; Winter et al, 1994; Kehoe & Kay, 2005). 
1.13.1 The biology of the filamentous phage 
Filamentous phages are viruses that infect prokaryotic Gram-negative bacteria such as 
E. coli TG1. The fi, M13 and fd phages, collectively called Ff (filamentous) phages 
share 98% genome identity and are most commonly used for phage display 
technology. The main feature of the Ff phages is that they are circular with a fixed 
diameter of 6 nm. The length varies slightly and depends on the genome size. The 
phage is encapsulated by five coat proteins namely: pIII, pVIII, pVI, pIX and pVII 
(Figure 1.8), and within these coat proteins, the circular single stranded (ss) DNA is 
enclosed. The ssDNA is crucial since after replication, it is converted to double 
stranded DNA which serves as a template for the synthesis of viral coat proteins and 
the single stranded DNA progeny (Smith, 1985; Sidhu, 2000; Pande et al, 2010). 
These coat proteins are categorised into the major coat protein (pVIII) which extends 
along the entire length of the phage, and the minor proteins (pIII, pVI, pIX and pVII) 
which are located at the edges of the phage. Of the five coat proteins, only the minor 
coat protein pIII (406-residues) and pVIII (50 residues) are commonly used for antibody 
display libraries (Kehoe & Kay, 2005). However, pVIII is not preferable because it only 
allows the insertion of short peptides (6-8 residues) and attempts to insert larger 
peptides results in compromised phage assembly (Greenwood et al, 1991; Iannolo et 
al, 1995) .  
 
The pIII coat protein is a more feasible and tolerant coat protein that can allow insertion 
of proteins longer than 100 residues without compromising phage assembly, and 
therefore is commonly used for antibody display (Kretzschmar & Geiser, 1995). When 
a foreign gene coding for the specific peptide was inserted into a virus pIII gene, the 
immunogenicity of the resultant peptide-pIII fusion was enhanced. The Ff phages 
initiate their infection by adhering via N-terminal residues of the pIII to the tip of the 




it uses a non-lytic mode which ensures that more virions are generated that 
outcompete the growth of the bacteria, thus resulting in turbid plaques when plated 
(McCafferty et al, 1990; McLaughlin et al, 1996). 
 
 
Figure 1.8: The schematic presentation of assembly of the M13 phage coat proteins. The 
M13 phage single stranded DNA is encapsulated by ̴ 2 700 copies of pVIII major coat protein 
and  ̴ 5 copies of each of pIII, pVI, pVII and pIX minor coat proteins (Willats, 2002).  
 
1.13.2 Vectors for phage display technology 
Phage and phagemid vectors are commonly used for displaying foreign proteins on the 
surface of the bacteriophage. Phagemid vectors are preferable for antibody phage 
display libraries because they exhibit high transformation efficiency, genetic stability 
and results in monovalent binders (high affinity) (Clausen et al, 1992). Phagemids are 
not complete filamentous phages because they lack other structural and non-structural 
genes (Lowman et al, 1991; Armstrong et al, 1996). To generate phagemids which 
display more of the phage characteristics, and thereby create conditions conducive for 
bacterial infectivity, a helper phage is introduced (Sahin et al, 2014). The M13KO7 
helper or ‘phage rescue’ provides all the coat proteins required for phage assembly. 
The helper phage is a mutated form of Ff, where a dysfunctional packaging signal and 
origin of replication is produced. The mutation in its origin of replication ensures limited 
packaging of the complete genome, i.e. only incorporates a favourable pIII gene 
(Barbas et al, 1991). The dysfunctionality of the packaging signal of the helper phage 
does not compromise the infectivity of the helper phage towards the bacterial cells. 
However, once the phagemid is introduced in the system, a phagemid will be 
assembled in preference to the helper phage because the phagemid carries an optimal 
packaging signal. The phagemid carries a kanamycin resistance gene which allows 
growth of helper-infected cells. The phagemid system is considered both 




derived either from wild type helper phage or recombinant phagemid (Marks & 
Bradbury, 2004). 
The phagemid vectors are derived from Ff particles and exhibit typical vector 
characteristics as shown in Figure 1.9 (Qi et al, 2012). This includes the coat protein, 
molecular tags, restriction enzyme recognition sites, origin of replication and a signal 
peptide. Phagemids are categorised based on the type of coat proteins they exploit for 
phage display libraries. Therefore, phagemids are mainly divided into type III and type 
VIII phagemids since these coat proteins are extensively used in phage display. These 
vectors differ in the length of foreign proteins they can accommodate, resultant copy 
number and mechanism of infection (Barbas et al, 1991). 
As mentioned before, type III phagemids accommodate larger proteins than type VIII 
phagemids. Type III only results in fewer than 5 copies of proteins, whilst type VIII 
yields more than 1000 copies of foreign proteins and this limits the length of foreign 
proteins that can be displayed via type VIII phagemids. In addition, these high copy 
numbers in VIII enhances an avidity effect rather than the desired binding affinity 
(Smith, 1993; Iannolo et al, 1995). Therefore to display antibodies with high affinity, 
type III phagemid are preferable notwithstanding its low copy numbers (Kretzschmar & 
Geiser, 1995), while VIII are selected when desiring to display antibodies with multiple 
affinities (avidity). To ensure the solubility and homogenous purification of the phage 
displayed foreign proteins, the molecular tags or amber codon tags are included 
through site-directed mutagenesis in the phagemid between the coat and foreign 
protein sequences (Qi et al, 2012). Restriction enzyme recognition sites incorporated 
after the foreign protein inserts are there to initiate the digestion of the coat protein 
from the phagemid in order to ascertain the synthesis of soluble proteins in the 
periplasm or cytoplasm (Geiger et al, 2011). The origin of replication remains inactive 







Figure 1.9: Phagemid vector used for displaying foreign proteins on the filamentous 
bacteriophage (Qi et al, 2012).  
 
1.13.3 The concept of antibody scFv fragments in phage display technology 
Antibodies comprise two 50 kDa heavy and two 25 kDa light peptide chains (Figure 
1.10). Each heavy chain is linked to a light chain via an inter-chain disulfide bond. This 
linkage forms a fragment antigen binding (Fab). Heavy chains are encoded by variable 
(VH), diversity (D), joining (J) and constant (CH) gene regions, while the light chain is 
encoded by VL, JL, and CL regions. The interaction between heavy chain V-D-J regions 
and light chain V-J regions forms an antigen-binding site (paratope) which is specific 
for a single epitope. The variable regions in both heavy and light chains (VH and VL) 
consist of three hyper variable or complementary determining regions (CDRs) which 
differ greatly in primary structure. The CDRs form an antigen-binding site where they 
interact with the antigen. 
Following papain digestion, antibody molecules are cleaved into two antigen-binding 
fragments called Fab and Fv (Porter, 1959). Fab (fragment antigen binding) consists of 
a VH-CH segment disulfide-bonded to its counterpart VL-CL segment. The smaller Fv 
(fragment variable) consists of VL and VH regions only. The recombinantly expressed 
form of Fv is called single-chain variable fragment (scFv). The scFv consist of two 
variable regions that are joined together by a peptide linker (Gly4Ser)3. This linkage 
results in the formation of the antigen-binding site. 
For the phage display library construction using phagemid vectors, scFv fragments in-
frame with gene III are routinely used compared to Fab fragments (Barbas et al, 1991). 




assembled in the phage particle compared to Fab libraries which encode for a larger 
sized DNA. Fabs are prone to degradation and yield fewer soluble fragments. 
However, the main disadvantage of the scFvs is that the short length (Gly4Ser)3 peptide 
linker promotes the interaction of VH of one scFv with VL of another, thus resulting in 
higher molecular weight products such as dimers (Holliger et al, 1993). 
 
 
Figure 1.10: Structural representation of Y-shaped IgG antibody molecule with 
associated fragments commonly used in antibody phage display. The fragment variable 
[Fv is made up of variable heavy (light blue) and variable light (light pink) chains], fragment 
crystallisable (Fc is in dark blue), fragment antigen binding [Fab is made up constant light 
(orange) and variable light (light pink) chains] and single-chain variable fragment (scFv is made 
up of variable heavy chain disulphide bonded to the variable light chain. Accessed on 30-
November 2014 from http://www.abdesignlabs.com/technical-resources/scfv-cloning/  
 
1.13.4 Types of phage antibody display libraries 
There are two different types of libraries that have been constructed for antibody 
production. These include immunised and non-immune libraries. The immunised 
phage library constitutes monospecific antibodies produced by immunising the animal 
with a particular target antigen, and therefore, are called immune “reptoires” or antigen 
biased. These immune libraries have been constructed from a number of species such 
as mouse (Chester et al, 1994), humans (Barbas III, 1993) and rabbit (Lang et al, 
1996). Antibodies generated through immune phage library are mainly used to treat 
infectious diseases (Hoogenboom et al, 1998; Sun et al, 2009). There are two main 
advantages of immune libraries: they result in antibodies that are antigen-specific 




selection and the donor’s immune system enhances affinity maturation thus resulting in 
a large number of high affinity antibodies (Clackson et al, 1991). The main drawbacks 
of this library are: it is not possible to manipulate the immune response in order to 
attain antibodies with desired characteristics, due to immune tolerance; it is impossible 
to produce antibodies against self-antigens and donors are susceptible to toxicity of 
foreign antigens. Other drawbacks of immune libraries is that it is laborious and time 
consuming because in order to produce antibodies with high antigen specificity, a new 
phage-antibody library must be constructed (i.e. repeat animal immunisation) for each 
and every unique antigen (Azzazy & Highsmith Jr, 2002). 
Non-immune libraries are subdivided into naïve, semi-synthetic and synthetic libraries. 
These libraries are collectively called “single-pot” libraries because they are 
constructed in such a way that their antibody binding fragments are accessible to 
almost any antigen (Hust & Dübel, 2004). The naïve and synthetic antibody libraries 
are differentiated based on the type of immunoglobulin genes they are constructed 
from. The naïve phage libraries are constructed from rearranged heavy and light chain 
V genes isolated from IgM mRNA of B cells isolated either from bone marrow, tonsils 
or blood lymphocytes of non-immunised donors (Marks et al, 1991; Hust & Dübel, 
2004). The naïve phage libraries are advantageous in that they allow selection of 
almost any antigen of interest (Holt et al, 2000). A variety of antibodies against self-
antigens (e.g. tumour necrosis factor) or foreign and toxic antigens (e.g. hapten, bovine 
serum albumin and doxorubicin) have been quickly (~2 weeks) screened from naïve 
libraries (Nissim et al, 1994; Vaughan et al, 1996). The main drawback of these 
libraries is that in order to obtain antibodies with high affinities, larger libraries (1x 1010) 
must be constructed (Vaughan et al, 1996). 
Synthetic library construction relies on the predetermination of the information 
regarding antigen-antibody interaction, affinity maturation and arrangement of variable 
regions (Goletz et al, 2002; Barderas et al, 2008; Volpe & Kepler, 2008). The 
complementarity determining regions (CDRs) which determine the specificity of 
antibodies are used to design synthetic libraries (Knappik et al, 2000). The VH-CDR3 is 
more variable in amino acid composition, length and is situated in proximity to the 
antigen binding site as compared to the other two CDRs with limited amino acid 
variability and located further from the antigen binding site. Therefore, for synthetic 
library construction, VH-CDR3 is randomised by site-directed mutagenesis which allows 
substitution of certain amino acids at specific positions along the CDR3 frame. This 
randomisation allows the manipulation of the sequence to generate the tertiary 




major advantage of the synthetic library over a naïve library is that it is diverse and 
adjustable to obtain amino acid properties which favour the production of high affinity 
antibodies. 
Nkuku® phage antibodies are antibodies derived from a large semi-synthetic chicken 
scFv library (Nkuku® library) (Van Wyngaardt et al, 2004). The ease of accessibility of 
chickens makes them a preferred source of recombinant antibodies compared to 
donors such as rabbits, camels and mice. In order to clone a gene from other sources 
like human, substantial effort is needed. For instance, in order to amplify V genes from 
human donors, a number of PCR primers are required. In chickens, immunoglobulin 
diversity is generated easily by VJ rearrangements in the light chain and VDJ 
rearrangements in the heavy chain. Once rearrangement is completed, variability is 
introduced by the incorporation of the pseudo V gene (Davies et al, 1995). The 
diversity in chicken antibodies attained by pseudo gene conversion means that all 
chickens contain conserved amino acid sequences at both 3' and 5' termini of light and 
heavy chains. Therefore, the diverse phage antibody library is constructed using a 
single set of primers for both the heavy and light chains (Andris-Widhopf et al, 2000). 
1.13.5 Selection of binders by bio-panning and screening  
In order to select for phage clones that specifically recognise the desired antigen, a 
technique called bio-panning is used. During bio-panning, the phage library is in vitro 
exposed to the immobilised antigen. Just like in ELISA, the non-binding clones are 
removed from positive binding clones by subsequent washes in appropriate buffers 
such as HCl or glycine and triethylamine buffers. Bound phages are then amplified in 
E. coli cells. Bio-panning rounds are repeated 2-4 times using precipitated phages from 
the preceding bio-panning round (e.g. phages obtained from round 1 are used for 
panning against the immobilised antigen during round two of panning) in order to 
enhance binding affinity (during the next panning round) to the target and therefore 
enrich for specific positive phage clones (Azzazy & Highsmith Jr, 2002; Willats, 2002) 
There are various in vitro methods that can be used to select for specific binders using 
bio-panning. The common selection method is panning based on binding affinities, i.e. 
the antigen of interest is immobilised on plastic tubes such as immunotubes, ELISA 
plates or columns (Marks et al, 1991). Selection on immunotubes is associated with 
limitations such as the need for a pure protein and high avidity limits the selection of 
specific positive clones (Griffiths & Duncan, 1998). The problems associated with 




uses biotinylated antigens which are selected in solution as a result of high affinity of 
biotin for streptavidin-coated beads (Hawkins et al, 1992). Panning using biotinylated 
antigens is advantageous due to its efficacy to select native proteins without disrupting 
the protein conformation and ability to optimise the concentration of the antigen to use 
in order to select for high affinity binders without a need to perform many panning 
rounds (Azzazy & Highsmith Jr, 2002). Panning is also performed by selection on  
adherent cells in which antigen specific antibodies are selected using cell surface 
markers containing antigen of interest grown as monolayers or in suspension 
(Hoogenboom et al, 1999). Also, an in vivo selection method is used for panning 
whereby the phage clones are injected in animals in order to allow for the host immune 
system to raise antibodies against the dominant phage clones. 
Once biopanning is completed using one of the methods mentioned above, polyclonal 
phage ELISA is used to screen for any positive binders. The polyclonal ELISA is then 
converted to mono-specific phage ELISA by allowing phages from the promising 
panning round to infect E. coli cells. This mixture is then plated on the agar plate 
followed by picking up single colonies in order to screen for enriched mono-specific 
antibodies against the antigen of interest (Kretzschmar & von Rüden, 2002). 
 
1.14 Aims and objectives of the present study 
The primary aim of the present study is to investigate the potential of a cysteine 
protease, TviCATL from T. vivax, to serve as a target for the development of 
chemotherapeutic drugs and a point of care species-specific serodiagnostic tool which 
are affordable to end-users. TviCATL shares high sequence identity with TcoCATL, the 
homologue from T. congolense that has been shown to participate in pathogenesis of 
T. congolense upon release in the host bloodstream by dying parasites. Presumably, 
TviCATL is likewise involved in the pathogenesis of T. vivax.  
Therefore the first objective is to determine the enzymatic characteristics of TviCATL. 
To attain this, it will be necessary to get sufficient quantities of the enzymatically active 
protein by recombinantly expressing the catalytic domain of TviCATL in the P. pastoris 
yeast expression system and purifying the protease to homogeneity. The pure 
protease will be used to determine the enzymatic characteristics such as pH optimum, 




both competitive reversible and irreversible inhibitors. These results are presented in 
Chapter 2 of this dissertation. 
The second objective is to raise antibodies for conducting a serological antibody-
detection test using an inhibition ELISA format. To this end antibodies will be raised in 
chickens through immunisation with recombinant TviCATL. Immunoglobulin Y (IgY) will 
be isolated from the chicken egg yolks. Antibody production and titres will be tested 
using enzyme-linked immunosorbent assays (ELISAs), dot and western blots. The 
antibodies will be affinity purified using a TviCATL-Aminolink® resin. The species-
specificity of the antibodies will be determined using an inhibition ELISA to detect IgG 
in serum from cattle experimentally infected with T. congolense. As an alternative to 
animal-based antibody production, antibody phage display will be attempted. A large 
semi-synthetic chicken scFv library called Nkuku® phage library will be used to select 
positive clones for TviCATL through biopanning. The polyclonal phage ELISA will be 
used to monitor the presence of phage pools after each successive round of panning. 
Lastly, the mono-specific phage ELISA will be used to further screen for enriched 
specific TviCATL-scFv antibodies. The results obtained are presented in Chapter 3. 
Finally, a discussion of all the findings of this study is presented in Chapter 4, the 













RECOMBINANT EXPRESSION, PURIFICATION AND ENZYMATIC 
CHARACTERISATION OF THE TRYPANOSOMAL CYSTEINE PROTEASE, 
TviCATL, FROM TRYPANOSOMA VIVAX. 
 
2.1 Introduction  
There is an accumulating evidence for the involvement of TcoCATL in the 
pathogenesis of T. congolense (Authié, 1994; Authié et al, 2001; Lalmanach et al, 
2002), but very little has been published about the cysteine protease TviCATL from T. 
vivax. TcoCATL and TviCATL show 61.81% sequence identity (Figure 2.1); therefore 
there is a high possibility that TviCATL is a virulence factor for T. vivax. Trypanosomal 
CATL-like proteases (Figure 2.1) contain a signal peptide, propeptide, a catalytic 
domain as well as the parasite-specific C-terminal extension. Many trypanosomal 
cysteine protease recombinant expression constructs are designed in such a way that 
they contain a propeptide and a catalytic domain (Caffrey et al, 2001; Vather, 2010; 
Boulangé et al, 2011). The propeptide is responsible for enzyme stability and folding 
(Sajid & McKerrow, 2002), while the function of the C-terminal extension has not been 
determined but it is not required for enzyme activity (Pamer et al, 1991; Eakin et al, 
1993).  
Large scale production of recombinant enzymes is of paramount importance for 
studies focused on determining their biochemical characteristics for the design of 
specific inhibitors. Both bacterial and eukaryotic expression systems have been 
exploited for recombinant expression of trypanosomal proteases. Initial attempts at 
heterologous expression of TcoCATL in both E. coli and balculovirus expression 
systems gave poor yields, solubility and protein folding and overall activity were 
suboptimal  (Boulangé et al, 2001). Subsequently, high protein yields and activity have 
been reported when TcoCATL was expressed in the P. pastoris yeast expression 
system (Boulangé et al, 2011). TcoCATL has been shown to be active against the 
classical cysteine protease peptide substrate, Z-Phe-Arg-AMC, and inhibited by the 
class-specific inhibitor E-64 and was also shown to digest gelatin substrate. The pH 




suggesting that the enzyme is active in the host bloodstream upon parasite lysis (Pillay 
et al, 2010; Vather, 2010; Boulangé et al, 2011). TcrCATL from T. cruzi has been 
expressed as an inactive, insoluble protein in the E. coli expression system. This 
insoluble fusion protein requires resolubilisation and refolding in urea (Eakin et al, 
1992; Eakin et al, 1993). Inclusion bodies have also been reported when a cysteine 
protease class B (CPB) from Leishmania mexicana  is recombinantly expressed in the 
E. coli system (Sanderson et al, 2000). Therefore, since P. pastoris expression often 
results in soluble, high yields of active, glycosylated proteins (Caffrey et al, 2001; Pillay 
et al, 2010; Vather, 2010; Boulangé et al, 2011), this system was used for TviCATL 
expression. 
In this part of the study, the catalytic domain of TviCATL (C-terminal extension not 
included in the construct) from T. vivax was recombinantly expressed in the P. pastoris 





































Figure 2.1: Sequence alignment of CATL-like proteases from T. b. rhodesiense 
(TbrCATL), T. congolense (TcoCATL), T. vivax Y468 (TviCATL) and T. cruzi (TcrCATL). 
TbrCATL accession no. CAC67416 (Caffrey et al, 2001), TcoCATL accession no. CAA81061 
(Fish et al, 1995), TviCATL accession no. CCD21670 and TcrCATL accession no. P52779 
(Lima et al, 2012) sequences were aligned using a Clustal Omega multiple sequence 
alignment program (Sievers & Higgins, 2014). The N-terminal signal and pro-peptide sequences 
are grouped within the red-dotted shape; the central catalytic domain residues are grouped 
within the purple-lined shape; the catalytic residues (C, H and N) are highlighted with a purple 
arrow: and the C-terminal extension residues (linked to the catalytic domain by a poly-proline 
sequence) are highlighted within the green-dotted shape. The predicted Asn-glycosylation site 
(Asn
288
) for T. vivax is blue underlined within the catalytic domain. 
 
 
TbrCATL         MPRTEMVRFVRLPVVLLAMAACLASVALGSLHVEESLEMRFAAFKKKYGKVYKDAKEEAF 60 
TcoCATL         -----MTRTLRFSVGLLAVAACFVPVALGVLHAEQSLQQQFAAFKQKYSRSYKDATEEAF 55 
TviCATL         -------MHAHALVTLLAAAVSVAPAAMAVLRADGPVEPLFAAFKQKYGRSYGTAAEEAF 53 
TcrCATL         ---MSGWARALLLAAVLVVMACLVPAATASLHAEETLTSQFAEFKQKHGRVYESAAEEAF 57 
                             . :*.  ......* . *:.: .:   ** **:*:.: *  * **** 
 
TbrCATL         RFRAFEENMEQAKIQAAANPYATFGVTPFSDMTREEFRARYRNGASYFAAAQKRLRKTVN 120 
TcoCATL         RFRVFKQNMERAKEEAAANPYATFGVTRFSDMSPEEFRATYHNGAEYYAAALKRPRKVVN 115 
TviCATL         RLRVFEDNMRRSRMYAAANPHATFGVTPFSDLTPEEFRTRYHNGERHFEAARGRVRTLVQ 113 
TcrCATL         RLSVFRENLFLARLHAAANPHATFGVTPFSDLTREEFRSRYHNGAAHFAAAQERARVPVK 117 
                *: .*.:*:  ::  *****:****** ***:: ****: *:**  :: **  * *  *: 
 
TbrCATL         VTTGRAPAAVDWREKGAVTPVKDQGQCGSCWAFSTIGNIEGQWQVAGNPLVSLSEQMLVS 180 
TcoCATL         VSTGKAPPAVDWRKKGAVTPVKDQGACGSCWAFSAIGNIEGQWKVAGHELTSLSEQMLVS 175 
TviCATL         VPPGKAPAAVDWRRKGAVTPVKDQGTCGSCWSFSAIGNIEGQWAAAGNPLTSLSEQMLVS 173 
TcrCATL         VEVVGAPAAVDWRARGAVTAVKDQGQCGSCWAFSAIGNVECQWFLAGHPLTNLSEQMLVS 177 
                *    **.***** :****.***** *****:**:***:* **  **: *..******** 
 
TbrCATL         CDTIDFGCGGGLMDNAFNWIVNSNGGNVFTEASYPYVSGNGEQPQCQMNGHEIGAAITDH 240 
TcoCATL         CDTTDYGCRGGLMDKSLQWIVSSNKGNVFTAQSYPYASGGGKMPPCNKSGKVVGAKISGH 235 
TviCATL         CDTKDNGCGGGLMDNAFEWIVKENSGKVYTEKSYPYVSGGGEEPPCKPRGHKVGATITGH 233 
TcrCATL         CDKTDSGCSGGLMNNAFEWIVQENNGAVYTEDSYPYASGEGISPPCTTSGHTVGATITGH 237 
                **. * ** ****:::::***..* * *:*  ****.** *  * *   *: :** *:.* 
 
TbrCATL         VDLPQDEDAIAAYLAENGPLAIAVDATSFMDYNGGILTSCTSEQLDHGVLLVGYNDSSNP 300 
TcoCATL         INLPKDENAIAEWLAKNGPVAIAVDATSFLGYKGGVLTSCISKGLDHDVLLVGYDDTSKP 295 
TviCATL         VDIPHDEDAIAKYLADNGPVAVAVDATTFMSYSGGVVTSCTSEALNHGVLLVGYNDSSKP 293 
TcrCATL         VELPQDEAQIAAWLAVNGPVAVAVDASSWMTYTGGVMTSCVSEQLDHGVLLVGYNDSAAV 297 
                :::*:**  ** :** ***:*:****:::: *.**::*** *: *:*.******:*::   
 
TbrCATL         PYWIIKNSWSNMWGEDGYIRIEKGTNQCLMNQAVSSAVVGGPTPPPPPPPPPSATFT--- 357 
TcoCATL         PYWIIKNSWSKGWGEEGYIRIEKGTNQCLMKNYARSAVVSG---PPPPPPPPASTFT--- 349 
TviCATL         PYWIIKNSWSSSWGEKGYIRIEKGTNQCLVAQLASSAVVGG---PGPTPTPTPTTNN--- 347 
TcrCATL         PYWIIKNSWTTQWGEEGYIRIAKGSNQCLVKEEASSAVVGG---PGPTPEPTTTTTTSAP 354 
                *********:. ***.***** **:****: : . ****.*   * *.* *..:* .    
 
TbrCATL         --------QDFCEGKGCTKGCSHATFPTGECVQTTGVGSVIATCGASNLTQIIYPLSRSC 409 
TcoCATL         --------QEFCEGAECQSGCTKATFPTGKCVQFGGAGSVIASCGSNNLTQIVYPLSSSC 401 
TviCATL         --------NNNND----------RTWP-------------IVKLHEDALQR--------- 367 
TcrCATL         GPSPSYFVQMSCTDAACIVGCENVTLPTGQCLLTTSGVSAIVTCGAETLTEEVFLTSTHC 414 
                        :               * *             *..   . * .          
 
TbrCATL         SGLSVPITVPLDKCIPILIGSVEYHCSTNPP---TKAARLVPHQ--------- 450 
TcoCATL         SGFSIPLTVPLDKCLPIVVGSVMYECSGKAP---TESARLVRHE--------- 442 
TviCATL         ----------------------------------------------------- 
TcrCATL         SGPSVRSSVPLNKCNRLLRGSVEFFCGSSSSGRLADVDRQRRHQPYHSRHRRL 467 





2.2 Materials and Methods 
2.2.1 Materials    
Recombinant expression in P. pastoris, protein purification and quantification: 
Glycerol stocks of P. pastoris GS115 cells containing recombinant pPic9-TviCATL 
were obtained from Professor Theo Baltz (University of Victor Segalen, Bordeaux, 
France). HiPrep® 16/60 Sephacryl® S-200 HR pre-packed column and ÄKTA purifier 
were purchased from GE Healthcare (Sweden). Amicon® Ultra-15 Centrifugal Filter 
devices were obtained from Merck Millipore (Bedford, USA). Pierce™ BCA Protein 
Assay Kit and 10 kDa Mr cut-off dialysis tubing were purchased from Pierce (Rockford, 
IL, USA). Nunc® - Immuno™ 96-well plates and Nunc® Black 96-well plates were 
purchased from Nunc InterMed (Denmark). The PageRuler prestained or unstained 
protein ladder was from Thermo Scientific (Lithuania). 
Antibodies: Primary antibodies against the recombinant C25A mutant full length 
inactive form of TviCATL were previously raised in chickens (Vather, 2010). The rabbit 
anti-IgY-HPRO conjugate was purchased from Sigma (Munich, Germany). 
Protein substrates and inhibitors: Bovine α2-macroglobulin (α2-M) was obtained from 
Boehringer (Mannheim, Germany), bovine haemoglobin, type I collagen from rat tails 
and bovine serum albumin (BSA) were purchased from Sigma (Munich, Germany). 
Peptide substrates and inhibitors: The fluorogenic peptide substrates H-D-Ala-Leu-
Lys-7-amino-4-methylcoumarin (AMC), H-D-Val-Leu-Lys-AMC, H-Pro-Phe-Arg-AMC 
and Z-Gly-Leu-Phe-chloromethylketone (CMK) were purchased from Bachem (King of 
Prussia, PA, USA). Benzyloxycarbonyl (Z)-Phe-Arg-AMC, Z-Gly-Pro-Arg-AMC, Z-Pro-
Arg-AMC, Z-Gly-Gly-Arg-AMC, Z-Arg-Arg-AMC, L-trans-epoxysuccinyl-leucylamido (4-
guanidino) butane (E64), antipain, chymostatin, leupeptin, bestatin, 
ethylenediaminetetra-acetic acid (EDTA), iodoacetate (IAA) and iodoacetamide (IAM) 
were obtained from Sigma (Munich, Germany). 
2.2.2 Recombinant expression of TviCATL in Pichia pastoris  
TviCATL was previously cloned into a pPic9 expression vector and the construct 
preserved as a glycerol stock of P. pastoris GS115 cells. The pPic9-TviCATL glycerol 




dextrose, 15 g/l bacteriological agar] containing tetracycline (50 µg/ml) and incubated 
at 30°C for 3 days. A single colony of P. pastoris was picked from the YPD plate for 
expansion in liquid YPD (50 ml) containing tetracycline (50 µg/ml). The YPD primary 
culture was incubated at 30°C in a baffled flask on an orbital shaking incubator (180 
rpm) for 2 days. The maximal biomass production was obtained by aseptically 
transferring YPD primary culture into 500 ml BMGY medium [1% (w/v) yeast extract, 
2% (w/v) peptone, 100 mM potassium phosphate buffer, pH 6.5, 1.34% (w/v) yeast 
nitrogen base without amino acids (YNB)]. This secondary culture was grown at 30°C 
for a further 3 days until an OD600 of 4-6 was reached. Cells were collected by 
centrifugation (6000 x g, 10 min, 4°C) and the pellet resuspended in 500 ml buffered 
minimal medium (BMM) [100 mM potassium phosphate buffer, pH 6.5, 1.34% (w/v) 
YNB, 0.00004% (w/v) biotin, 5% (v/v) methanol]. The BMM expression culture was 
grown in a baffled flask, and aeration enhanced by covering the flasks with 3 layers of 
cheesecloth. The BMM culture was incubated at 30°C in an orbital shaking incubator 
for 7 days, and expression induced by supplementing the culture with 0.5% (v/v) 
methanol daily (to compensate for methanol consumption and evaporation) as the sole 
carbon source. For the duration of expression, samples were taken (1 ml culture) every 
24 hours, centrifuged (6000 x g, 10 min) and supernatants stored at -20°C for use 
during the analysis of protein secreted in expression supernatants. After 7 days of 
expression, the entire volume of expression cultures were centrifuged (6000 x g, 10 
min, 4°C), and since TviCATL is secreted into the culture medium, supernatants were 
stored in plastic vessels at -20°C until further use. Expression supernatants collected 
on each day of expression were analysed by 12.5% reducing SDS-PAGE and silver 
stained, Section 2.2.7.  
2.2.3 Purification of the recombinant TviCATL by three phase partitioning (TPP) 
The expression supernatants were filtered through Whatman No.1 filter paper and the 
pH adjusted to pH 4.2 using phosphoric acid to effect autocatalytic processing of 
TviCATL (Vernet et al, 1991; Eakin et al, 1992). In order to concentrate and purify 
TviCATL, three phase partitioning (TPP) as described by Pike and Dennison (1989) 
was used. Tertiary-butanol (t-butanol) was added to the expression supernatant to 
constitute 30% (v/v) of the total supernatant volume and thoroughly mixed. Ammonium 
sulfate [40% (w/v) of the final volume of the supernatant plus t-butanol] was added and 
stirred until entirely dissolved. The mixture was centrifuged (6000 x g, 10 min, 4°C) in a 
swing-out rotor to ensure that all three phases were completely separated. The 




buffered saline (PBS) dialysis buffer [137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 
and 1.76 mM KH2PO4, pH 7.2] and subjected to dialysis overnight at 4°C using a 10 
kDa cut-off dialysis bag (Thermo Scientific Snakeskin® pleated dialysis tubing) against 
PBS with magnetic stirring. The optimal removal of all traces of the ammonium sulfate 
and t-butanol was achieved by 3 changes of dialysis PBS buffer. The dialysed sample 
was concentrated using dialysis against solid polyethylene glycol (PEG) Mr 20 000. 
The PEG-concentrated TPP samples were quantified using BCA assay (Section 2.2.6) 
and analysed by a 12.5% reducing SDS-PAGE (Section 2.2.7). 
2.2.4 Molecular exclusion chromatography (MEC) 
Molecular exclusion chromatography (MEC) was used for further purification of 
recombinant TviCATL. The HiPrep® 16/60 Sephacryl® S-300 HR column (16 x 600 
mm, flow rate of 0.5 ml/min, 120 ml, GE Healthcare, Sweden) connected to an ÄKTA 
purifier (GE Healthcare, Sweden) was used. The preparation and storage of the 
column was as per the manufacturer’s instructions. Briefly, the column was equilibrated 
with two column volumes of MEC buffer [50 mM NaH2PO4, 300 mM NaCl, pH 8.0] and 
calibrated with 1 ml of protein mix containing proteins of known molecular weights. 
These included 3 mg/ml blue dextran (2000 kDa), 5 mg/ml of each of BSA (68 kDa), 
ovalbumin (45 kDa) and myoglobin (16.6 kDa). To ensure the optimal resolution of 
proteins according to size, the sample volume to be loaded on the column never 
exceeded 2% of the column volume, Vc. The elution volume (Ve) of the higher 
molecular weight blue dextran was equivalent to the column void volume (Vo). The 
column calibration curve was constructed by determining the availability constant (Kav) 
of each standard protein using the equation: Kav = (Ve-Vo) / (Vt-Vo) and the Fischer’s 
plot (Figure 2.2) to represent the relationship between protein elution volume and its 
molecular weight in order to estimate the size of the protein with unknown molecular 
weight (Dennison, 1999).  
2.2.5 Concentration of MEC-purified TviCATL 
The pure MEC fractions were pooled and concentrated using Amicon® Ultra-15 
Centrifugal Filter devices (with molecular weight cut-off of 10 kDa) (Merck Millipore, 
Bedford, USA) as per the manufacturer’s instructions. Alternatively, dialysis against 
solid PEG (Mr 20 000) was used to concentrate the pure sample contained within a 10 




Prior to reducing SDS-PAGE (Section 2.2.7), samples with very low protein 
concentration were concentrated 5-fold using the SDS-KCl precipitation method. 
Briefly, sample (100 µl) was mixed with 5% (w/v) SDS (10 µl) followed by 3 M KCl (10 
µl). The mixture was inverted and centrifuged (12 000 x g, 2 min, RT), the pellet was 
re-dissolved in stacking gel buffer (10 µl) plus reducing treatment buffer (10 µl).  
 
Figure 2.2: Elution profile for the calibration of the MEC column and a Fischer’s plot for 
estimation of protein molecular weights. A, the calibration protein mix [Blue dextran (A), 
BSA (B), ovalbumin (C) and myoglobin (D)] was loaded to the Sephacryl-300 HR column (25 x 
650 mm, flow rate of 0.2 cm/min) in MEC buffer [20 mM Tris-HCl-buffer, pH 7.6, 0.02% (w/v) 
NaN3]. B, Fischer’s plot for the estimation of protein molecular weights. The elution of each 
standard protein was determined and plotted against the protein log Mr in order to construct a 
calibration curve with the trend line equation y = -0.0223x + 3.2039 and correlation coefficient of 
0.9986. 
 
2.2.6 BCA protein quantification assay 
The purified recombinant form of TviCATL was quantified using the bicinchoninic acid 
(BCA) protein assay (Pierce, Rockford, IL, USA). The BCA assay progresses through a 
Biuret reaction whereby the Cu2+ is reduced to Cu+ in the presence of a protein in a 
basic pH (Lang et al, 1996). The rate of formation of the cuprous cation (Cu2+) depends 
on the number of protein peptide bonds and favours the presence of cysteine, 
tryptophan and tyrosine residues. This reaction is measured by the formation of a 
purple-coloured reaction complex that absorbs maximally at 595 nm. Briefly, the 
Pierce™ BCA Protein Assay Kit comprises BSA standards and reagents A and B. The 
BSA standards were used to construct a calibration curve (Figure 2.3) by serial diluting 




reagent A and B in a ratio of 50:1 (v/v). Each BSA standard (25 µl) and protein of 
unknown concentration (25 µl) were pipetted (in duplicate) into a 96 well Nunc® plate, 
followed by the addition of 200 µl working reagent. The plate was covered and 
incubated at 37°C for 30 minutes. Colour development was measured at 595 nm using 
the FLUORStar Optima Spectrophotometer (BMG Labtech, Offenburg, Germany). 
 
 
Figure 2.3: The BCA calibration curve for quantification of recombinant TviCATL. BSA 
standard solution (2000-25 µg/ml) were combined with BCA working reagent, the absorbance 
values measured at 595 nm, and a calibration curve was constructed by plotting  of absorbance 
at 595 nm against BSA concentration. The equation of the trend line is y = 0.0005x + 0.0085 
with a correlation coefficient of 0.996.       
 
2.2.7 SDS-PAGE analysis 
Protein samples were analysed by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) described by Laemmli (1970). A discontinuous buffer 
system was used comprising a running gel buffer (1.5 M Tris-HCl, pH 8.8) and a 
stacking gel buffer (500 mM Tris-HCl, pH 6.8). The protein samples were combined 
with the reducing treatment buffer [125 mM Tris-HCl, 4% (w/v) SDS, 20% (v/v) 
glycerol, 10% (v/v) 2-mercaptoethanol]. SDS-PAGE was conducted at 40 mA per 2 
gels in a tank buffer (250 mM Tris-HCl buffer, pH 8.3, 192 mM glycine, 0.1% (w/v) 
SDS) using the BioRad Mini protein III electrophoresis apparatus (BioRad, CA, USA). 
After electrophoresis, gels were stained for 4 hours or overnight with Coomassie Blue 
[0.125% Coomassie Blue R-20, 50% (w/v) methanol, 10% (v/v) acetic acid], destained 
in destaining solution I [50% (v/v) methanol, 10% acetic acid] followed by complete 
destaining and gel swelling to original size in several changes of distilled water. In 




proteins of known sizes were separated on reducing SDS-PAGE. The measurement of 
the relative migration distance (Rf) of individual standard proteins, was used to 
construct a calibration curve (Figure 2.4) in order to determine the molecular weight of 
protein of unknown size. 
 
 
Figure 2.4: Reducing SDS-PAGE relative migration standard curve. In order to estimate the 
molecular weight of protein of unknown size, the molecular weight marker that comprises 
proteins of known sizes were separated by 12.5% reducing SDS-PAGE. The relative migration 
distance was measured and plotted against log Mr. The equation of the standard curve was y = 
-5.8668x + 11.97 with a correlation coefficient of 0.9916. 
 
In order to visualise very low amounts of protein on SDS-PAGE gels, a very sensitive 
silver staining method was used (Blum et al, 1987). Following reducing SDS-PAGE, 
the gel was placed in a thoroughly cleaned (with 70% ethanol) glass container and 
incubated with a fixing solution [50% (v/v) methanol, 12% (v/v) glacial acetic acid, 0.5% 
(v/v) formaldehyde] for 1 hour or overnight at room temperature on an orbital shaker. 
The gel was rinsed in 50% (v/v) ethanol (3 x 20 min), and soaked in pre-treatment 
solution [0.4% (w/v) Na2S2O3. 5H2O]. After washing in distilled water (3 x 20 min), the 
gel was incubated with an impregnation solution [0.2% (w/v) silver AgNO3, 0.75% (v/v) 
37% formaldehyde] for 20 min. The gel was washed once more in distilled water (3 x 
20 min) and incubated in developing solution [0.4% (w/v) Na2S2O3. 5H2O] until protein 
bands were visible. The gel was immediately placed in the stopping solution [50% (v/v) 





2.2.8 Western blot analysis 
Western blot analysis of proteins was conducted according to the protocol described 
by Towbin et al (1979). Proteins separated by reducing SDS-PAGE (Section 2.2.7) 
were electrophoretically transferred from the gel onto a nitrocellulose membrane that 
was briefly pre-soaked in blotting buffer [45 mM Tris-HCl buffer, pH 8.3, 173 mM 
glycine and 0.1% (w/v) SDS] using a Sigma Semi-phor® semi-dry blotting apparatus at 
constant voltage (20V) and maximum current for 50 minutes. Upon completion of 
protein transfer to the nitrocellulose, the effectiveness of protein transfer to the 
membrane was checked by transiently staining with Ponceau S [0.1% (w/v) Ponceau S 
in 1% (v/v) glacial acetic acid]. After marking the positions of the molecular mass 
markers using a pencil, the nitrocellulose membrane was destained with several 
changes of distilled water. All the unoccupied sites on the membrane were blocked 
with blocking solution [5% (w/v) Elite® fat-free powder milk dissolved in Tris buffered 
saline (TBS, 20 mM Tris-HCl buffer, pH 7.4, 200 mM NaCl)] for 1 hour, after which the 
membrane was washed in TBS (3 x 5 min) and subsequently probed overnight at 4°C 
with antibodies raised against the recombinant full length inactive form of TviCATL 
(anti-ΔFLM TviCATL IgY, 10 µg/ml) diluted in 0.5% (w/v) BSA-TBS. The membrane 
was washed in TBS (3 x 5 min) and incubated in rabbit anti-IgY conjugated to 
horseradish peroxidase (HRPO) diluted in 0.5% (w/v) BSA-TBS. Following washing in 
TBS (3 x 5 min), the membrane was placed in substrate solution [(0.06% (w/v) 4-
chloro-1-naphthol, 0.1% (w/v) methanol, 0.0015% (v/v) H2O2 in TBS] until bands were 
visible. Alternatively, an enhanced chemiluminescence detection kit (Pierce, Rockford, 
USA) was used. The image was captured using the Sys Gene® imaging system 
(Syngene®, USA). 
2.2.9 Determining the glycosylation status of TviCATL 
To assess the glycosylation status of TviCATL, TviCATL was treated with 
endoglycosidase H. Endoglycosidase H is a glycosidase that specifically cleaves Asn-
glycosylated proteins. Cleavage is evidenced by size reduction or increased migration 
on SDS-PAGE as compared to untreated sample (Caffrey et al, 2001). The protein was 
mixed with denaturing and reducing agents [5% (w/v) SDS and 10% (w/v) 2-
mercaptoethanol], followed by boiling at 100°C for 5 minutes. After cooling for 5 
minutes at room temperature, 1/10 (v/v) 0.5 M sodium citrate, pH 5.5 was added in 
order to re-adjust the pH of the mixture to the optimal pH for Endoglycosidase H. The 




Endoglycosidase H (500 U), while the other served as an untreated control. The 
samples were incubated at 37°C for 3 hours, before the reaction was stopped by 
addition of reducing treatment buffer [125 mM Tris-HCl, 4% (w/v) SDS, 20% (v/v) 
glycerol, 10% (v/v) 2-mercaptoethanol] and boiling for 5 min. The resulting samples 
were analysed by 12.5% reducing SDS-PAGE (Section 2.2.7). 
2.2.10 Gelatin-substrate SDS-PAGE and TviCATL interaction with inhibitors 
The proteolytic activity of recombinant TviCATL was analysed on a gelatin containing 
Laemmli SDS-PAGE gel as described by Heussen and Dowdle (1980). Gelatin [1% 
(w/v)] was dissolved in 1.5 ml of SDS-PAGE running gel at 37°C, and combined with 
the rest (2.25 ml) of the running gel buffer for casting a 12.5% SDS-PAGE as 
described in Section 2.2.7. Samples were treated with equal volumes of non-reducing 
treatment buffer [125 mM Tris-HCl buffer pH 6.8, 4% (w/v) SDS and 20% (v/v) 
glycerol]. Following electrophoresis, SDS was removed from the gel by incubation in 
two changes of 2.5% (v/v) Triton X-100 for an hour at room temperature. The gel was 
then incubated in TviCATL assay buffer [100 mM bis-Tris buffer, pH 6.5, 4 mM EDTA, 
0.02% (w/v) NaN3, 6 mM DTT] for 3 hours at 37°C. The gel was stained with amido 
black solution [0.1% (w/v) amido black, 30% (v/v) methanol, 10% (v/v) glacial acetic 
acid, 60% (v/v) water] for 1 hour and subsequently destained in several changes of 
destaining solution [30% (w/v) methanol, 10% (v/v) acetic acid, 60% (v/v) distilled 
water]. Also, the effect of inhibitors on proteolytic activity of TviCATL was investigated 
by including different inhibitors in the assay buffer. The gels were incubated at 37°C 
overnight in assay buffer-containing the respective inhibitors [chymostatin (10 µM), 
bestatin (10 µM), antipain (10 µM), E-64 (10 µM), leupeptin (10 µM), iodoacetate (10 
µM), Z-Gly-Leu-Phe-CMK (50 µM), stefin B (80 µM) and EDTA (10 mM)]. 
2.2.11 Incubation of recombinant TviCATL with protein substrates  
The method described by Dvořák et al (2009) was used to monitor the effect of 
incubating recombinant TviCATL with different protein substrates. Briefly, recombinant 
TviCATL (~1 µg) was combined with 1 mg/ml of each of bovine serum albumin, type I 
collagen from rat tail, bovine haemoglobin and bovine α2-macroglobulin in assay buffer 
[50 mM citrate, 100 mM sodium phosphate buffer, pH 5-10] containing 2 mM DTT. The 
reaction was stopped by addition of reducing treatment buffer followed by boiling at 
100°C for 2 minutes. These samples were analysed on either 12.5% or 15% reducing 




2.2.12 Active site titration 
Active site titration was conducted according to Barrett et al (1982) using the 
irreversible cysteine protease inhibitor, L-transepoxysuccinylleucylamido (4-guanidino) 
butane (E-64) in order to determine the active concentration (E0) of TviCATL . TviCATL 
[1 µM diluted in 0.1% (w/v) Brij-35] was incubated with E-64 (0-1 µM) diluted in 0.1% 
(w/v) Brij-35 in TviCATL assay buffer [100 mM Bis-Tris buffer, pH 6.5, 4 mM EDTA, 
0.02% (w/v) NaN3, 6 mM DTT] at 37°C for 30 minutes. The rate of hydrolysis of Z-Phe-
Arg-AMC (20 µM) was measured by reading fluorescence (Ex360 nm; Em460 nm) using the 
FLUORStar Optima spectrophotometer (BMG Labtech, Offenburg, Germany). The plot 
of fluorescence against E-64 concentrations was used to obtain an estimate of the 
active concentration of TviCATL. Approximately 20% of recombinant TviCATL was 
active (Figure 2.5), and this is equivalent to 13.8 µM active enzyme. 
 
Figure 2.5: Active site titration of TviCATL. TviCATL (1 µM) was titrated against different 
concentrations of E-64 (0-1 µM) and incubated at 37°C
 
for 30 min and residual activity against 
H-D-Val-Leu-Lys-AMC was measured. Each data point represents the mean activity of the 
three replicates. 
 
2.2.13 Optimum pH for hydrolysis of H-D-Val-Leu-Lys-AMC by TviCATL 
The optimum pH for hydrolysis of H-D-Val-Leu-Lys-AMC by pure TviCATL was 
determined using the constant ionic strength acetate/Mes/Tris (AMT) buffers (100 mM 
Na-acetate, 200 mM Tris, 100 mM Mes, 8 mM DTT and 4 mM EDTA) titrated from pH 
4 to pH 9 (in 1 pH increments) using NaOH or HCl. The enzyme, TviCATL [1.5 ng 




5 minutes at 37°C. The substrate H-D-Val-Leu-Lys-AMC (20 µM) was added and 
fluorescence measured (Ex360 nm; Em460 nm) using the FLUORStar Optima 
Spectrophotometer (BMG Labtech, Offenburg, Germany). 
2.2.14 Fluorometric peptide substrate specificity of TviCATL 
The hydrolysis of AMC was followed using the FluorStar Optima spectrophotometer 
(BMG Labtech, Offenburg, Germany) equilibrated at 37°C in order to calibrate the 
instrument and determine the relative endpoint for enzymatic hydrolysis of AMC 
peptide substrates. A series of AMC dilutions (5 x10-3-15 µM) were prepared in distilled 
water and incubated with TviCATL assay buffer for 5 minutes at 37°C. Fluorescence 
was measured (Ex360 nm; Em460 nm) using the FLUORStar Optima Spectrophotometer 
(BMG Labtech, Offenburg, Germany) and the AMC fluorescence standard curve was 
constructed, Figure 2.6. 
 
 
Figure 2.6: The AMC standard curve to determine the relative amount of fluorescence 
released upon hydrolysis of the AMC substrates. The fluorescence was measured at Ex360 
nm; Em460 nm and the equation of the line was y= 3457.3x + 970.28 with a correlation coefficient 
of 0.9943. 
 
The kinetic parameters for complete definition of the substrate specificity of the 
enzyme were determined by measuring the parameters as per revised Michaelis-
Menten equation by Briggs and Haldane (1925) and Salvesen and Nagase (1989), 
respectively: 




Where in equation (1): v0 is the initial steady-state velocity, Vmax the maximum velocity 
of enzyme catalysed reaction, [S] the substrate concentration, Km the Michaelis-
Menten constant; and in equation (2): kcat is the turnover of the enzyme and [Eo] the 
active concentration of an enzyme. 
The substrate specificity of recombinant TviCATL was experimentally determined by 
pre-incubation of TviCATL [1.5 ng diluted in 0.1% (w/v) Brij-35] in TviCATL assay 
buffer for 5 minutes at 37°C. The activated enzyme mixture was combined with 
different substrate concentrations (0-50 µM) and substrate hydrolysis was followed by 
measuring fluorescence at (Ex360 nm; Em460 nm) using the FLUORStar Optima 
Spectrophotometer (BMG Labtech, Offenburg, Germany). The initial steady state 
velocity (v0) (gradient) was determined relative to the gradient of the AMC standard 
curve (Figure 2.6). The substrate concentrations and calculated relative v0 values were 
plotted using Hyper32© software (1991 – 2003, Dr. J.S. Easterby, University of 
Liverpool, Liverpool, UK) in order to construct the Lineweaver-Burk plots for 
determination of Vmax and Km. 
2.2.15 Reversible inhibition 
The reversible competitive inhibition of an enzyme-substrate reaction occurs in a time-
independent manner. As described by Salvesen and Nagase (1989), reversible 
inhibition is followed by defining the parameters in equations (3) and (4): 
ѵ0/ѵi = 1 + [I]/Ki(app)        (3)                              Ki = Ki(app)/1 + [S]/Km       (4) 
Where in equation (3): ѵ0 is an uninhibited rate for the substrate hydrolysis, ѵi is the 
inhibited rate upon addition of the substrate, [I] is the inhibitor concentration and Ki(app) 
is the apparent inhibition constant. In equation (4): Ki is the true equilibrium constant, 
[S] is the initial substrate concentration used and Km is the Michaelis-Menten constant 
for the used substrate. 
To experimentally follow the reversible inhibition of the substrate hydrolysis by an 
enzyme, 1.5 ng active TviCATL [diluted in 0.1% (w/v) Brij-35] was activated in TviCATL 
assay buffer for 15 minutes at 37°C. The specific substrates Z-Phe-Arg-AMC and H-D-
Ala-Leu-Lys-AMC (20 µM) were added and released fluorescence quickly measured 
using the FLUORStar Optima Spectrophotometer (BMG Labtech, Offenburg, 
Germany) at Ex360 nm and Em460 nm in order to determine the uninhibited rate, v0. The 
dilution series of inhibitor (2.5-40 µM) was added, followed by measuring fluorescence 




the calculation of the Ki(app from the slope. The Ki was then calculated by substitution of 
the parameters as per equation (4). 
2.2.16 Irreversible inhibition of TviCATL 
The effect of irreversible inhibitors towards the activity of TviCATL was followed 
through pseudo-first-order kinetics at which the inhibitor concentration is kept 10-fold 
higher than the enzyme concentration (Salvesen and Nagase, 1989). Briefly, the active 
TviCATL [1.5 ng = 0.056 nM diluted in 0.1% (w/v) Brij-35] was pre-activated in 
TviCATL assay buffer for 15 minutes at 37°C. Aliquots in triplicate were removed and 
assayed in separate experiments against 20 µM Z-Phe-Arg-AMC or H-D-Ala-Leu-Lys-
AMC in order to measure the uninhibited rate, ѵ0. To the enzyme-assay buffer mixture, 
the irreversible inhibitor (1.8 nM) was added and incubated at 37°C. At various 5 
minute intervals, triplicate aliquots were removed and assayed for residual activity 
against the two substrates in order to measure the activity after addition of the inhibitor, 
ѵt. The observed rate of inactivation kobs was determined using the equation:  In ѵt/ѵ0 = -
kobs x t . The apparent rate of association kass was calculated using the relationship: kass 
= kobs/[I], where [I] is the concentration of the inhibitor. In order to determine the 
inhibitor concentration required for 50% inhibition (IC50) of the enzyme during the 
incubation time, the assumption that for the pseudo-first-order, IC50 is equivalent to 
half-life t1/2 was used in the following equation: t1/2 = 0.693/ kass (Salvesen and Nagase, 
1989). 
2.3 Results 
2.3.1 Recombinant expression and purification of the catalytic domain of 
TviCATL  
The P. pastoris yeast expression system was used to recombinantly express TviCATL 
from T. vivax. Silver stained reducing SDS-PAGE analysis of expression supernatants 
indicated that TviCATL is expressed in two forms as evidenced by two bands at 29 and 
33 kDa on reducing SDS-PAGE (Figure 2.7, panel A). This figure also revealed that 
there was an increase in intensity of bands from day 3 to day 6, signifying a time 
dependent increase in expression levels. However, at day 7, there was a decrease in 
intensity of bands as compared to day 3-6 samples, thus signifying a decrease in 
expression levels. Thus for the next expression, induction was allowed to proceed for 
only 6 days. The expression medium yielded mainly the desired protein, with very few 




molecular weight bands of TviCATL (29 kDa) indicates that autocatalytic processing of 
the propeptide occurred in the expression supernatants during the autocatalytic 
maturation process of the pro-enzymes at pH 4.2 to release a processed and mature 
active enzyme, as is the case for other cysteine proteases (Vernet et al, 1991; 
Boulangé et al, 2001).  
Three phase partitioning using 40% ammonium sulfate allowed optimal precipitation of 
TviCATL and partial purification of TviCATL from the expression medium as evidenced 
by two prominent bands at 29 and 33 kDa on reducing SDS-PAGE (Figure 2.7, panel 
B). 
 
Figure 2.7: Reducing SDS-PAGE (12.5%) analysis of expression and purification of 
recombinant TviCATL by TPP. A, aliquots were collected for the duration of expression. 
Supernatants collected from day 3-7 were concentrated by the SDS-KCl method prior to loading 
on a reducing gel that was afterwards silver stained. B, the final supernatant volume at day 7 of 
expression was concentrated by three phase partitioning using 40% ammonium sulfate. 
Dialysed and concentrated sample (10 µg) was separated on the gel and stained with 
Coomassie blue R-250.  
 
Three phase partitioning did not adequately remove all contaminating proteins; hence 
further purification was necessary to remove the higher molecular weight 
contaminants. Molecular exclusion chromatograph (MEC) using an AKTA Sephacryl-
300 column was used to further purify TviCATL (Figure 2.8, panel A). According to the 
MEC calibration curve (Figure 2.2, panel B), the retention volumes for TviCATL were 
predicted to be 75.57 ml for a 33 kDa protein and 78.1 for a 29 kDa protein. The first 




corresponded to the higher molecular weight contaminants. The last two peaks at 
around 80.7 ml and 104 ml corresponded to the co-eluted 33 and 29 kDa bands 
respectively, representing TviCATL; these retention volumes were larger than those 
predicted (75.57 ml for a 33 kDa protein and 78.1 for a 29 kDa protein). Higher 
retention volumes of TviCATL could be due to the glycosylated nature of this protein.  
The residual activity of each MEC eluted fraction was measured against the specific 
substrate, Z-Phe-Arg-AMC. The activity plot shows three peaks that overlap with the 
elution profile peaks. Interestingly, it is evident that the last two TviCATL peaks [which 
correspond to 33 and 29 kDa fractions on the SDS-PAGE gel (Figure 2.8, panel B)] 
had the highest enzymatic activity as compared to the first peak which corresponds to 
the higher molecular weight contaminants. The eluted fractions corresponding to the 
two peaks with the highest purity and activity were pooled and concentrated. This 
activity shows that successive purification methods did not compromise the activity of 
the enzyme.  
Analysis by reducing SDS-PAGE of MEC purified samples (Figure 2.8, panel B), 
indicates that the higher molecular weight contaminates were eluted from 72 to 80 ml. 
At 80 ml, there was a mixture of a hardly visible higher molecular weight contaminant 
and a prominent 33 kDa band corresponding to the TviCATL form. From fractions 82 to 
96, the 33 kDa and 29 kDa bands co-eluted at almost the same intensity. Lower 
molecular weight degradation products were visible in the latter fractions. 
Table 2.1 shows that TPP adequately removed contaminating proteins as indicated by 
an increase in specific activity as compared to that of the expression lysate. The TPP 
sample further subjected to purification by MEC indicates an increase in specific 
activity while the concentration and total protein decreased significantly due to removal 
of contaminants. The final yield is very high but that is in line with findings of other 
workers in the field who used TPP to purify proteins from expression supernatants. 
These values may not be precise due to the possibility of over estimation of the total 






Figure 2.8: Purification of TviCATL on a Sephacryl
®
 S-300 HR MEC column. TviCATL was 
subjected to MEC (column: 16 x 600 mm, flow rate of 0.5 ml/min, 120 ml, 2 ml/fraction) in MEC 
buffer (50 mM NaH2PO4, 300 mM NaCl, pH 8). Panel A, elution profile (blue, A280 nm) and the 
approximate calibration sizes and their corresponding retention volumes are diagrammatically 
represented at the top of panel A. For all fractions, residual activity was measured against Z-
Phe-Arg-AMC peptide substrate (red). B, MEC fractions (including those eluted from 72-96 ml) 
were analysed by 12.5% reducing SDS-PAGE followed by silver staining.  
 
Table 2.1: Purification of recombinant expression supernatant of TviCATL by 


















Supernatant  480 0.538 258 7528 29 1 100 
TPP  5.5 8.28 45.54 42915 942 32.5 570 
MEC  1.5 6.63 10.02 44368 4428 153 589 
a 
BCA assay was used to quantify protein and 
b
 residual activity was determined by measuring 
the hydrolysis of Z-Phe-Arg-AMC (20 µM) by TviCATL pre-activated at 37°C in assay buffer 
(100 mM Bis-Tris, pH 6.5, 4 mM EDTA, 0.02% (w/v) NaN3, 8 mM DTT) 
 
Western blot analysis was carried out using chicken anti-full length inactive mutant 
TviCATL IgY antibodies in order to confirm the identity of the recombinantly expressed 
and purified TviCATL. Both bands observed at approximately 29 and 33 kDa (before 
and after purification by TPP and MEC), were faintly detected using this antibody 
(Figure 2.9). Despite extensive optimisation of the antigen concentration, and dilution 




was achieved (results not shown). In subsequent work (see Chapter 3) improved 
results were obtained by using enhanced chemiluminescence for western blots.  
 
Figure 2.9: Western blot analysis of expression and purification (TPP and MEC) of 
TviCATL. Purified expression supernatants were analysed by 12.5% reducing SDS-PAGE. 
Panel A, TviCATL from expression supernatants (SDS-KCl concentrated), TPP, MEC and 
MEC-33 kDa fractions were loaded at 5 and 10 µg. The gel was Coomassie blue R-250 stained 
to serve as a reference gel. Panel B, duplicate gel as in panel A was transferred to a 
nitrocellulose membrane, probed with anti- chicken anti-full length inactive mutant TviCATL 
IgY (30 µg/ml) and detected by rabbit anti-IgY-HRPO conjugate (1: 1000 dilution) followed by 
colour development using a 4-chloro-1-naphthol and H2O2. TviCATL bands are indicated by 
arrows.   
2.3.2 Glycosylation status of recombinant TviCATL 
The electrophoretic migration of TviCATL as two bands at 33 and 29 kDa even after 
purification by MEC suggests that TviCATL may contain one or more glycosylation 
sites in its sequence. The glycosylation status of TviCATL was assessed by treatment 
(prior to electrophoresis) of the sample containing both 33 and 29 kDa TviCATL bands 
that co-eluted from MEC as well as the 33 kDa fraction that partially separated from the 
29 kDa fraction. Figure 2.10, shows that for the MEC (29 and 33 kDa) sample treated 
with endoglycosidase H (+ Endo H), the 33 kDa band disappeared as compared to the 
untreated sample (- Endo H) which migrated as both 29 and 33 kDa. When a 33 kDa 
eluted fraction was treated with endo H (+ Endo H), there was a decrease in 




endoglycosidase treatment proved that the 33 kDa of TviCATL is as a result of Asn-
glycosylation. 
 
Figure 2.10: Glycosylation status of recombinant TviCATL. MEC eluted fractions containing 
29 and 33 kDa or 33 kDa forms of TviCATL only, were treated with endoglycosidase H prior to 
analysis by 12.5% reducing SDS-PAGE that was Coomasie blue R-250 stained. (+) Endo H 
refers to endoglycosidase H treated samples while (-) Endo H refers to the untreated control 
samples. Molecular marker (M) lane was loaded as size reference. 
 
2.3.3 Gelatin SDS-PAGE 
The gelatinase activity of TviCATL was compared to that of TcoCATL, which is the 
cysteine protease that shares approximately 62% sequence identity with TviCATL. 
Both enzymes efficiently and comparably hydrolysed the gelatin substrate as 
evidenced by clear zones over a darky stained background (Figure 2.11). Non-
reducing conditions resulted in migration of the enzymes at molecular sizes higher than 
their migration under reducing conditions (2-mercaptoethanol plus boiling of samples, 
Figure 2.8). The approximate molecular weights for TviCATL are 50 and 33 kDa, while 





Figure 2.11: Analysis of proteolytic activity of TviCATL and TcoCATL by 12.5% non-
reducing SDS-PAGE copolymerised with a gelatin substrate. During sample preparation, 
neither reducing agent nor boiling of sample was performed prior to gel loading. Approximate 
molecular mass, M, are presented on the first left lane. The gel was stained with Amido black. 
 
To evaluate how different inhibitors affect the gelatinase activity of TviCATL, different 
inhibitors were included in the TviCATL assay buffer for incubation of the gelatin SDS-
PAGE gels. Figure 2.12 shows that as compared to the no inhibitor control, the 
gelatinase activity of TviCATL was completely inhibited by the specific cysteine 
protease inhibitor, E-64. Complete inhibition was also seen when cysteine/serine 
inhibitors, antipain, leupeptin and iodoacetate were used. The irreversible cysteine 
protease inhibitors, Z-Gly-Leu-Phe-CMK, chymostatin and stefin B partially inhibited 
the gelatinase activity of TviCATL. Gelatinase activity was neither inhibited by a 
specific aminopeptidase inhibitor (bestatin) nor by a specific metalloprotease inhibitor 
(EDTA). Therefore these results prove that TviCATL is a cysteine protease. 
2.3.4 pH optimum 
The pH optimum of the purified TviCATL was determined by measuring the rate of 
hydrolysis of H-D-Val-Leu-Lys-AMC [a substrate also pre-determined to be specific for 
this enzyme (Vather, 2010)] in constant ionic strength AMT buffers set at different pH 
values. Results shown in Figure 2.13 indicate that the recombinant TviCATL was 
active at a pH range between 6.5 and 7.5 suggesting that the enzyme would be active 






Figure 2.12: The effect of inhibitors on gelatinase activity of TviCATL. TviCATL (0.25 µg) 
was separated by a 12.5% non-reducing SDS-PAGE containing gelatin. During sample 
preparation, neither reducing agent nor boiling of the sample was performed prior to gel 
loading. Upon removal of SDS by Triton X100, a number of gel strips were incubated overnight 
at 37°C in TviCATL assay buffer supplemented with the respective inhibitors at the indicated 
concentrations. In one strip, inhibitor was not added to serve as a positive control. Inhibitor 
concentrations: chymostatin (10 µM), bestatin (10 µM), antipain (10 µM), E-64 (10 µM), 
leupeptin (10 µM), iodoacetate (10 µM), Z-Gly-Leu-Phe-CMK (50 µM), stefin B (80 µM) and 




Figure 2.13: The pH optimum of TviCATL. Constant ionic strength Acetate-Mes-Tris buffers 
(AMT), pH 4-9, were combined with purified TviCATL (1.5 ng) at 37°C for 5 minutes, followed 
by measuring residual activity against the peptide substrate, H-D-Val-Leu-Lys-AMC (20 µM). 





2.3.5 Incubation of TviCATL with protein substrates 
To evaluate if the proteolytic enzyme TviCATL could potentially be involved in 
pathogenesis of trypanosome parasites by degrading host proteins and tissues, and to 
evaluate at which pH this hydrolysis occurs optimally, TviCATL was incubated with 
different protein substrates, i.e. bovine serum albumin, bovine haemoglobin, type I 
collagen and bovine α2-macroglobulin (Figure 2.14). Panel A for hydrolysis of BSA (68 
kDa) by TviCATL, shows that there was optimal hydrolysis at pH 7 and 7.5. At pH-
values below 7, no noticeable hydrolysis occurred while at pH 8 and 9, hydrolysis was 
partial with observed degradation products at around 35 and 40 kDa. At pH 10, no 
hydrolysis occurred since the band at 68 kDa appears exactly as that seen in the lane 
for an untreated control sample, U.  
Bovine haemoglobin migrated as a major band at 15 kDa which is a representative of 
haemoglobin alpha and beta monomers and a faint band at around 30 kDa 
representing the alpha-beta dimers (Foot et al, 2009). Panel B shows that haemoglobin 
was completely hydrolysed in the pH range 6-7.5 as evidenced by complete 
disappearance of the major 15 kDa and a minor 30 kDa band. At pH-values below and 
above this range, no hydrolysis occurred since the intensity of the 15 kDa and the 30 
kDa bands appeared almost the same as the untreated control sample, U.  
Collagen separates on SDS-PAGE as doublets at 115 and 130 kDa and another 
doublet at 215 and 235 kDa. Panel C shows that at pH 5-7, there was partial hydrolysis 
of a lower molecular doublet with pH 6.5 and 7 being optimal for this particular 
hydrolysis. However, the higher molecular weight doublet was more resistant to 
hydrolysis in the pH range 5-7 as evidenced by the minor decrease in the prominence 
of these bands. At pH 7.5-10, there was no hydrolysis as the band intensity of these 
doublets stained similarly as that of an untreated control sample, U.  
Reducing SDS-PAGE analysis of the interaction of TviCATL with α2-macroglobulin is 
presented in panel D. The untreated control (lane 1), showed that α2-macroglobulin 
migrates as a “slow” 170 kDa band, and this is the expected α2-macroglobulin 
monomer size under reducing conditions. At pH 5- 7.5 there was an accumulation of 
cleavage bands called the “fast” α2-macroglobulin form which corresponds to the 
cleaved bait region of α2-macroglobulin under reducing conditions. These degraded 
bands are at approximately 95 and 85 kDa and the intensity of these bands was more 
pronounced at pH 5, meaning this was a partial hydrolysis of α2-macroglobulin. At pH 




hydrolysis occurred in these pH ranges. Surprisingly, at pH 7.5, no hydrolysis was 
evidenced. At pH 9 and 10, no significant hydrolysis occurred as the protein bands 
separated the same as an untreated control sample, U. 
 
Figure 2.14: The hydrolysis of protein substrates by TviCATL. Recombinant TviCATL (1 
µg) was incubated with bovine serum albumin (A), bovine haemoglobin (B), type I collagen (C) 
and bovine α2-macroglobulin (D) overnight at 37°C in assay buffer [50 mM citrate, 100 mM 
sodium phosphate containing 2mM DTT] (pH 5-10). For A and B, samples were separated on a 
15% reducing SDS-PAGE gel, while for C and D samples were separated on a 10% reducing 
SDS-PAGE gel. The untreated protein substrate (U, no enzyme added and protein diluted in 
distilled water) was included to serve as a control. All gels were silver stained. 
 
2.3.6 Substrate specificity of TviCATL 
The ability of TviCATL to hydrolyse different fluorogenic peptide substrates was 
assessed by reacting TviCATL with a range of fluorogenic peptide substrates that 
differed in the amino acid residues in P1, P2 and P3. Table 2.2 indicates that Z-Phe-Arg-
AMC is the best substrate for TviCATL as indicated by the lower Km value of 4.125 µM 
and higher catalytic efficient (kcat/Km) value of 29.39 s
-1 mM-1. Results also show that H-
D-Ala-Leu-Lys-AMC (kcat/Km = 16.95 s




3.81 s-1 mM-1) are good substrates for TviCATL. H-D-Val-Leu-Lys-AMC has been 
previously described as the best substrate for recombinant TviCATL (Vather, 2010; 
Jackson, 2011), but in this case, low catalytic efficiency was obtained. The reason for 
this discrepancy is not clear. These results indicate that pronounced hydrolysis of the 
peptides by TviCATL occur if the basic amino acids Lys or Arg occupies the P1 
substrate position (which binds to the S1 of the active site cleft) and large hydrophobic 
amino acids Leu or Phe at the P2 substrate position (which binds to the S2 of the active 
site cleft). From these observations, it can be concluded that Z-Phe-Arg-AMC and H-D-
Ala-Leu-Lys-AMC or H-D-Val-Leu-Lys-AMC are the best substrates for the 
recombinant form of TviCATL. Consistent with all cysteine proteases, S2 is the primary 
determinant of substrate specificity. 
As evidenced by a relatively high kcat/Km of 14.69 s
-1 mM-1, TviCATL also hydrolysed a 
substrate with proline at the P2 position of the endopeptidase substrate (Z-Pro-Arg-
AMC), however, the presence of small hydrophobic amino acids Gly or Val at P3 
compromised the potential of TviCATL to hydrolyse substrates containing Pro at P2 (Z-
Gly-Pro-Arg-AMC and Boc-Val-Pro-Arg-AMC). TviCATL was unable to hydrolyse a 
substrate lacking a P2 residue (H-Leu-AMC) and an arginine rich substrate, Z-Arg-Arg-
AMC.  
Overall, TviCATL preferentially cleaved peptide bonds at which the P2 position is 
occupied by hydrophobic amino acid residues and this preference is best described by 
the following order: Phe>Leu. The preference at P1 is Arg>Lys. Due to the promiscuity 
of the P3 position, no preference trend could be deduced since a variety of amino acid 












Table 2.2: The kinetic parameters for the cleavage of the peptide substrates by 
recombinant TviCATL. TviCATL (1.5 ng) pre-activated at 37°C in assay buffer (100 
mM Bis-Tris, pH 6.5, 4 mM EDTA, 0.02% (w/v) NaN3, 8 mM DTT) was incubated with a 
series of fluorogenic substrates ranging from a concentration of 0-50 µM. Hydrolysis 
was monitored by measuring fluorescence (Ex360 nm; Em460 nm). Hyper32
© software was 
used to determine Km. 
Substrates Km (µM) Vmax kcat (s
-1) kcat/Km (s
-1 mM-1) 
Z-Phe-Arg-AMC 4.125 1.673 0.1212 29.39 
H-D-Ala-Leu-Lys-AMC 19.83 4.638 0.3361 16.95 
H-D-Val-Leu-Lys-AMC 56.01 2.945 0.2134 3.81 
Z-Pro-Arg-AMC 11.48 2.328 0.1687 14.69 
H-Pro-Phe-Arg-AMC 26.38 0.4770 0.03456 1.310 
Z-Gly-Gly-Arg-AMC 55.55 0.3189 0.02311 0.4161 
Substrates with no activity detected even after long time incubation at 37°C: Z-Gly-Pro-Arg-
AMC, Boc-Val-Pro-Arg-AMC, H-Leu-AMC and Z-Arg-Arg-AMC 
 
2.3.7 Competitive reversible and irreversible inhibition of TviCATL  
TviCATL was reacted with a series of reversible inhibitors to determine their inhibitory 
effect on the hydrolysis of the substrates, Z-Phe-Arg-AMC and H-D-Ala-Leu-Lys-AMC. 
Results in Table 2.3 indicate that leupeptin is the best reversible inhibitor of TviCATL in 
the presence of a preferred substrate (Z-Phe-Arg-AMC) since it has the lowest Ki 
(3.34) as compared to other inhibitors. There is no significant difference between Ki 
values of chymostatin and antipain. When reversible inhibition was assayed in the 
presence of H-D-Ala-Leu-Lys-AMC, antipain and chymostatin inhibited substrate 
hydrolysis to comparable levels, but their Ki values did not differ much from the Ki value 
of leupeptin. Bestatin and EDTA did not yield any inhibitory effect on the activity of 
TviCATL against either substrates and this is consistent with results obtained for the 
evaluation of gelatinase inhibition. 
TviCATL was also reacted with irreversible protease inhibitors and residual activity 
assayed against specific substrates Z-Phe-Arg-AMC and H-D-Ala-Leu-Lys-AMC (Table 
2.4). Both iodoacetate and iodoacetamide showed very similar kinetic values against 
both Z-Phe-Arg-AMC and H-D-Ala-Leu-Lys-AMC and are considered to be better 
inhibitors as compared to Z-Gly-Leu-Phe-CMK since they have large values of 
association constants with the lowest half-lives. The serine protease inhibitors, PMSF 





Table 2.3: The inhibition of recombinant TviCATL by competitive reversible 
inhibitors. TviCATL (1.5 ng) pre-activated at 37°C in assay buffer (100 mM Bis-Tris, 
pH 6.5, 4 mM EDTA, 0.02% (w/v) NaN3, 8 mM DTT) was incubated with competitive 
reversible inhibitors (2.5 – 40 µM). The hydrolysis of the specific substrates Z-Phe-Arg-
AMC and H-D-Ala-Leu-Lys-AMC was monitored by measuring fluorescence (Ex360 nm; 
Em460 nm).  
Substrate  Z-Phe-Arg-AMC  H-D-Ala-Leu-Lys-AMC  
Inhibitor  Ki (µM) x 10
3  Ki (µM) x 10
3  
Leupeptin  3.34  1.8  
Chymostatin  4.06  1.18  







ND: Refers to bestatin (10 µM) and EDTA (10 mM) for which no reversible 
inhibition towards hydrolysis of peptides was observed. 
 
 
Table 2.4: Competitive irreversible inhibition of recombinant TviCATL. TviCATL 
(1.5 ng) pre-activated at 37°C in assay buffer (100 mM Bis-Tris, pH 6.5, 4 mM EDTA, 
0.02% (w/v) NaN3, 8 mM DTT) was incubated with competitive irreversible inhibitors 
(28 nM ).The hydrolysis of the specific substrates Z-Phe-Arg-AMC and H-D-Ala-Leu-
Lys-AMC was monitored by measuring fluorescence (Ex360 nm; Em460).                                                                                                                                                                                                                                                                                     
Substrate  Z-Phe-Arg-AMC  H-D-Ala-Leu-Lys-AMC 
Inhibitor  kass (mM
-1.s-1)a t1/2 (s)  kass (mM
-1.s-1)a 𝑡1 2⁄  (s)  
Iodoacetate  71.4±0.025                                                             319  71.4±0.025                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           319
Iodoacetamide 35.70±0.01  638  35±0.025                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      639
Z-Gly-Leu-Phe-
CMK  
28.57±0.02  798  7.1±0.01 3192 
a kass ± SD (n=3) 
No inhibition was detected using PMSF (phenylmethanesulfonyl) and TPCK (L-1-







Figure 2.15: Lineweaver-Burk plots for determination of the substrate specificity of 
TviCATL. TviCATL was reacted with a series of peptide substrates over a range of 
concentrations. The substrate concentrations and relative steady state velocity, v0 values were 
subjected to Hyper32
©






The effective control of the neglected tropical disease, African animal trypanosomiasis 
depends on an accurate species-specific diagnostic tool at an early developmental 
stage of the parasitic infection, followed by treatment with trypanosome-specific 
chemotherapeutic drugs. A cysteine protease TviCATL from T. vivax is thought to be 
involved in pathogenesis, therefore serves as a good target for the development of 
effective diagnostic tools. In the present study, TviCATL was recombinantly expressed, 
purified and enzymatically characterised for possible use as a diagnostic target. 
There is a wide variety of prokaryotic and eukaryotic expression systems available for 
the production of recombinant proteins. Each system is associated with advantages 
and disadvantages, therefore, recombinant expression of proteins remain a matter of 
trial-and-error. Factors such as resultant protein stability, folding, solubility, 
posttranslational modifications and production yields, are considered when choosing 
an expression system for recombinant protein production (Goeddel, 1990). The 
prokaryotic Escherichia coli is usually the first choice for heterologous expression of 
proteins (Baneyx, 1999). The E. coli expression system is preferable due to rapid 
growth in inexpensive media and availability of a variety of cloning vectors and host 
strains (Terpe, 2006). The shortcomings associated with the E. coli expression system 
include production of unfolded or inactive proteins or inclusion of the expressed protein 
in the insoluble inclusion bodies, lack of posttranslational modifications and 
overexpression of proteins is associated with accumulation of endotoxins that are 
detrimental to bacterial cell growth and biomass production which in turn results in 
altered protein expression patterns (Makrides, 1996; Hoffmann & Rinas, 2004). 
The first papain-like protease to be expressed in an E. coli system containing a T7 
promoter was a human cysteine protease, cathepsin L, for which expression levels 
were very low and the resultant protein was included in inactive insoluble aggregates 
(Smith & Gottesman, 1989). An attempt to express TcoCATL from T. congolense in an 
E. coli system was unsuccessful as it yielded incorrectly folded and inactive enzyme. 
However, expression of an active enzyme at marginal yields was achieved through a 
more expensive and complicated Balculovirus expression system (Boulangé et al, 
2001). A cysteine protease from Leishmania braziliensis  was also expressed in E. coli 
mostly as an insoluble protein where denaturation followed by on column re-naturation 
steps were the only options to harvest the refolded and active enzyme (Lanfranco et al, 
2008). In an attempt to evaluate the potential of alanyl aminopeptidases from T. 




These proteases were expressed as insoluble fusion proteins which required 
solubilisation and refolding steps to attain the enzyme activity (Pillay et al, 2013a). 
Due to the shortcomings of the expression systems mentioned above, the eukaryotic 
methylotrophic yeast Pichia pastoris has been identified as an alternative expression 
system for heterologous proteins (Macauley-Patrick et al, 2005; Cregg, 2007; Li et al, 
2007). The common advantages of the P. pastoris expression system over bacterial 
expression include posttranslational modifications such as glycosylation, disulfide bond 
formation, proteolytic processing, folding, and maximal biomass production on a 
defined medium with minimal salt content (Cregg & Higgins, 1995; Wu & Letchworth, 
2004). This expression system also constitutes a leader or signal sequence (prepro-
peptide α-factor of Saccharomyces) which allows the secretion of the heterologous 
protein into expression media. Another remarkable advantage of the Pichia system is 
its insignificant secretion of endogenous proteins and this promotes high levels of 
expression of heterologous proteins in expression media, and this significantly 
simplifies the purification procedure (Laroche et al, 1994). Examples of successful 
expression of trypanosomal cysteine proteases in the Pichia system include: TcoCATL 
variants that were expressed at maximal yields as a soluble and active enzyme (Pillay 
et al, 2010; Boulangé et al, 2011) and TbrCATL from T. b. rhodesiense (Cazzulo et al, 
1990). Also, the surface antigens called invariant surface glycoprotein (ISG75) from T. 
b gambiense as well as the variant surface glycoprotein (VSG) RoTat 1.2 from T. 
evansi, were successfully expressed in the Pichia system (Rogé et al, 2013).   
In the present study, the successful expression and enzymatic characterisation of the 
catalytic domain, TviCATL, from T. vivax was reported. TviCATL was successfully 
expressed at maximal yields and activity in the P. pastoris GS115 system. The overall 
yield obtained was significantly higher than that reported by Vather (2010). TviCATL 
migrated on reducing SDS-PAGE as two bands at 29 and 33 kDa. The presence of two 
bands suggested that the secreted protein may be asparagine-glycosylated as 
expected when using the P. pastoris expression system (Macauley-Patrick et al, 2005). 
Upon treatment of TviCATL with endoglycosidase H, which cleaves between a 
chitobiose (two linked N-acetyl glucosamine residues) core of high mannose-type N-
linked glycoproteins (Maley et al, 1989), the double band was transformed into a single 
band at approximately 29 kDa, and the band at 33 kDa disappeared. This suggests 
that the potential glycosylation site (Figure 2.1), Asn288 (as predicted by NetNGlc 1.0 
server, www.cbs.dtv.dk/services/NetNglyc ), was deglycosylated. The Asn-
glycosylation of TbrCATL was also reported in the study conducted by Caffrey et al 




was determined by treatment with Asn-glycosidase PNGase F prior to electrophoresis. 
It was noted that the higher molecular weight band disappeared. This suggested that 
the glycosylation site (Asn295-Ala) was deglycosylated. 
When comparing the recombinant TviCATL to native TviCATL, native TviCATL was 
distinguished using chicken anti-TviCATL C-terminal extension peptide antibodies, as 
a band at 56 kDa (Jackson, 2011), while in the present study, the recombinant 
TviCATL was expressed as 29 and 33 kDa forms of protein. The reason for the higher 
molecular weight for the native protein is due to the fact that the native protein had an 
intact C-terminal extension, while in the recombinant catalytic domain form of TviCATL, 
the C-terminal extension was truncated. Beside the fact that the C-terminal domain 
was truncated, the pro-region of TviCATL was included in the expression constructs 
since it has been largely associated with correct folding, stability and secretion of many 
expressed cathepsins (Smith & Gottesman, 1989; Vernet et al, 1991). The importance 
of the prodomain for activity of CATL proteases was verified by the fact that when a 
variant of TcrCATL in which the prodomain was deleted, and expressed, the variant 
was inactive, unstable and prone to precipitation upon storage at cold temperatures 
(Eakin et al, 1992). The same phenomenon was observed for a variant of cathepsin L 
in which a prodomain was truncated  (Smith & Gottesman, 1989). 
As is the case of other cysteine proteases, the autocatalytic activation of TviCATL 
(removal of the pro-region) into a mature active enzyme, was facilitated by acidification 
of the expression supernatant (Vernet et al, 1991; Eakin et al, 1992). This activation is 
similar to that observed for recombinant TcrCATL, in which auto-processing of the 
proenzyme resulted in activation of the catalytic domain (Eakin et al, 1992). The fact 
that the recombinant catalytic domain of TviCATL can be expressed as a functional 
enzyme, proves and is in accordance with previous findings that the C-terminal domain 
is not essential for enzymatic activity of trypanosomal cysteine proteases (Eakin et al, 
1993). The successful expression of the catalytic domain of TviCATL is consistent with 
the expression of  its homologue, TcoCATL, which was relatively stable and expressed 
at five-fold higher levels than the native full-length form (Boulangé et al, 2011). 
The TPP purification technique was the first choice for the concentration of the large 
volumes of expression supernatants and the purification of the recombinant protease. 
Three phase partitioning is similar to conventional salting out, since both techniques 
employ ammonium sulfate as a precipitating agent. As compared to conventional 
salting out, TPP incorporates tertiary butanol which lessens the proteins’ density, thus 




sink with ammonium sulfate in salting out. Therefore, the protein-rich disc appears 
between the ammonium sulfate and t-butanol liquid phases (Pike & Dennison, 1989). 
The two bands of recombinant TviCATL observed in reducing SDS-PAGE analysis 
prior to purification were also observed after purification by TPP. This suggests that 
activation of the propeptide at pH 4.2 prior to TPP did not disrupt the glycosylation 
status of TviCATL. 
As the higher molecular weight contaminants were not sufficiently removed by TPP, 
molecular exclusion chromatography was used for purifying TviCATL to homogeneity. 
Notably, the 29 and 33 kDa bands were not fully separated, implying that 
chromatographic separation posed no effect on the glycosylation status of TviCATL. 
The final protein yield (589%) is higher than that obtained by a previous researcher, 
143% (Vather, 2010). The higher yields and specific activity after purification by TPP 
are consistent with the observation that many proteases’ activity is not altered by the 
presence of t-butanol. When proteinase K was purified by TPP, the specific activity 
was 210% as compared to 100% obtained for protease that was not TPP-purified. To 
understand the factors contributing to enhancement of the protease activity after TPP, 
the crystal structure of the TPP-purified protease was resolved. From the structure, it 
was concluded that activity enhancement is attributed to the rearrangement in the 
active site in which an acetate ion was introduced and that the protease appeared to 
exist in an excited state (Singh et al, 2001). The bands of the recombinantly expressed 
TviCATL, before purification and after purification by TPP and MEC, were efficiently 
recognised by antibodies raised against the full length inactive form of TviCATL. 
Consistent with a requirement shared by all cysteine proteases, TviCATL activity was 
stimulated by the presence of the reducing agent DTT, which is responsible for 
maintaining the active site cysteine residue in a reduced state (Mbawa et al, 1992; 
Troeberg et al, 1996). The pre-activated recombinant TviCATL enzyme, at very low 
amounts, showed high proteolytic activity in gelatin substrate SDS-PAGE. This activity 
was comparable to that observed for recombinant TcoCATL. However, the high level of 
gelatinase activity of recombinant TviCATL outweighs the activity reported for native 
TviCATL, for which no substantial gelatin proteolysis was observed under standard 
conditions (Jackson, 2011). The TviCATL gelatinase activity was inhibited in the 
presence of classical clan CA protease inhibitors such as E-64 and leupeptin.  
TviCATL in the constant ionic strength AMT buffer, had an optimum pH at 6.5 and 7.5 
against a peptide substrate. This pH optimum (6.5 and 7.5) is comparable to that 




even at acidic pH-values of 4-5 (Jackson, 2011). The neutral optimal pH of 
recombinant TviCATL makes it convincing that this parasitic protease could remain 
active in the bloodstream upon parasite lysis, and that TviCATL has potential to be a 
virulence factor. Recombinant TcoCATL is also active at pH-values of 6 or 6.5 (Mbawa 
et al, 1992; Pillay et al, 2010).  
The involvement of TviCATL in pathogenesis is supported by the fact that, at a pH 
around psychological pH, TviCATL was able to degrade endogenous protein 
substrates such as bovine haemoglobin, bovine serum albumin, bovine α2-
macroglobulin which is an endogenous inhibitor found in the host bloodstream, as well 
as type I collagen from rat tails (a model substrate). Also, the protein substrate 
fibrinogen, was degraded by native TviCATL (Jackson, 2011). The potential for 
hydrolysis of protein substrates by TviCATL is in accordance with the limited 
proteolysis of fibrinogen and bovine serum albumin reported for TcoCATL  isolated 
from the bloodstream form of the T. congolense life-cycle (Mbawa et al, 1992) as well 
as the hydrolysis of α2-macroglobulin by TcoCATL (Huson et al, 2009). The 
collagenolytic activity has been also reported for a prolyl oligopeptidase from T. brucei 
and is thought to allow the parasite to penetrate through the endothelial cells, cross 
blood barriers and multiply within the host (Bastos et al, 2010).    
The knowledge of the substrate specificity of trypanosomal proteases is essential for 
the development of inhibitors with anti-trypanosomal potential. The substrate specificity 
of all proteases depends on the characteristic of the amino acid (whether hydrophobic, 
basic or non-charged) on the substrate peptide sequence which is susceptible to 
hydrolysis by an enzyme. The position of the peptide bond to be cleaved also matters. 
This is called positional specificity, and is divided into: endopeptidases, 
aminopeptidases and carboxypeptidases (Nägler et al, 1999). TviCATL was reacted 
with fluorogenic substrates in order to find its substrate preference. For all CATL-like 
endoproteases, the P2 is known as a specificity determining position  (Turk et al, 1998). 
The significance of the presence of an amino acid residue in P2 of the substrate for 
hydrolysis is supported by the inability of the enzyme to hydrolyse the aminopeptidase 
substrate, H-Leu-AMC, which lacks a P2 site. The recombinant TviCATL showed a 
pronounced preference for hydrophobic residues Phe or Leu at P2 position. This 
preference also relies on the presence of the basic residues Arg or Lys in the P1 
position. Therefore, Z-Phe-Arg-AMC, H-D-Ala-Leu-Lys-AMC and H-D-Val-Leu-Lys-
AMC were the substrates with a relatively high kcat/Km ratio, therefore high affinity for 
the TviCATL active site for hydrolysis. The presence of structurally constrained 




potential of TviCATL even in the presence of Phe or Leu at the P2 position. This is 
evidenced by the relatively slow rate of hydrolysis of H-Pro-Phe-Arg-AMC. This 
preference for hydrophobic residues at P2 was also reported for the native TviCATL 
(Jackson, 2011), recombinant TcoCATL (Pillay et al, 2010; Vather, 2010), recombinant 
TcrCATL (Eakin et al, 1992; Nery et al, 1997) and TbbCATL (Lonsdale-Eccles & Grab, 
1987). These substrates considered as best substrates for recombinant TviCATL were 
able to somewhat discriminate the preferences between Phe and Leu at the P2 
position. This is evidenced by the fact that the kcat/Km of an endopeptidase substrate (Z-
Phe-Arg-AMC) containing Phe at P2 position is larger than that of the substrate 
containing Leu at P2 (H-D-Ala-Leu-Lys-AMC). This preference for Phe over Leu at P2 
was also reported for TcrCATL and TcoCATL (Caffrey et al, 2001; Jackson, 2011). 
However, TbrCATL showed an equal preference for Phe and Leu at P2, and this is 
attributed to the presence of an Ala residue at the bottom of the S2 position, making it 
difficult to hydrolyse arginine-containing substrates (Caffrey et al, 2001). 
The ability of TviCATL to cleave Z-Pro-Arg-AMC was a new characteristic observed for 
this protease. Z-Pro-Arg-AMC is the specific substrate for mammalian cathepsin K, 
which has a marked preference for proline residues at the P2 position (Lecaille et al, 
2003). The ability of TviCATL to hydrolyse a cathepsin K substrate could be explained 
by the fact that the residues at the bottom of the S2 subsite of TviCATL and TcoCATL 
are identical to residues of the S2 of cathepsin K which contains Leu205 (papain 
numbering). The ability to hydrolyse a proline containing peptide substrate is consistent 
with the finding that TviCATL is able to cleave a protein substrate, collagen which is a 
proline-rich substrate. This preference is in contrast with the specificity of cathepsin B 
proteases which has a glutamyl residue in position 205 (papain numbering) at the 
bottom of the S2 subsite. The presence of a glutamyl residue accounts for dual 
specificity of cathepsin B and TcrCATL at which both Arg and Phe are preferentially 
accommodated at the P2 position (Musil et al, 1991; McGrath et al, 1995; Chagas et al, 
1997; Gillmor et al, 1997). Therefore the inability of TviCATL to cleave Z-Arg-Arg-AMC 
suggests that this protease lacks the cathepsin B-like activity.  
The enzyme was effectively inhibited by the reversible aldehyde inhibitors antipain, 
chymostatin and leupeptin, which contain a basic arginine residue at P1. This inhibition 
further confirms that the enzyme prefers a basic Arg residue at P1. This inhibition is 
similar to that reported for native TviCATL (Jackson, 2011), native and recombinant 
TcoCATL (Pillay et al, 2010; Vather, 2010) and TcrCATL (Garcia et al, 1998). The lack 
of inhibition of the TviCATL peptidase and gelatinase activity by bestatin which 




suggests that TviCATL is not an aminopeptidase; therefore the synthesis of specific 
potent inhibitors against TviCATL requires that the N-terminus of the peptide is 
blocked. The enzyme was insensitive towards the addition of the metalloprotease 
inhibitor, EDTA, but it rather activated the gelatinase activity of the enzyme probably by 
chelating all the ions that might have been reactive towards the SH group in the active 
site. 
The effective inhibition of TviCATL hydrolytic activity against specific fluorogenic 
peptide and gelatin substrates by thiol-specific irreversible inhibitors such as E-64, 
iodoacetate and iodoacetamide, further confirm that TviCATL is a cysteine protease. 
The recombinant TviCATL was partially inhibited by Z-Gly-Leu-Phe-CMK. The native 
TviCATL was also inhibited by this inhibitor as well as by H-D-Ala-Phe-Lys-CMK 
(Jackson, 2011). These inhibition patterns further show that in P2, Phe and Leu 
residues are important for efficient substrate hydrolysis.  
In the work reported in this chapter, recombinant TviCATL was successfully expressed 
and purified to homogeneity. Enzymatic characterisation of TviCATL was conducted in 
order to evaluate the pH optimum, substrate specificity, interaction with reversible, 
irreversible and host protease inhibitors. It can be concluded that recombinant 
TviCATL have a pronounced preference for hydrophobic residues Phe or Leu at P2 
position, and that its activity is inhibited by the class specific cysteine protease 
inhibitors. TviCATL also have the activity against host serum protein at physiological 
pH. Further studies such as RNA interference (RNAi) gene silencing are necessary 
steps towards determining if TviCATL is a pathogenic factor. In work described in the 
next chapter, recombinant TviCATL was used for antibody production and to find scFvs 
binders in the Nkuku® semi-synthetic phage display library in order to evaluate the 
















ANTIBODY PRODUCTION IN CHICKENS AND SELECTION OF SINGLE-CHAIN 




To effectively control African animal trypanosomiasis, it is of paramount importance to 
develop sensitive and species-specific point-of-care serological diagnostic tests that 
are affordable to the end-users. Antigen and antibody detection enzyme-linked 
immunosorbent assays (ELISAs), in an indirect  or inhibition format, are the commonly 
used serological tests that are affordable, and relatively simple procedures for large 
scale screening (Luckins, 1977; OIE, 2012). Both antigen and antibody detection 
ELISAs have been used for diagnosis of T. vivax, T. congolense and T. brucei infection 
in cattle (Nantulya & Lindqvist, 1989; Eisler et al, 1998; Bossard et al, 2010; Pillay et al, 
2013b; Fleming et al, 2014; Zhou et al, 2014) as well as T. evansi infections in 
buffaloes and horses (Singh et al, 1995; Lejon et al, 2005; Tran et al, 2009). The 
efficacy of some of these antigen and antibody detection ELISAs is limited by the 
requirement of the whole or crude parasite lysates which are unstable. Furthermore 
there is a lack of standardisation for antigen preparations, need for ethical clearance 
for culturing parasites in vivo, as well as the lack of reproducibility of the procedure 
(Greiner et al, 1997; Rebeski et al, 2000; Desquesnes et al, 2009).  
Therefore, to circumvent the challenges mentioned above, it is necessary to screen for 
antigens with immunodiagnostic potential. Research has focused on serological 
antibody tests using trypanosomal antigens that are recombinantly produced. These 
antigens are non-variant and immunogenic trypanosomal antigens which have been 
identified as suitable candidates for serodiagnostic purposes. These antigens include: 
heat shock protein 70 (HSP70) closely related to a mammalian immunoglobulin binding 
protein (BiP) (i.e. BiP/HSP70) in sera of T. congolense infected cattle (Boulangé & 
Authié, 1994; Boulangé et al, 2001; Boulangé et al, 2002; Bannai et al, 2003; Bossard 




(Tran et al, 2008) and flagellar associated-protein, GM6 from T. vivax (Pillay et al, 
2013b) and TcP46 from T. congolense (Fleming et al, 2014; Zhou et al, 2014). Further 
antigens serve as potential diagnostic antigens because they express tandem repeat 
domain which largely elicit B-cell response in trypanosomal parasites such as T. evansi 
(Goto et al, 2011; Thuy et al, 2012).  
Trypanosomal cysteine proteases are virulence factors involved in the pathogenesis of 
African animal trypanosomiasis hence may serve as plausible immunodominant 
antigens for the development of serodiagnostic tools for AAT (Authié et al, 1992; 
Authié et al, 2001; Lalmanach et al, 2002). Serological diagnosis through an inhibition 
ELISA format has an advantage that it can be used to diagnose trypanosomiasis in 
different species without the need for different anti-species enzyme-labelled detection 
antibodies. The inhibition ELISA format requires that enough antibodies against the 
target recombinant antigen are produced. Egg yolk immunoglobulin (IgY) technology is 
a preferred method for the generation of antibodies. Immunoglobulin IgY which is 
equivalent to mammalian IgG, is isolated from chicken egg yolks (Polson et al, 1980). 
Immunoglobulin IgY antibodies are advantageous in that they are produced at high 
concentrations and titres against parasite antigens (Morty et al, 1999; Eyssen, 2014), 
lack cross-reactivity with mammalian IgGs, therefore serve as an inexpensive source 
of antibodies for diagnostic purposes (Hädge & Ambrosius, 1984; Larsson et al, 1993; 
Kricka, 1999; Dias da Silva & Tambourgi, 2010). Alternatively, the need for animal 
immunisation for antibody production can be replaced by panning with TviCATL for 
single-chain variant fragments (scFvs) acquired from the semi-synthetic phage display 
library called Nkuku® chicken antibody reptoire as described by Van Wyngaardt et al 
(2004). The phage-produced scFvs are considered as renewable immunoreagents for 
diagnostic purposes using an easily standardised ELISA assay. The phage-produced 
scFvs can be sequenced to confirm their identity and the soluble scFvs can be 
produced in large quantities by heterologous expression systems (Verma et al, 1998; 
Fehrsen et al, 2005b; Chiliza et al, 2008; Rakabe et al, 2011; van Wyngaardt et al, 
2013). 
In this chapter, the production, purification and characterisation of IgY antibodies 
against the recombinant cysteine protease, TviCATL is reported. These antibodies 
were characterised by ELISA and western blot analysis and used in an antibody 
detection inhibition ELISA format for diagnosis of trypanosomiasis in sera from 
experimentally infected cattle. The initial Nkuku® phage display trials for the production 





3.2 Production of anti-TviCATL IgY antibodies in chickens 
3.2.1 Materials 
Chicken IgY antibodies: Freund’s complete and incomplete adjuvants and rabbit anti-
chicken IgY-HRPO conjugate were obtained from Sigma (Munich, Germany). Nunc®- 
Immuno™ 96-well plates and Nunc® Black 96-well plates were purchased from Nunc 
(Intermed, Denmark). Filter paper was obtained from Whatman (Middlesex, UK). 
Aminolink® matrix was purchased from Pierce (Rockford, IL, USA). ABTS was from 
Roche (Mannheim, Germany). The PageRuler™ prestained or unstained protein 
ladders (M) were from Thermo Scientific (Lithuania). Novex® ECL Chemiluminescent 
Substrate Reagent Kit was obtained from Invitrogen™ (Van Allen Way, California). 
 
T. congolense-infected sera: Sera from infected (labelled as +) and non-infected 
(labelled as -) cattle were obtained from ClinVet International (PTY) LTD, 
Bloemfontein, South Africa. 
 
Nkuku® phage display library: TG1 E. coli cells, M13KO7 helper phage and Nkuku® 
library stocks were obtained from Prof. Dion du Plessis, Immunology Division, 
Onderstepoort Veterinary Institute, Onderstepoort, 0110, Republic of South Africa. 
Immuno™ Tubes Nunc® Maxisorp were purchased from Nunc Intermed (Roskilde, 
Denmark). Corning® Costar® cell culture plates, 96 well with low evaporation lid were 
from Corning (USA). HRP-labelled-anti-M13 mAb was purchased from Amersham 
(Pharmacia, Biotech, USA). Sheep or goat anti-mouse IgG-HRPO conjugates were 
obtained from Sigma (Munich, Germany).  
3.2.2 Immunisation of chickens 
The MEC-purified TviCATL (Section 2.2.4) was used for immunisation of chickens to 
raise anti-TviCATL IgY antibodies. Briefly, three chickens were injected intramuscularly 
into the breast muscle with 50 µg antigen emulsified in Freund’s complete adjuvant [1:1 
(v/v)]. The chickens received three immunisation boosts (at weeks 2, 4 and 6) with 50 
µg antigen emulsified in Freund’s incomplete adjuvant [1:1 (v/v)]. Eggs were collected 




3.2.3 Isolation of IgY from egg yolks 
The polyethylene glycol (PEG) precipitation method described by Polson et al (1980) 
and modified by Goldring and Coetzer (2003) was used for the isolation and 
purification of IgY from egg yolks. Briefly, under running water, the egg yolk was 
separated from the egg white and and then poured into a measuring cylinder. The yolk 
volume was determined, and mixed with 2 volumes of IgY isolation buffer [100 mM Na-
phosphate buffer, pH 7.6, 0.02% (w/v) NaN3], followed by the addition of 3.5% (w/v) 
solid polyethylene glycol (PEG) Mr 6 000. After gently dissolving the PEG, the mixture 
was centrifuged (4 420 x g, 30 min, RT) and the lipid fraction removed from the 
supernatant by filtering through absorbent cotton wool. The volume of the filtered 
supernatant was determined and 8.5% (w/v) PEG dissolved in this supernatant. After 
centrifugation (12 000 x g, 10 min, RT), the pellet was resuspended in IgY isolation 
buffer in a volume equivalent to that obtained after filtration. Polyethylene glycol [12.5% 
(w/v)] was added, dissolved by magnetic stirring and centrifuged (12 000 x g, 10 min, 
RT). The IgY buffer containing [0.1% (w/v)] sodium azide was used to resuspended the 
final resultant antibody pellet in 1/6 of the original yolk volume. The concentration of 
each IgY pool was determined by measuring the A280 nm of IgY diluted 1/40 in IgY 
buffer, and the concentration of the undiluted IgY was calculated using the extinction 
coefficient,  1.25 = E280 nm
1 mg/ml
 (Goldring & Coetzer, 2003). 
3.2.4 Enzyme-linked immunosorbent assays (ELISA) and cross-reactivity of 
trypanosomal antibodies 
The ELISA was used to evaluate the antibody production and cross-reactivity of these 
antibodies with other trypanosomal antigens. The 96-well ELISA plates were coated 
overnight at 4°C with TviCATL antigen (0.5, 1 or 2 µg/ml, 150 µl per well) diluted in 
PBS, pH 7.2. The unoccupied sites on the wells were blocked by incubating with 
blocking buffer [0.5% (w/v) BSA-PBS; 200 µl per well] for 1 hour at 37°C. The wells 
were washed 3x with PBST [PBS-0.1% (v/v) Tween-20] using a BIOTEK® ELx50™ 
Microplate washer (BioTek® Instruments, Inc., USA) and incubated for 2 hours at 37°C 
with chicken anti-TviCATL IgY diluted in blocking buffer (100 µl per well). After washing 
3x with PBST, the wells were incubated for 1 hour at 37°C with rabbit anti-chicken IgY-
HRPO conjugate (1:10 000, 100 µl per well) diluted in the blocking buffer. Colour 
development in the dark followed addition of the chromogen-substrate solution [0.05% 
(w/v) ABTS; 0.015% (v/v) H2O2 in 150 mM citrate phosphate buffer, pH 5; 145 μl per 




was used to monitor the absorbance at 405 nm every 15 min until an absorbance at 
405 nm was as close as possible to 1. 
3.2.5 Western blot analysis 
Western blot analysis was conducted as described in Section 2.2.8 
3.2.6 Preparation of TviCATL affinity column for purification of IgY antibodies 
Aminolink® resin (2 ml of 50% resin slurry) was added to the affinity chromatography 
column to provide 1 ml gel after settling. The resin storage solution was drained, but 
at all times, the resin bed was never allowed to get dry. The column was equilibrated 
by adding 3-resin-bed volumes (3 ml) of pH 10 coupling buffer [0.1 M sodium citrate 
dihydrate, 0.05 M sodium carbonate, pH 10]. After draining the pH 10 coupling buffer, 
the column was capped at the bottom, followed by addition of 1 ml MEC-purified 
TviCATL protein (3 mg/ml) diluted in pH 10 coupling buffer. Protein sample (100 µl) 
was kept for determination of the coupling efficiency. The resin and the protein were 
allowed to mix for 4 hours at room temperature using an end-over-end rotor. This 
continual rotation allowed the resin aldehydes to react with the primary amine of the 
proteins through the formation of unstable Schiff base bonds. The unbound protein 
was drained into a new collection tube, and the column washed with 3 ml pH 7.2 
coupling buffer. To form stable secondary amine bonds between the resin aldehydes 
and the protein, 1 ml of pH 7.2 coupling buffer containing 50 mM sodium 
cyanoborohydride was added to the column reaction slurry and mixed on an end-over-
end rotor overnight at 4°C. The unoccupied sites were then blocked by passing 
through 2 ml quenching buffer (1 M Tris-HCl, pH 7.2), followed by addition of 1 ml 
quenching buffer supplemented with 50 mM sodium cyanoborohydride to form stable 
secondary amine bonds between aldehydes and the Tris, and mixed by end-over-end 
rotating for 30 minutes at room temperature. The column was washed with 
approximately 5 ml wash solution (1 M sodium chloride) until A280 nm = 0 was reached. 
The column resin was then washed with 3 ml PBS containing 0.05% (w/v) sodium 
azide and the column stored upright at 4°C with at least 1 ml of this buffer covering the 
resin bed. To determine the coupling efficiency, the concentrations of TviCATL prior to 
coupling and the eluted unbound protein were measured. The coupling efficiency was 




3.2.7 TviCATL affinity purification of chicken anti-TviCATL IgY antibodies  
The ELISA was used to identify antibody pools (from eggs from each of the three 
chickens) with high antibody titres. The antibody pools were filtered through Whatman 
no.1 filter paper before passing through the TviCATL affinity column pre-equilibrated 
with 3 ml PBS. The antibody pool was allowed to pass through the resin in a forward 
direction and the flow rate was controlled using a Micro Tube pump MP-3 (Tokyo 
Rikakikai, Japan), followed by reversing the direction of flow and this reverse cycling 
was allowed to continue for overnight at RT. The unbound antibodies were eluted 
(through forward direction of flow) and the column washed with 10 ml PBS. The bound 
antibodies were eluted using IgY elution buffer [0.1 M glycine-HCl, pH 2.8]. These 
antibodies (900 µl per fraction) were eluted into collection tubes containing 100 µl 
neutralisation buffer [1 M NaH2PO4, 0.02% (w/v) NaN3, pH 8.5]. Antibody elution was 
monitored by measuring A280 nm. The fractions with the highest A280 nm values were 
pooled, and the concentration determined by dividing the A280 nm values by the IgY 
extinction coefficient, 1.25. 
3.2.8 Antibody detection in an inhibition ELISA format  
The ability of T. congolense infected sera to prevent the binding of chicken anti-
TviCATL IgY antibodies to the immobilised capture TviCATL antigen on the plate was 
investigated in an inhibition ELISA format (Figure 3.1) as described by Bossard et al 
(2010). The 96-well ELISA plates were coated at 4°C for 16 hours with TviCATL (5 
µg/ml, 100 µl per well) diluted in PBS, pH 7.2. Each serum was tested in triplicate and 
the corresponding uncoated triplicate wells were included as a no coat control. After 
blocking the nonspecific sites with 200 µl per well blocking buffer [0.5% (w/v) BSA-
PBS-0.1% (v/v) Tween-20] for 1 hour at 37°C, the wells were washed 3x with PBST 
[PBS-0.1% (v/v) Tween-20] using a BIOTEK® ELx50™ Microplate washer. The wells 
were then incubated for 1 hour at 37°C with the respective bovine serum samples 
(1:100, diluted in blocking buffer). The no serum control quadruplicate wells were 
included and incubated with blocking buffer instead of serum. The wells were washed 
3x with PBST and incubated for 1 hour at 37°C with affinity purified chicken anti-
TviCATL IgY (5 µg/ml, 100 µl per well) diluted in blocking buffer. After washing 3x with 
PBST, the wells were incubated for 1 hour at 37°C with rabbit anti-chicken IgY-HRPO 
conjugate (1:10 000, 100 µl per well) diluted in blocking buffer. The plate was washed 
3x and incubated with the substrate solution [0.05% (w/v) ABTS; 0.015% (v/v) H2O2 in 




absorbance values at 405 nm using a FLUOStar Optima microplate reader (BMG 
Labtech, Offenburg, Germany). 
The average absorbance (triplicate samples, antigen-coated wells) for each serum was 
calculated and corrected by subtracting the average absorbance (triplicate samples, 
non-coated wells) of the corresponding uncoated control wells. The average 
(quadruplicate samples, antigen-coated wells) for no serum control (0% inhibition) was 
determined and also corrected by subtracting the average of the uncoated wells. The 
percentage (%) inhibition was determined using the following equation: 
% inhibition =
A405 nm (no serum control)−A405 nm ( serum)
A405 nm (no serum control)





Figure 3.1: Schematic diagram summarising the steps in an inhibition ELISA format. 
There is a final colour development which in turn results in a signal at A405 when a non-infected 
serum is used (A) while there is no colour development which in turn results in no signal at A405 




3.2.9 Assay for immunoinhibition of TviCATL activity by chicken anti-TviCATL 
antibodies 
The influence of chicken anti-TviCATL antibodies on the activity of TviCATL was 
investigated as described by Troeberg et al (1997) and Huson et al (2009). TviCATL 
(100 ng active enzyme) diluted in 0.1% (w/v) Brij-35 was incubated for 15 minutes at 
37°C with anti-TviCATL IgY (1000-15 µg/ml) serially diluted in phosphate buffer [200 
mM sodium phosphate buffer, pH 7.2, 4 mM Na2EDTA and 0.1% (v/v) Tween-20]. The 
incubation mixture at each respective concentration was aliquoted (50 µl in triplicate) 
into 96-well Nunc® Black plates and activated with TviCATL assay (25 µl) buffer 
containing 8 mM DTT for 1 min at 37°C. This was followed by the addition of 25 µl Z-
Phe-Arg-AMC (20 µM) and further incubation at 37°C for 5 min. The rate of hydrolysis 
of Z-Phe-Arg-AMC was measured by reading fluorescence (Ex360 nm; Em460 nm) using 
the FLUORStar Optima spectrophotometer (BMG Labtech, Offenburg, Germany).   
3.3 Nkuku® phage display for production of scFvs monospecific antibodies 
3.3.1 Culturing the E. coli TG1 cells 
The E. coli TG1 glycerol stock was streaked on TYE agar [15 g agar, 8 g NaCl, 1 g 
tryptone, 5 g yeast in 1L double distilled deionised water]. After allowing the colonies to 
grow at 37°C overnight, a single colony was inoculated in 5 ml 2xYT medium [16 g 
tryptone, 10 g yeast extract, 5 g NaCl dissolved in 1L double distilled deionised water] 
and left to grow overnight at 37°C (220 rpm shaking incubator). One ml of the overnight 
culture was diluted in 100 ml 2xYT medium and allowed to grow at 37°C until the log 
phase was reached (OD600 = 0.5), followed by storage at 4°C and used within 5 days 
(or as fresh as possible). The TG1 glycerol stock was made by adding glycerol [15% 
(v/v) final concentration] to the overnight cultured TG1 cells and kept at -70°C. 
3.3.2 Titering and culturing M13KO7 helper phage 
To determine the concentration (plaque forming units per ml) of the initial M13KO7 
glycerol stock, serial dilutions (10-2-10-10) were made in sterile 2xYT medium. To 
induce the bacterial infection by phages, 100 µl of the respective dilutions were mixed 
with 100 µl of the log phase TG1 cells for 5 min at room temperature. This mixture 
together with 3 ml top agar [44°C 2xYT containing 0.7% (w/v) agar], were sprinkled on 
the set pre-warmed 2xYT plates containing 1.5% (w/v) agar, and swirled gently to allow 




inverted and incubated at 37°C overnight. The pfu/ml was determined for plates with 
30 ≥300 plaques (single distributed plaques).  
 
To culture the M13KO7 cells, a single isolated plaque was punched out (from the 
titered plate) using the reverse end of a yellow pipette tip, inoculated into 4 ml 2xYT 
medium containing 40 µl overnight grown TG1 cells and finally incubated at 37°C (100 
rpm orbital shaking incubator for 2 hours). This primary culture was inoculated into 400 
ml 2xYT medium for 1 hour at 37°C (100 rpm shaking) followed by the addition of 50 
µg/ml kanamycin and left for further growth overnight. The overnight culture was 
centrifuged (10 800 x g, 15 min, 4°C) and the supernatant was precipitated with ¼ 
volume of phage precipitating buffer [20% (w/v) PEG Mr 6000, 2.5 M NaCl] for 30 
minutes on ice or 4°C. This was followed by two successive centrifugation steps: (10 
800 x g, 15 min, 4°C followed by 2000 x g, 2 min, 4°C). The final pellet was suspended 
in sterile PBS, filter-sterilised (0.22 µM) and the titer (pfu/ml) determined by measuring 
the absorbance at 268 nm as described by Tonikian et al (2007).  
3.3.3 Culturing the Nkuku® phagemid library 
The Nkuku® phagemid glycerol stock (~250 µl) was inoculated into 500 ml 2xYT 
medium containing 0.22 µm filter sterilised 2% (w/v) glucose and 100 µg/ml ampicillin. 
The volume of phagemid added was adjusted until the initial OD600 was as close as 
possible to 0.05. This culture was incubated at 37°C with shaking at 240 rpm until 
OD600 = 0.5. Once the log phase was reached, 100 ml of this phagemid culture was 
phage rescued with M13KO7 helper phage (8x 109 pfu/ml) at 37°C (30 minutes 
standing, 30 minutes shaking at 100 rpm). The rest of the phagemid culture was further 
grown for 3 hours, centrifuged (3300 x g, 15 min, 4°C), the pellet suspended in 1/100 
2xYT medium, followed by addition of 50% (v/v) glycerol to form a glycerol stock at a 
final glycerol concentration of 15% (v/v). The glycerol stock was kept at -70°C. The 
portion that was rescued by M13KO7 helper phage, was centrifuged (3300 x g, 15 min, 
4°C), pellet suspended in 1L 2xYT medium containing 100 µg/ml ampicillin and 25 
µg/ml kanamycin in a 5L flask. This culture was left overnight at 30°C (240 rpm orbital 
shaking incubator) overnight. The overnight culture was centrifuged (3300 x g, 20 min, 
4°C) and the supernatant precipitated in 1/4 (v/v) phage precipitating buffer [20% (w/v) 
PEG Mr 6000, 2.5 M NaCl] for 1 hour on ice, followed by two successive centrifugation 
steps: (3300 x g, 30 min, 4°C followed by 2000 x g, 2 min, 4°C). The final pellet was 
suspended in 20 ml PBS and re-centrifuged (11 000 x g, 2 min, 4°C). The supernatant 




3.3.4 Titering the Nkuku® phagemid library 
In order to determine the titre of the cultured library, the cultured Nkuku® phagemid 
library was titered through serial dilution (10-2-10-6) in 2xYT medium. The respective 
dilutions (100 µl) were infected for 5 minutes at room temperature with 100 µl log 
phase E. coli TG1 cells. The entire mixture (200 µl) was then spread onto pre-warmed 
TYE A/G plates [15 g agar, 8 g NaCl, 1 g tryptone, 5 g yeast in 1L double distilled 
deionised water; 2% (w/v) glucose and 100 µg/ml ampicillin]. The uninfected phagemid 
and TG1 cells alone were also spread on separate plates in order to monitor for 
contamination. Plates were inverted and incubated at 30°C overnight. The colony 
forming units (cfu/ml) was determined for the plates with 30 ≥300 colonies. The 
absence of colonies on the TG1 cells alone plate and the Nkuku® phagemid alone 
plate implied the absence of contamination. 
3.3.5 Selection/ panning of scFvs against TviCATL from the Nkuku® library 
The scFvs against recombinant TviCATL were selected from the Nkuku® phagemid 
library using an affinity selection method called bio-panning (Figure 3.2). TviCATL 
(100-10 µg/ml) diluted in PBS was coated into the immunotube and left overnight at 
4°C. The unbound antigen was removed by washing 3x with PBS. The unoccupied 
sites were blocked for 1 hour at 37°C with 5 ml 2% (w/v) Elite® fat-free milk powder in 
PBS. The immunotube was washed 2x with PBST [PBS-0.2% (v/v) Tween-20] followed 
by 2x washes with PBS alone. Pre-incubated (30 min, RT) Nkuku® phagemid library 
(3.5 ml; 1 x 1013 TU, diluted in PBST containing 2% (w/v) milk powder) was added. The 
immunotube was rotated for 30 min at RT using an end-over-end rotor, followed by 
standing for 90 minutes. After washing 20x with PBST followed by 20x washes with 
PBS alone, log phase TG1 cells (3.5 ml) were added to this immunotube and 
incubated for 30 min at 37°C, and placed on ice. This was centrifuged (3300 x g, 10 
min, 4°C) and the pellet suspended in 1 ml 2xYT medium. This 1 ml phage culture was 
plated onto 3 TYE/AG agar plates (~333 µl per plate) and incubated at 30°C overnight. 
The resultant colonies were suspended in ~10 ml 2xYT medium, and the glycerol stock 
made by adding glycerol to a final concentration of 15% (v/v). To obtain a large amount 
of phagemid from each panning round, ~500 µl of suspended colonies or prepared 
glycerol stock were inoculated into 50 ml 2xYT/AG medium and ensuring that the initial 
OD600 was as close as possible to 0.05. This phagemid culture was grown at 37°C until 
OD600 = 0.5. Five ml of this log phase phagemid culture was phage rescued with 




at 100 rpm. This culture was then centrifuged 2x (3300 x g, 10 min, 4°C) and the final 
pellet suspended in 25 ml 2xYT medium containing 100 µg/ml ampicillin and 25 µg/ml 
kanamycin. The culture was grown overnight at 30°C in a 240 rpm shaking incubator. 
The overnight culture was centrifuged (3300 x g, 20 min, 4°C) and the supernatant 
precipitated in 1/5 (v/v) phage precipitating buffer [20% (w/v) PEG Mr 6000, 2.5 M 
NaCl] for 1 hour at 4°C, followed by two successive centrifugation steps (3300 x g, 30 
min, 4°C). The final pellet was suspended with 1 ml PBS, followed by centrifugation 
(1100 x g, 2 min, RT). The supernatant was filter-sterilised through a 0.22 µm filter. 
Sterilised respective panning round phages (0.5 ml) were used for the next panning 
round at which the immunotubes were coated with TviCATL (100-10 µg/ml). The 
successive panning rounds were done up to a total of four rounds. 
3.3.6 Screening for binders by polyclonal phage ELISA 
The polyclonal ELISA was conducted in a similar way as the ELISA described in 
Section 3.2.4 except that 50 µl of TviCATL diluted in PBS was used for coating wells at 
concentrations of: 100, 75, 50, 25, 10 and 1 µg/ml. The control wells were coated with 
PBS. Wells were blocked with 300 µl 3% (w/v) BSA-PBS for 1 hour at 37°C. From each 
panning round, phage dilutions (1:200, 1:100, 1:50, 1:25) were made in 6% (w/v) BSA-
PBS-0.2% (v/v) Tween-20, followed by further dilution in an equal volume of 6% (w/v) 
BSA-PBS-0.2% (v/v) Tween-20. Each respective dilution (25 µl) was added to the 
respective wells and incubated at 37°C for 1 hour. After washing 3x with PBST [PBS- 
0.1% (v/v) Tween-20], the plate was incubated with 50 µl mouse-anti-M13 monoclonal 
antibody (1:8000 diluted in 3% (w/v) BSA-PBS-0.2% (v/v) Tween-20) for 1 hour at 
30°C. After washing 3x with PBST, the plate was incubated with 50 µl sheep anti-
mouse IgG-HRPO secondary antibody (1:1000 diluted in 3% (w/v) BSA-PBS-0.2% 







Figure 3.2: Flow diagram summarising the panning of Nkuku
®
 phage scFvs against 
recombinant TviCATL.  
 
3.3.7 Screening for phage-displayed binders by monospecific ELISA 
For each panning round with detectable polyclonal antibodies, the phage stock was 
titered as described in Section 3.3.4. Under sterile conditions near the flame, 48 single 
colonies were randomly picked and inoculated into individual wells of 96-well Costar® 




the incubator with shaking at 220 rpm. This plate was called the master plate. The 
glycerol stock was made by adding 50 µl 60% (v/v) glycerol and stored at -70°C. From 
the master plate, 5 µl inoculum per well was inoculated into a new individual plate wells 
containing 150 µl 2xYT A/G medium, and grown at 37°C for 2 hours at 220 rpm. This 
plate was called the clone plate. The phages in each well of the clone plate were 
rescued by adding 100 µl M13 helper phage (2 x 109 pfu/ml) diluted in 2xYT medium, 
followed by incubation at 37°C for 30 minutes. The plate was centrifuged (600 x g, 10 
min, RT), and all the supernatants were decanted. To each well containing the pellets, 
150 µl 2xYT medium (containing 100 µg/ml ampicillin and 25 µg/ml kanamycin) was 
added, and the plate incubated at 30°C overnight with shaking at 220 rpm. After 
centrifugation (600 x g, 10 min, 4°C), the supernatant was mixed with an equal volume 
of 4% (w/v) milk-PBS-0.2% (v/v) Tween-20. These phages were used for monospecific 




3.4.1 Evaluation by ELISA of chicken anti-TviCATL IgY antibody production 
A checkerboard ELISA (Crowther, 1995) was performed (results not shown) for the 
optimisation of TviCATL coating concentrations and primary antibody concentrations. 
The checkerboard titration curve indicated that 0.5 µg/ml TviCATL coating 
concentration probed with 75 µg/ml chicken anti-TviCATL IgY resulted in an optimal 
A405 signal. The progress of anti-TviCATL antibody production in eggs collected from 3 
chickens for a 16 week period was determined by ELISA (Figure 3.3). This ELISA 
shows that for chicken 1 there was a linear increase in antibody production from weeks 
1-8, after which a decrease was seen up to week 14, followed by an insignificant 
increase in signal at weeks 15 and 16. For chicken 1, two prominent peaks were 
observed at weeks 4 and 8. Chicken 2 and 3 showed a similar trend in that there was 
an increase in antibody production from weeks 1-6, followed by a drastic decrease at 
weeks 7-8, followed by a brief recovery at week 9 and a fluctuating pattern of antibody 
production from weeks 10-16. Chicken 2 showed prominent peaks of antibody 
production at week 6, 9 and 13, while chicken 3 showed prominent peaks of antibody 
production at weeks 6 and 9. Overall, chickens 1 and 3 showed the best antibody 





Figure 3.3: Evaluation by ELISA of antibody production in chickens (1, 2 and 3) 
immunised with recombinant TviCATL. The ELISA plates were coated with 0.5 µg/ml 
TviCATL. The immobilised antigen was probed with the primary antibodies isolated from each 
egg yolk (1 egg/chicken/week) over a period of 16 weeks. The antibodies were used at a 
concentration of 75 µg/ml as pre-determined by a checkerboard ELISA. Rabbit anti-chicken 
IgY-HRPO conjugate (1:15 000) was used for the detection of the interaction between TviCATL 
and anti-TviCATL antibodies. The colour development upon addition of ABTS-H2O2 substrate 
was monitored over 45 minutes (15 min intervals) at 405 nm and the average of duplicate 
samples plotted against week number. 
 
After determining the antibody production using 1 egg per week, the antibodies were 
isolated as pools based on results from the ELISA presented in Figure 3.3.  For 
chicken 1, pools were as follows: weeks 4-9, 10-13, and 14-16; chicken 2: weeks 5-9, 
10-13, and 14-16; and chicken 3: weeks 4-8, 9-13, and 14-16. The antibody titre of 
each IgY pool for each chicken was determined by primary antibody titration ELISA 
(Figure 3.4). This ELISA shows that the highest levels of antibody were found in pool 
4-9 for chicken 1 (Panel A), 4-8 for chicken 2 (Panel B) and 5-9 for chicken 3 (Panel 
C). The signals were lower than those reported in Figure 3.3, suggesting that pooling 
together different pools compromised the overall antibody titers. All anti-TviCATL IgY 
pools showed higher antibody responses than the pre-immune IgY. The IgY pools 
obtained from all chickens showed similar levels of anti-TviCATL antibodies, but 





Figure 3.4: The titration ELISA showing the antibody levels for chickens immunised with 
recombinant TviCATL. The ELISA plates were coated with TviCATL (0.5 µg/ml). The primary 
antibodies used were pools from each chicken (chicken 1: A, chicken 2:  B, and chicken 3: C) at 
concentrations ranging from 0.05-12.5 µg/ml. Rabbit anti-chicken IgY-HRPO conjugate (1:15 
000) was used for detection. The colour development upon addition of ABTS-H2O2 substrate 
was monitored over 45 minutes (15 min intervals) at 405 nm and the average of duplicate 
samples plotted against week number. 
 
In an attempt to improve the absorbance measured in the ELISA (A405 less than 1, 
Figure 3.4), further optimisation of the TviCATL coating concentrations was performed. 
Higher coating concentrations, 1 and 2 µg/ml were used and probed with 0.05-12.5 
µg/ml anti-TviCATL IgY pools from each of the 3 chickens which previously showed 
relatively high antibody levels (Figure 3.4). However, results showed no significant 
improvement in signal when plates were coated with 1 and 2 µg/ml TviCATL, Figure 
3.5. Once again for 1 µg/ml (Figure 3.5 A), chicken 1 weeks 4-9 pool showed the 
highest signal, while for 2 µg/ml (Figure 3.5 B), all the pools showed very similar 
signals as indicated by their curves bunched together around the same level. Improved 




further ELISA was conducted in order to optimise the secondary antibody 
concentrations (results not shown). The A405 signal improved (up to ~0.8), but it was 
noted that nonspecific background was accumulating since the pre-immune signal was 
very high (~0.35). 
 
 
Figure 3.5: Re-optimisation of TviCATL coating concentrations in order to improve signal 
at A405. ELISA plates were coated with 1 µg/ml (A) and 2 µg/ml (B) TviCATL. The primary 
antibodies used were IgY pools at the concentrations ranging from 0.05-12.5 µg/ml. Rabbit anti-
chicken IgY-HRPO conjugate (1:15 000) was used for detection. The colour development upon 
addition of ABTS-H2O2 substrate was monitored over 45 minutes (15 min intervals) at 405 nm 
and the average of duplicate samples plotted against week number. 
 
 
To improve the specificity of the chicken anti-TviCATL antibodies, the crude IgY 
antibody pools which showed relatively high levels of antibody isolated from each 
chicken’s eggs, were subjected to affinity purification using an affinity column prepared 
by immobilising TviCATL on an Aminolink® coupling resin. A satisfactory coupling 
efficiency of 72% (equivalent to 2.2 mg/ml) was obtained. The individual pools of 
chicken anti-TviCATL were separately cycled through the affinity column and specific 
antibodies eluted using low pH buffer (Figure 3.6). The elution profiles indicate that the 
pooled IgY from chicken 1 gave the highest absorbance (therefore highest antibody 
concentration) but only in one fraction, after which there was a drastic decrease in 
absorbance. The IgY pool from chicken 3 showed two fractions with an absorbance 
close to 1. In comparison to the IgY from chickens 1 and 3, the IgY from chicken 2 had 
the lowest absorbance values (less than 0.5) consistent with the results shown in 
previous Figures 3.3 and 3.4. Figure 3.6 also showed that even though the absorbance 




collected from three chickens, the elution profile was the same in the sense that at 





Figure 3.6: Elution profile for affinity purification of chicken anti-TviCATL IgY pools. The 
crude IgY was purified with TviCATL coupled to an Aminolink
®
 resin. The elution of pure IgY 
fractions was achieved by low pH buffer [0.1 M glycine HCl, pH 2.8] and monitored by 
measuring absorbance at 280 nm. 
 
 
An ELISA was conducted to evaluate the affinity purification of the chicken anti-
TviCATL IgY antibodies (Figure 3.7). The antibodies were successfully affinity purified 
as evidenced by the increase in A405 signals for the three affinity purified IgY 
preparations when compared to those obtained for the pre-purified crude IgY as well 
as the pre-immune IgY. It was noted that even though the A405 signal of the affinity 
purified antibodies was higher than that for the unbound IgY fraction, the signal of the 
unbound IgY was relatively high. This indicated that a large pool of antibodies did not 
bind to the resin, hence the unbound fraction was reapplied to the column to obtain as 





Figure 3.7: Evaluation by ELISA of affinity purification of anti-TviCATL IgY antibodies. 
The ELISA plates were coated overnight at 4°C with 0.5 µg/ml TviCATL in carbonate coating 
buffer, pH 9.6 and probed with antibodies (pre-purified crude IgY, affinity purified pools from 3 
chickens, unbound IgY from the affinity column and pre-immune IgY) serial diluted from 100-
0.718 µg/ml. Rabbit anti-chicken IgY-HRPO conjugate (1:10 000) was used for detection. The 
colour development upon addition of ABTS-H2O2 substrate was monitored over 45 minutes (15 
min intervals) at 405 nm and the average of duplicate samples plotted against log chicken IgY 
concentrations. 
 
3.4.2 Cross-reactivity of anti-trypanosomal antigen antibodies 
An ELISA was conducted to check the possibility of cross-reactivity of antibodies 
against trypanosomal antigens with similar characteristics. In this ELISA, TviCATL and 
TcoCATL antigens were probed with chicken anti-TviCATL, chicken anti-TcoCATL, 
chicken anti-TcoCATL N-terminal peptide (TcoCATLpept) and chicken anti-full length 
TcoCATL (TcoCATLFL) antibodies. Figure 3.8 indicates that each antibody showed 
best recognition of its specific antigen and some cross-reactivity with the homologue 
was observed. This was evidenced by the lower signals obtained where the chicken 
anti-TcoCATL IgY and chicken anti-TcoCATLpept IgY were titrated against TviCATL or 
where chicken anti-TviCATL IgY was titrated against TcoCATL. However, it was noted 
that the chicken anti-TcoCATLFL IgY showed substantial cross-reaction with TviCATL. 
The pre-immune IgY antibodies shows a dose dependent increase in binding, 
however, the level of binding is less than the level at which the antibodies were used to 
detect their specific antigens. Overall, these results indicate that the cross-reactivity of 





Figure 3.8: Evaluation by ELISA of cross-reactivity of anti-trypanosomal antigen 
antibodies. The ELISA plates were coated overnight at 4°C with 1 µg/ml TviCATL or TcoCATL 
and probed with chicken antibodies (affinity purified anti-TviCATL, anti-TcoCATLFL, and anti-
TcoCATLpept, non-affinity-purified anti-TcoCATL and the pre-immune IgY) serial diluted from 
100-0.718 µg/ml. Rabbit anti-chicken IgY-HPRO conjugate (1:10 000) was used for detection. 
The colour development upon addition of ABTS-H2O2 substrate was monitored over 45 minutes 
(15 min intervals) at 405 nm and the average of duplicate samples plotted against log chicken 
IgY concentrations. 
 
3.4.3 Serological antibody-detection in an inhibition ELISA format 
The diagnostic potential of TviCATL was assayed in an inhibition ELISA using sera 
from cattle experimentally infected with T. congolense. The T. vivax infected sera were 
not available, hence only T. congolense sera were used. The sera from cattle prior to 
experimental infection were called [185 (-6), 109 (-7) and 183 (-10)] and sera collected 
post-infection were labelled as [181 (+19), 18 (+23), 149 (+28) and 152 (+45)]. Figure 
3.9 indicates that in the presence of uninfected cattle serum, there was no inhibition as 
expected. This is because pre-infection sera do not contain antibodies against the 
coated TviCATL antigen on the ELISA plate; therefore there is no antigen-serum 
interaction, hence the chicken anti-TviCATL IgY binds to the coated antigen which in 
turn results in binding of HRPO labelled rabbit anti-chicken IgY. When the substrate is 
added, there will be colour development, thus absorbance at 405 nm. When a positive 
serum is added that contains anti-TviCATL antibodies, these would bind to the coated 
TviCATL antigen and hence the chicken anti-TviCATL IgY will not be able to bind, 
resulting in decreased binding of HRPO labelled rabbit anti-chicken IgY and lower A405-




(+23), 149 (+28) and 152 (+45)], inhibition up to approximately 22% was observed for 
positive sera as expected since the sera could contain antibodies against the coated 
antigen. The results show discrimination between negative and positive sera and 
suggests cross-reactivity between TcoCATL (in the sera) and the chicken anti-TviCATL 
IgY antibodies.  
To validate the observed results where there was some cross-reactivity between 
TcoCATL (in sera) and chicken anti-TviCATL antibodies, it was necessary to compare 
these findings with results obtained for the positive control [i.e. ELISA plates coated 
with TcoCATL/ TcoCATLFL, probed with TcoCATL sera (same sera used for TviCATL 
inhibition ELISA), followed by chicken anti-TcoCATL/ anti-TcoCATLFL antibodies and 
detection with rabbit anti-chicken IgY-HRPO). Due to the limitation of these antigens 
and the sera, these results were obtained from Eyssen (2014) for comparative 
purposes only. The means to optimise the TcoCATL inhibition ELISA was 
unsuccessful, only the indirect antibody ELISA was successfully optimised. Therefore, 
the TviCATL inhibition ELISA findings of the present study were compared with those 
obtained by Eyssen (2014) for TcoCATLFL inhibition ELISA. Moderate cross-reactivity 
between TviCATL antigen and chicken anti-TcoCATLFL IgY was reported in Section 
3.4.2, thus making TcoCATLFL inhibition ELISA a suitable positive control. Figure 3.9 
panel B showed that no inhibition was obtained for non-infected serum [185 (-6)] as 
expected, however the non-infected sera [109 (-7) and 183 (-10)] unexpectedly 
showed some inhibition; 21 and 32%, respectively. All the positive sera expectedly 
resulted in satisfactory inhibition, with 149 (+28) giving highest % inhibition (48%). This 
inhibition ELISA was not able to discriminate between infected and non-infected sera, 
since two out of three negative sera unexpectedly showed some inhibition equivalent 
or greater than some of the infected sera. The discrepancy between TviCATL and 
TcoCATL inhibition ELISAs might be contributed by the fact that the sera dilution used 
were not the same, 1:100 for TviCATL inhibition ELISA while 1:20 sera dilution was 
used for TcoCATLFL inhibition ELISA. The discrepancies between the two inhibition 
ELISAs made the extent of cross-reactivity between TcoCATL antibodies (in sera) and 






Figure 3.9: Serological antibody detection in an inhibition ELISA format. Panel A: the 
ELISA plates were coated with TviCATL (5 µg/ml) in and probed with sera (1:100) from cattle 
experimentally infected with T. congolense or with negative sera collected prior to infection. For 
a 0% serum inhibition control, the quadruplicate wells received blocking buffer instead of serum.  
This was followed by the addition of the affinity purified chicken anti-TviCATL IgY (5 µg/ml) and 
detected with secondary rabbit anti-chicken IgY-HRPO conjugate (1:10 000). The colour 
development upon addition of ABTS-H2O2 substrate was monitored over 45 minutes (15 min 
intervals) at 405 nm and the average of triplicate samples plotted against serum number. The 
no serum control was included in quadruplicate. This inhibition ELISA was expressed as a 
percentage inhibition and the error bars represent an average of three independent readings. 
Panel B: The TcoCATLFL inhibition ELISA obtained from Eyssen (2014) for comparative 
purposes only. The ELISA plates were coated with TcoCATLFL (1 µg/ml), probed with sera 
(1:20) from cattle experimentally infected with T. congolense or with negative sera collected 
prior to infection, followed by the addition of the affinity purified chicken anti-TcoCATLFL IgY (0.5 
µg/ml) and detected with secondary rabbit anti-chicken IgY-HRPO conjugate (1:15 000). The 
colour development upon addition of ABTS-H2O2 substrate was monitored over 45 minutes (15 
min intervals) at 405 nm and the average of triplicate samples plotted against serum number. 
This inhibition ELISA was expressed as a percentage inhibition. 
 
3.4.4 Western and dot blot analysis of antibodies 
The crude IgY pools with high titres were further used in a dot blot assay for the 
optimisation of antigen and antibody concentrations for use in western blot analysis. A 
dot blot (Figure 3.10) showed that 10 µg/ml chicken anti-TviCATL IgY resulted in the 
best detection of TviCATL antigen. The recognition pattern of the antigen at different 
concentrations (10-100 µg/ml) was similar, therefore for a western blot analysis, it was 
concluded that as little as 10 µg/ml TviCATL would be optimally recognised by 10 
µg/ml chicken anti-TviCATL IgY antibodies. The ability to get the highest signal at 
lowest antibody concentration and no signal at higher antibody concentrations 
indicates that these antibodies are prone to the phenomenon called the prozone effect. 
No signal was obtained for controls at which the primary and secondary antibodies 





Figure 3.10: Dot blot of TviCATL antibodies. Nitrocellulose strips were each spotted with 
TviCATL (10-100 µg/ml in duplicate). Each strip was then incubated with the respective chicken 
anti-TviCATL IgY antibody concentration (0-100 µg/ml). The negative controls were: omission of 
primary or secondary antibodies as well as the use of a pre-immune IgY. 
  
The optimised primary antibody concentrations were used for western blot analysis. 
Figure 3.11 Panel B shows that the 29 and 33 kDa bands of TviCATL were strongly 
recognised by this optimised antibody concentrations. However, it was noted that the 
antibodies were not specific since they were able to recognise the higher molecular 
weight contaminants in the TPP-purified sample. The pre-immune antibodies were 






Figure 3.11: Characterisation of chicken anti-TviCATL antibodies by western blot 
analysis. The TPP-purified TviCATL samples were separated by 12.5% reducing SDS-PAGE. 
Panel A, SDS-PAGE of TviCATL TPP samples (5 and10 µg) followed by Coomassie blue R-
250 staining to serve as a reference. Panel B, same gel as panel A was transferred onto a 
nitrocellulose membrane, probed with chicken anti-TviCATL IgY (10 µg/ml) and detected with 
rabbit anti- chicken IgY-HRPO conjugate (1:5 000 dilution) followed by colour development 
using 4-chloro-1-naphthol and H2O2.  
 
The non-specificity observed for the antibodies necessitated further purification using 
the TviCATL-Aminolink® affinity resin. Western blot analysis of affinity purified 
antibodies indicated that all nonspecific reactive epitopes were removed (Figure 3.12). 
This is evidenced by the inability of the purified antibodies to recognise the higher 
molecular weight contaminants on the TPP-purified sample. This antibody recognised 
the 29 and 33 kDa bands of TviCATL in the expression supernatant, TPP and MEC 
samples. There was an increase in prominence of bands in the MEC sample compared 
to those in the expression supernatant and TPP samples. However, it was noted that 
the antibody fairly cross-reacted with TcoCATL and that is expected due to the high 
levels of sequence identity of these antigens. Cross-reactivity of these antibodies was 
thus expected and is consistent with results reported in Sections 3.4.2 and 3.4.3. The 
pre-immune (negative control) antibodies were unable to recognise these antigens as 





Figure 3.12: Characterisation of affinity purified chicken anti-TviCATL IgY by western 
blot analysis. Expression supernatants, TPP and MEC-purified TviCATL as well as TcoCATL 
control samples were analysed by 12.5% reducing SDS-PAGE and transferred onto the 
nitrocellulose membrane, probed with affinity purified chicken anti-TviCATL IgY (1 µg/ml) and 
detected with rabbit anti-chicken IgY-HRPO conjugate (1:5 000 dilution) followed by incubation 
with ECL substrate. 
 
3.4.5 Immunoinhibition of TviCATL activity by chicken anti-TviCATL IgY 
antibodies 
The effect of chicken anti-TviCATL IgY antibodies on the activity of TviCATL against Z-
Phe-Arg-AMC substrate hydrolysis was followed by assaying this enzyme with chicken 
anti-TviCATL IgY with high titres. Samples where no antibody was added or pre-
immune IgY was added served as negative controls. Figure 3.13 indicates that as the 
concentration of chicken anti-TviCATL IgY antibody increases, there was a 
proportional decrease in activity. The activity in the presence of chicken anti-TviCATL 
IgY is less than the activity in the presence of the pre-immune antibodies, but the trend 
line are effectively identical indicating that the inhibition of TviCATL activity was not 





Figure 3.13: The inhibition of TviCATL activity by varying concentrations of chicken anti-
TviCATL IgY antibodies. TviCATL (100 ng) was incubated with chicken anti-TviCATL IgY 
(1000-15 µg/ml) and residual activity measured against Z-Phe-Arg-AMC. The data represent an 
average of three independent assays. 
 
3.5 Selection of scFvs against recombinant TviCATL 
The large semi-synthetic Nkuku® phage display library was used to select for scFvs 
against recombinant TviCATL. These phages were subjected to four consecutive 
rounds of panning against TviCATL (100-10 µg/ml). The phage titering followed by 
polyclonal ELISA was used to monitor the enrichment of scFv binders against 
TviCATL. Overall, the signals (after subtracting the signal for non-antigen-coated milk 
binders) were very weak and any means to optimise the antigen coating, phage and 
secondary antibody concentrations were all futile (Figure 3.14). Panning round 1 (100 
µg/ml), 2 (75 µg/ml) and 4 (10 µg/ml) had very low signals compared to panning round 
3 (25 µg/ml), suggesting that only at panning round 3 (25 µg/ml) the polyclonal phage 
populations against TviCATL were enriched. In this ELISA, the TviCATL coating 
concentrations (10 and 1 µg/ml) probed with a 1:25 phage dilution resulted in the 





Figure 3.14: Polyclonal phage ELISA for monitoring the enrichment of polyclonal 
TviCATL-scFvs populations after four consecutive rounds of panning. The wells were 
coated with TviCATL (1-100 µg/ml) in PBS, pH 7.4 and no antigen control wells were coated 
with PBS only. After blocking the nonspecific sites, the wells were incubated with phage from 
each respective panning round [R1 (A), R2 (B), R3 (C) and R4 (D)] at respective phage 
dilutions (1:200, 1:100, 1:50 and 1:25) and probed with the primary HRPO-anti-M13 monoclonal 
antibody (1:8 000). The sheep anti-mouse IgG- HRPO conjugate (1:1 000) was used for 
detection and the colour development upon addition of ABTS-H2O2 substrate was monitored by 
taking A405 nm readings. Plots are averages of duplicate experiments. 
 
It was identified that the polyclonal populations were mostly enriched during round 3 of 
biopanning. These phage populations were titered through bacterial infection. Each 
bacteriophage colony or clone from panning round 3 was further screened to identify 
possible monospecific phage antibodies. Fourty eight colonies (clones) were randomly 
chosen for screening by monospecific phage ELISA in order to identify any fusion 
phages specific for TviCATL antigen. As according to Van Wyngaardt et al 
(2004),  A405 nm (after subtracting the signal for milk binders) that is greater than 0.2 
was used as a criterion for identifying positive TviCATL-scFv fusion clones. It is shown 




had the highest signal (~0.4) which was 2-fold more than the signals obtained for 
polyclonal ELISA (Figure 3.14). Clones 15 and 28 also had promising signals at ~0.2. 
However, when the higher concentration of TviCATL (75 µg/ml) was used for coating, 
there was a reduction in signals (to ~0.2) of the promising clones (results not shown). 
Further optimisation of the ELISA conditions is required in order to improve the signal 
of the promising clone 38. 
 
 
Figure 3.15: Monospecific phage ELISA for monitoring the enrichment of monospecific 
TviCATL-scFvs antibodies after round 3 (R3) of panning. The wells were coated with 
TviCATL (10 and 75 µg/ml) in PBS, pH 7.4 and no antigen control wells were coated with PBS 
only. After blocking the nonspecific sites, wells were incubated with the respective phage clones 
and probed with primary anti-M13 monoclonal antibody (1:8000). Goat anti-mouse IgG-HRPO 
conjugate (1:1 000) was used for detection and colour development upon addition of ABTS-




Monospecific antibodies have important applications in diagnosis of African animal 
trypanosomiasis. In this study, we report the production of anti-TviCATL antibodies for 
use in a serological diagnosis of AAT. Animal hosts such as rabbits, mice, goats and 
chickens are available for antibody production. The choice of the host depends on the 
ability to meet the ethical welfare of the animal to be immunised as well as an ability to 
obtain antibodies with high titres and affinity for the targeted antigen. In chickens, the B 
cell response triggers the continuous production of IgY into the blood, which is then 




attacking pathogens to their offspring (Schade et al, 1996; Tini et al, 2002). The 
chicken antibodies are collected from egg yolks; therefore providing a more humane 
way of harvesting antibodies than by bleeding of the animals. In addition, due 
evolutionary distance, chickens results in the pronounced immune response to parasite 
antigens (Morty et al, 1999; Eyssen, 2014) as well as the lack of cross-reactivity of IgY 
antibodies with mammalian IgG antibodies. Chicken IgY does not cross-react with 
mammalian IgG antibodies since it does not activate the rheumatoid and complement 
factors in mammalian serum. The lack of IgY cross-reactivity with IgG is associated 
with improved sensitivity and decreased background in an immunological assay such 
as the ELISA. Therefore, chickens are the preferred hosts for the production of 
antibodies for diagnostic purposes (Larsson et al, 1993; Tini et al, 2002).  
There are many precipitation and isolation procedures that have been introduced for 
the precipitation of IgY. These include: water dilution method (Akita & Nakai, 1992), 
PEG precipitation (Polson et al, 1980; Goldring & Coetzer, 2003), ammonium sulfate 
(Svendsen et al, 1995), dextran sulfate (Jensenius et al, 1981) and chromatographic 
techniques (Schade et al, 1996). All these methods share one commonality in that they 
all require a delipidation step to remove all traces of insoluble lipids and lipoproteins 
(Hansen et al, 1998). The choice of a method for IgY isolation depends on the 
availability of technical equipment or reagents, scale of purification, impact on 
environment and cost. In this study, PEG precipitation was chosen since it is a simple, 
short and effective method that results in relatively high yields of electrophoretically 
homogenous antibodies (Goldring & Coetzer, 2003).  
In this study, the analysis by ELISA of anti-TviCATL IgY production in chickens showed 
that a satisfactory levels of antibody was obtained. These high titres are as a result of 
the pronounced immune response of this antigen in chickens upon immunisation 
possibly as a result of the evolutionary distance between the parasite immunogen and 
the chicken immune system. This immune response over a long time is attributed to 
the use of adjuvants during immunisations. Freund’s adjuvant forms an antigen-depot 
at the site of injection so that the antigen emulsion is slowly released to the lymph 
nodes. This prolongs the host B-cell immune response, thus resulting in prolonged 
antibody production (Leroux-Roels, 2010). The relevance of including adjuvants for 
immunising with trypanosomal antigens is supported by the fact that rabbits immunised 
with TcoCATL alone (no adjuvant) produced very low titres of anti-TcoCATL compared 
to that produced when adjuvants were included (Huson et al, 2009). In addition, these 




Immunoinhibition was an important factor necessary for the design of anti-disease 
vaccines (Huson et al, 2009). The pattern for antibody production in chickens against 
TviCATL is similar to that reported for antibody production against the inactive full 
length form of T. vivax (Vather, 2010). The antibody titres for TviCATL peaked from 
weeks 4-9, while they peaked from weeks 5-9 for the inactive full length mutant of T. 
vivax (Vather, 2010). As observed for TcoCATL in Freund’s adjuvant (Huson et al, 
2009), TviCATL in Freund’s adjuvant also elicited antibodies with moderate ability to 
inhibit the activity of TviCATL against the hydrolysis of the cysteine protease substrate, 
Z-Phe-Arg-AMC. However, in order to confirm that the observed inhibition is as a result 
of chicken anti-TviCATL IgY, it will be necessary to design a TviCATL peptide 
corresponding to the active site sequence. This peptide is expected to compete with 
TviCATL for binding to the chicken anti-TviCATL IgY epitopes, thus decreasing the 
inhibitory effect of these antibodies. This phenomenon was reported by Coetzer et al 
(1992) where the cathepsin L active site-associated peptide was able to hinder the 
immunoinhibition of cathepsin L by chicken anti-cathepsin L IgY. Therefore, it was 
concluded that the active-site region of cathepsin L is responsible for the production of 
chicken anti-cathepsin L IgY with immunoinhibitory properties (Coetzer et al, 1992). 
The nonspecific peptides can also be used as a negative control; therefore if the 
antibody inhibitory effect is specific, the substrate hydrolysis will not be altered by the 
presence of the unrelated peptides. Since TviCATL is able to hydrolyse bovine α2-
macroglobulin (see Chapter 2), the neutralising potential of anti-TviCATL antibodies 
can be improved by exploiting α2-macroglobulin as an adjuvant. Thus, in order to 
produce anti-disease trypanosomal vaccines, it is very likely that antibodies produced 
against TviCATL coupled with α2-macroglobulin would be inhibitory towards the activity 
of TviCATL in vitro. This inhibitory phenomenon against recombinant and native 
(trypanosomal lysate) TcoCATL was observed when antibodies were raised in rabbits 
against a TcoCATL- α2-macroglobulin complex (Huson et al, 2009). The ability to 
inhibit native TcoCATL was a very promising feature in the context of an anti-disease 
vaccine since when these antibodies are used as vaccines; they would be able to 
trigger the immunoinhibition mechanism against the native trypanosomal TcoCATL 
protease they encounter in the host upon infection by the parasite.  
The affinity (as measured by ELISA) and specificity of the anti-TviCATL for TviCATL 
antigen was improved by affinity purification of these antibodies using a TviCATL-
affinity column. In most cases, protein A and G immobilised on the affinity columns are 
used to purify mammalian IgG since they are capable of binding to the Fc-region of IgG 




lack IgY binding sites (Schade et al, 2005). Therefore, the crude IgY antibodies were 
purified by coupling the pure recombinant TviCATL onto the Aminolink® resin. Analysis 
by ELISA of the affinity purified IgY indicated a slight increase in signals compared to 
the pre-purified IgY pools. The reason for the low signals even after optimising the 
coating buffer, antigen coating and primary antibody concentrations, is not clear, but it 
is suspected that the effectiveness of the secondary antibody (rabbit anti-chicken IgY-
HRPO conjugate) used has been lowered. These low ELISA signals when using the 
same secondary antibody used in the present study, were also reported by Mnkandla 
(2013).  
The chicken anti-TviCATL antibodies were able to strongly detect TviCATL antigen on 
dot and western blots analysis using both 4-chloro-1-naphthol (colorimetric) and ECL 
(chemiluminescent) chromogens. On the dot blot, the prozone effect was observed, i.e. 
the lower antibody concentrations showed a higher signal than the higher antibody 
concentrations. The prozone effect is a common feature for many trypanosomal 
antibodies including the chicken anti-nLiTat 1.3 IgY antibodies (Mnkandla, 2013). The 
signals were strong when the ECL substrate was used. The use of ECL instead of 4-
chloro-1-naphthol offers advantages such as sharp, intense or prominent bands even 
at lower antigen and primary antibody concentrations, blots can be stripped and 
reprobed to optimise blot conditions and is a relatively fast procedure (Novex® ECL 
chemiluminescent substrate reagent Kit, Invitrogen™). 
The chicken anti-trypanosomal antibodies were assayed by ELISA for their cross-
reactivity with homologous antigens from different trypanosomal species. In all cases, 
the antibodies significantly recognised their respective antigens. However, the 
exception was that the chicken anti-full length TcoCATL IgY (anti-TcoCATLCFL) 
antibodies showed some of recognition of the TviCATL antigen suggesting that the 
chicken anti-TcoCATLCFL antibodies were able to recognise the conserved sequences 
or epitopes between TcoCATL and TviCATL. However, in all cases, cross-detection 
signals were lower than those observed for the specific antigen. Due to the fact that 
TviCATL is not a surface protein like VSGs and due to the unavailability of T. vivax 
parasite lysates in our laboratory, it was not possible to use these antibodies in order to 
conduct localisation studies through immunofluorescence microscopy. This could be 
used to establish if TviCATL is developmentally regulated (i.e. if TviCATL 
predominates in the procyclics, epimastigotes, metacyclics or blood stream forms). 
Since TviCATL shares high sequence identity with TcoCATL which is highly expressed 
in the blood stream form (insect-infective stage) (Pillay et al, 2010), TviCATL likewise 




Phe-Arg-AMC by the blood stream form of TviCATL (Mbawa et al, 1991; Mbawa et al, 
1992). The presence of TviCATL in the bloodstream form is also confirmed by an 
ability to isolate native TviCATL from blood stream form of the T. vivax strain Y486 
stabilate (Jackson, 2011). 
The immunodiagnostic potential of the TviCATL antigen was tested through an 
antibody inhibition ELISA format for the detection of any cross-reactivity in the sera 
from cattle experimentally infected with T. congolense. The upper and lower limits were 
set as 0-100% in order to distinguish between the trypanosome-infected and non-
infected bovine sera (Eyssen, 2014). Serum (1:100 dilution) were found optimal and 
this is consistent with conditions reported by Pillay et al (2013b). Although the % 
inhibition values obtained were very low even for trypanosome-infected sera, the 
antibodies were able to distinguish between infected and non-infected sera. Although 
the sera used were from T. congolense infected cattle and not T. vivax cattle, cross-
reactivity was expected because of the level of sequence identity between TviCATL 
and TcoCATL. For comparative purposes, TcoCATLFL inhibition ELISA was previously 
performed by Eyssen (2014). The chicken anti-TcoCATLFL antibodies were able to 
compete (inhibit) with sera collected post infection. However it was also noted that 
some inhibition was obtained with negative sera. Therefore, the extent of cross-
reactivity between the two species remains an inconclusive matter. It is therefore 
necessary to further optimise TviCATL and TcoCATL inhibition ELISAs in order to 
further investigate the cross-reactivity of T. vivax and T. congolense sera, therefore 
improve the reliability of the pan-trypanosome point-of-care diagnostic tool. It is also 
important to test the antigen against sera from cattle infected with Anaplasma, Babesia 
and Theileria to confirm the specificity of these antibodies by checking if there is any 
cross-reactivity (Bossard et al, 2010). Due to the limited sera, we were unable to 
further investigate the repeatability and reproducibility of the test. This is a necessary 
to validate the obtained experimental results. 
The cross-reactivity between antibodies produced against T. vivax and T. congolense 
antigens is a common phenomenon. When the anti-T. congolense HSP70/BiP antibody 
was used for serological diagnosis, cross-reactivity within the Trypanosoma genus was 
reported. The anti-T. congolense HSP70/BiP antibodies were able to cross-react 
(therefore lower A405 values due to inhibition of the signal) with sera from T. vivax and 
T. brucei infected cattle (though at a very low extent) (Bossard et al, 2010). Also when 
T. vivax GM6 antigen was used for diagnostic assays, cross-reactivity (albeit very low 
sensitivity) with T. congolense-infected sera was reported (Pillay et al, 2013b). In that 




infected and non-infected sera. These types of ELISAs (antibody detection inhibition or 
indirect antibody detection) are disadvantageous in that it is unable to differentiate 
between current and past infections in cattle sera since antibodies may persist in the 
host immune system for a long time after recovery (Van den Bossche et al, 2000; 
Lejon et al, 2003). Therefore this can be substituted by an antigen capture ELISA 
which is advantageous in that it detects circulating trypanosomal antigens in the blood 
of the infected cattle, which is similar to parasitological diagnosis which detects existing 
infections (Nantulya, 1990; Bengaly et al, 1995; Eisler et al, 1998). 
In an attempt to find more convenient, cheap and reusable immunodiagnostic 
reagents, TviCATL binders from a large semi-synthetic Nkuku® phage display library 
was partially optimised. In this study, the recombinant scFvs against pure TviCATL 
adsorbed on immunotubes were screened through four consecutive panning rounds. 
During these rounds of panning, the large pool of Nkuku® scFv reptoires were 
screened by enriching for paratopes that are highly accessible and complementary to 
the immobilised TviCATL antigen. In general, the specific binders for the antigen of 
interest should be enriched relative to the number of panning rounds. In this study, as 
determined by ELISA, it was observed that the polyclonal TviCATL-scFv fusions were 
enriched up to round 3, followed by a large decrease in polyclonal phage at round 4. 
Though the polyclonal fusion phages were enriched at panning round 3, the signal was 
very low and it was unfortunate that the unpanned Nkuku® library was not included as 
a control for comparison in the polyclonal ELISA for monitoring the enrichment. There 
are many factors that may have attributed to poor screening for polyclonal TviCATL-
scFv fusions. It has been reported that the conformational changes of some proteins 
when immobilised on polystyrene wells could compromise the ease of accessibility to 
all antigen epitopes (Butler et al, 1993). The coating efficiency of VP7, the structural 
protein of bluetongue virus, was improved by using the poly-histidine-Grab Ni2+ 
chelate-coated plates which bind antigen of interest through poly-histidine tails. The 
main disadvantage of this protocol is that there was a need for eluting fusion scFvs 
using the anti-bluetongue virus hyperimmune rabbit and guinea pig sera followed by 
concentrated triethylamine at high pH (Rakabe et al, 2011). 
The four panning rounds were titered through exposure to bacterial TG1 cells and 
plating on TYE A/G plates. The randomly picked bacterial colonies (called clones) were 
tested in a monospecific ELISA. The specificity of these scFv clones was confirmed by 
the ability of one clone to sufficiently recognise the TviCATL antigen immobilised on an 
ELISA plate. It will be necessary to further select for soluble scFvs using an ELISA in 




will be coated on ELISA plate, probed with monospecific TviCATL-scFv, followed by 
detection of scFvs with mouse anti-c-myc tag monoclonal antibody 9E10 (myc-tag is 
fused to the C-terminus of the scFv) and rabbit anti-mouse IgG-HRPO conjugate (Van 
Wyngaardt et al, 2004). The identity of each soluble clone can be determined by 
sequencing using suitable primers. The soluble scFvs will be then expressed on large 
scale by IPTG induction (Kramer, 2002). The temperature stability of expressed scFvs 
can be evaluated. The specificity of the soluble scFvs can be further confirmed by 
investigating its usability in a serodiagnostic scFvs inhibition ELISA format.  
In the present study, good levels of chicken anti-TviCATL IgY were produced in 
chickens as evaluated by ELISAs, dot and western blot analysis. These antibodies 
showed moderate immunoinhibition of the hydrolysis of Z-Phe-Arg-AMC by TviCATL in 
vitro. TviCATL immobilised on ELISA plate for antibody detection inhibition ELISA, also 
showed some cross-reactivity with TcoCATL antibodies (in sera from T. congolense 
infected cattle) as evidenced by the ability to discriminate between the T. congolense-
infected and non-infected cattle sera. Further optimisation of inhibition ELISA 
conditions are necessary to investigate the extent of cross-reactivity between 
antibodies produced against T. vivax and T. congolense antigens. The initial trials of 
Nkuku® phage display library were conducted through panning against the recombinant 
TviCATL antigen. Monospecific TviCATL-scFvs were enriched as evidenced by a 
signal (albeit very low) on a monospecific phage ELISA. The optimisation of panning 
conditions is a necessary step in order to enhance the enrichment of specific TviCATL-











African animal trypanosomiasis (AAT) or nagana is a neglected tropical disease that is 
a major constraint to agricultural-based economies with losses estimated to 
approximate $4.75 billion yearly on the African continent (Swallow, 2000; Van den 
Bossche & Delespaux, 2011). This disease is caused by the parasites of the genus 
Trypanosoma, in which the prevalent species include Trypanosoma congolense, T. 
vivax and T. brucei brucei. These parasites are mainly transmitted from host to host by 
the haematophagous tsetse flies which infest approximately 10 million km2 of the 
African continent (Rogers & Randolph, 2002; Van den Bossche & Delespaux, 2011).  
The major control methods for AAT include the use of chemotherapeutic drugs, 
trypanotolerant cattle and vector control strategies. The Trypanocidal drugs 
isometamidium, homidium and diminizine have been in use for more than 50 years to 
treat animal trypanosomiasis, but there is an alarming increase of drug resistance 
which hampers the drug-based control strategies (Geerts et al, 2001; Delespaux et al, 
2008a; Delespaux et al, 2008b). Vector control strategies including spraying of 
insecticides using a sequential aerosol technique (Vreysen et al, 2013), odour-baited 
traps as well as the sterile insect technique had variable success (Vreysen et al, 2000; 
Abd-Alla et al, 2013). Trypanotolerant cattle (N’Dama) breeds are distributed only in 
West and Central Africa and this breed is relatively small in size and thus less 
attractive to farmers (Holmes, 1997; d’Ieteren et al, 1998). Due to antigenic variation in 
which the parasite constantly switches expression of its surface variable surface 
glycoproteins (VSGs), no anti-parasite vaccines have been successfully developed 
(Donelson et al, 1998). There is therefore an urgent need to develop new AAT control 
methods such as new chemotherapeutic agents. 
As an alternative to the anti-parasite vaccination approach, the feasibility of an anti-
disease vaccination approach which targets the infection-associated pathology, rather 
than the parasite, was investigated (Authié, 1994; Authié et al, 2001). When 
trypanotolerant and trypanosusceptible cattle were immunised with the cysteine 
protease, TcoCATL, and exposed to primary T. congolense infections, it was observed 
that there was an increase in the IgG antibody response in trypanotolerant cattle as 
opposed to susceptible cattle. Therefore, this led to the conclusion that TcoCATL is a 




the pathogenesis of the parasite and that anti-TcoCATL antibodies may regulate 
trypanosome-associated pathologies. These antibodies correlate with the ability to 
tolerate infections in trypanotolerant cattle.  
For the effective control of AAT, the development of definitive species-specific 
serodiagnostic tests is of utmost importance to ensure appropriate administration of 
drugs (Brun et al, 2010). Serological tests are considered to be specific and sensitive 
(Ndao, 2009). More specifically, enzyme-linked immunosorbent assay (ELISA) is 
considered as a sensitive, affordable and simple procedure for diagnosis of 
trypanosomiasis (OIE, 2012). ELISA is subdivided into antibody capture ELISA 
(AbELISA) which detects anti-trypanosomal antigen antibodies in the parasite lysate; 
and antigen capture ELISA (AgELISA) in which circulating antigens in the host 
bloodstream are detected. Both tests are limited by the fact that crude or whole 
parasite lysates are the source antigen; a procedure that lacks standardisation and 
requires culturing of the parasite in vivo or in vitro (Reid & Copeman, 2002).  
To avoid the use of unstable native parasite antigens for diagnosis, several antigens 
with diagnostic potential have been identified and produced using optimisable and 
standardised recombinant technology. The ideal trypanosomal antigens with diagnostic 
potential are the immunodominant antigens in the bloodstream developmental stage of 
trypanosomal species (Hutchinson et al, 2004; Goto et al, 2011; Thuy et al, 2012). 
Trypanosomal cysteine proteases are considered as immunodominant antigens with 
ideal potential for the development of serodiagnostic tools against AAT (Authié et al, 
1992; Authié et al, 2001; Lalmanach et al, 2002). Therefore, the aim of the present 
study was to recombinantly express and enzymatically characterise the 
immunodominant cysteine protease, TviCATL from T. vivax and produce antibodies for 
serodiagnosis of AAT using the antibody detection inhibition ELISA format. 
Sequence alignment of TviCATL from T. vivax (Accession no. CCD21670) with 
TcoCATL from T. congolense (Accession no. CAA81061) showed high sequence 
identity (61.8%). TcoCATL has been elucidated as a pathogenic factor and an 
immunodominant antigen with diagnostic potential (Authié et al, 1992; Authié et al, 
2001; Lalmanach et al, 2002). Hence, the findings about recombinant TviCATL in the 
present study were mainly compared to those obtained for recombinant TcoCATL.  
The production of recombinant antigen over isolation of native proteins was considered 
since recombinant technology is a standardised procedure which eliminates the use of 
in vivo methods for antigen production (Rogé et al, 2014). In the present study, the 




TviCATL. In the expression construct, the pro-region (which is important for protein 
stability, folding and secretion) as well as the catalytic domain (responsible for the 
activity of cysteine proteases) were included (Vernet et al, 1991). The C-terminal 
extension was not included since it is not crucial for the activity of trypanosomal 
cysteine proteases (Eakin et al, 1993). TviCATL was recombinantly expressed as a 
soluble protein and at  yields significantly higher than those reported by Vather (2010). 
The expression of TviCATL as a soluble, glycosylated protein and at higher yields, is in 
accordance with the advantages associated with the Pichia system (Macauley-Patrick 
et al, 2005; Cregg, 2007). Such success has also been reported for recombinant 
TcoCATL variants expressed in the Pichia system (Pillay et al, 2010; Boulangé et al, 
2011).  
TviCATL migrated on reducing SDS-PAGE as two bands at 29 and 33 kDa. As is the 
case for all trypanosomal cysteine proteases, TviCATL was synthesised as an inactive 
pro-enzyme or a zymogen. This inactivity is as result of the presence of the propeptide 
which is considered to be a potent inhibitor of its associated protease’s catalytic 
domain (Fox et al, 1992; Yamamoto et al, 2002). This inactive pro-enzyme was 
transformed to an active enzyme through autocatalytic cleavage of the propeptide 
which was effected by acidification (pH 4.2) of the expression supernatants (Boulangé 
et al, 2011). Three phase partitioning followed by molecular exclusion chromatography 
were used to concentrate and purify TviCATL to homogeneity. The identity of the 
purified TviCATL was confirmed by western blot analysis by probing with chicken anti-
full length mutant TviCATL antibodies produced in a previous study by Vather (2010). 
The treatment of TviCATL with endoglycosidase H proved that TviCATL is an N-
glycosylated protein. Glycosylation is associated with advantages such as protein 
folding and stability (Dwek, 1998). Glycosylation of TviCATL is as a result of the 
presence of the N-glycosylation site (Asn288) in the catalytic domain. The sequence 
alignment of the two closely related cysteine proteases, TviCATL and TcoCATL, 
showed that the glycosylation site of TviCATL (T. vivax, accession no. NCBI 
CCD2167.0) is located within the active site while the potential glycosylation sites for 
TcoCATL (T. congolense: NCBI accession no. CAA81061.1) are found in the 
proregion. TcoCATL may exist as a non-covalent dimer at neutral pH (Boulangé et al, 
2011), however, glycosylation is not possible as its glycosylation sites are found in the 
propeptide which are cleaved off during spontaneous activation of the pro-enzyme in 
vivo. TcrCATL from T. cruzi shares the same glycosylation feature with TviCATL since 
it also contains three asparagine-glycosylation sites: two sites located in the catalytic 




bands does not always mean that the protein is glycosylated, in other proteases, some 
bands are due to the presence of several cleavage sites during activation of the 
enzyme in vitro (Vernet et al, 1990; Eakin et al, 1992). Papain and human procathepsin 
L are examples of proteases that contain several possible cleavage sites for 
autocatalytic processing at lower pH (Vernet et al, 1990; Ménard et al, 1998). The 
cleavage sites for papain are found between Gly108 and Asp107 within the propeptide, 
while the cleavage sites for procathepsin L are found between the propeptide and the 
central domain at Phe89-Gln90 and Gln90-Glu91 (Vernet et al, 1990; Ménard et al, 1998).  
In-depth biochemical characterisation of trypanosomal cysteine proteases is of eminent 
importance for designing anti-trypanosomal chemotherapeutic drugs. This is necessary 
in order to identify unique and similar biochemical features shared amongst host and 
pathogen CATL-like proteases. Biochemical characterisations include: determination of 
pH optimum and stability, substrate specificity including hydrolysis of host proteins and 
interaction with synthetic and host endogenous inhibitors. In the present study, 
recombinant TviCATL exhibited high gelatinase activity as compared to that reported 
for a native form of TviCATL (Jackson, 2011). After incubation with thiol cysteine 
protease inhibitors (E-64, antipain, leupeptin, iodoacetate and iodoacetamide), 
gelatinase activity was inhibited proving that TviCATL is a cysteine protease. Cysteine 
proteases are lysosomally located in the parasite, and are released into the host 
bloodstream upon parasite death and lysis. In the host, cysteine proteases’ hydrolysing 
potential is usually controlled by endogenous inhibitors such as cystatins, kininogens 
and stefins (Turk et al, 1997). However, in the present study, endogenous inhibitors 
cystatin and stefin B (including previous results from W. Mpaphane, personal 
communication), did not fully inhibit gelatinase activity, some activity was observed. 
Previous studies also reported that instead of endogenous inhibitors (kininogens, 
serpins and stefin B) posing inhibitory effects towards the parasitic cysteine proteases, 
active TbCATL protease-inhibitor complexes were formed (Lonsdale-Eccles et al, 
1995). The formation of the proteolytic active-inhibitor complexes were also reported 
for mammalian cathepsin L and the bloodstream forms of  Leishmanial proteases in 
vitro (Pike et al, 1992; Mottram et al, 1998). However, TbbCATL  was inhibited by 
kininogens and cystatins while a serine oligopeptidase from T. b brucei was not 
inhibited by serpins or α2-macroglobulin (Troeberg et al, 1996). The failure of host 
protease inhibitors to inhibit released proteases leads to an inevitable progression of 





In the constant ionic strength AMT buffers, the hydrolysis of Z-Phe-Arg-AMC by 
recombinant TviCATL had an optimum pH at 6.5 and 7.5, and this is consistent with 
findings reported by Vather (2010). This pH is similar to the pH optimum (6 or 6.5) 
reported for TcoCATL (Mbawa et al, 1992; Pillay et al, 2010). The pH optima around 
physiological pH suggest that these proteases will remain active when released into 
the host bloodstream upon parasite lysis and could therefore be pathogenic factors. At 
an acidic pH (pH 4), the recombinant TviCATL was inactive. This contradicts with the 
lysosomal localisation of trypanosomal cysteine proteases within the parasite (Mbawa 
et al, 1992). However, this suggests that although the enzyme is located within the 
lysosomes of the parasite; its extracellular functionality in the host bloodstream differs 
from its functionality within the parasite. This phenomenon was reported for other 
cysteine proteases such as TcoCATL (Sajid & McKerrow, 2002; Serveau et al, 2003). 
A notable finding from the present study is that, at around physiological pH, TviCATL 
was able to hydrolyse endogenous protein substrates (BSA, type I collagen and bovine 
haemoglobin) as well as the general plasma protease inhibitor bovine α2-macroglobulin 
in vitro. The ability to hydrolyse collagen, a prolyl-rich protein, was a new feature 
observed for a trypanosomal cysteine protease. This prolyl-digesting ability of TviCATL 
was further substantiated by an ability of TviCATL to efficiently hydrolyse a peptide 
substrate (Z-Pro-Arg-AMC) with Pro in P2. Collagenolytic activity is a common feature 
for trypanosomal serine prolyl oligopeptidases (Santana et al, 1997; Bastos et al, 
2010). Collagenolytic activity facilitates the distribution of the protease within the host 
extracellular matrix and invasion of the host tissues (Piña-Vázquez et al, 2012). The 
ability to hydrolyse protein substrates such as collagen and BSA has been reported to 
be optimal at an acidic pH range for an epimastigote-stage isolated 30 kDa T. cruzi 
cysteine protease (Garcia et al, 1998). The triple helical collagenolytic activity was also 
reported at 37°C for mammalian cathepsin L. Upon incubation of the protease with 
glucosaminoglycan, the protease collagenolytic activity was potently inhibited (Li et al, 
2004). 
The recombinant TviCATL exhibits optimal haemoglobinolytic activity at pH around 6-7. 
This haemoglobinolytic activity is similar to that reported for a thiol protease from 
Schistosoma mansoni (Dvořák et al, 2009). It was noted that the pattern on SDS-
PAGE for haemoglobinolytic activity of TviCATL suggest that the haemoglobinolytic 
activity of TviCATL is very rapid in that hydrolysis does not yield any detectable 
cleavage products on SDS-PAGE. This is unfortunate because the presence of 
quantifiable cleavage products is of particular interest since the resultant cleavage 




substrates. The use of a lower amount of TviCATL in the assay may result in partial 
haemoglobinolytic activity which in turn could provide cleavage products on SDS-
PAGE for N-terminal sequencing analysis. 
Recombinant TviCATL was able to cleave bovine α2-macroglobulin, a promiscuous 
proteinase-inhibiting glycoprotein. Alpha-2-macroglobulin inhibits a large range of 
proteases due to the presence of multiple binding sites (Barrett & Starkey, 1973). 
Alpha-2-macroglobulin consists of four subunits linked together by thioester bonds. 
Each subunit consists of a “bait” region susceptible to cleavage by proteases. As a 
result of conformational changes of α2-macroglobulin upon “bait” cleavage by the 
protease, the protease remains entrapped within the “bait” region. However, the 
protease active site is not blocked, thus is capable of interacting with small peptide 
substrates and inhibitors (Borth, 1992). The cleavage of the “bait” region exposes 
residues which have a high affinity specific receptors on antigen presenting cells. 
Therefore, protease-α2-macroglobulin complexes are efficiently recognised by 
macrophages and this results in pronounced antibody production (Chu & Pizzo, 1993; 
Chu et al, 1994).  
At pH 6-7, TviCATL optimally cleaved the “bait” region of α2-macroglobulin as 
evidenced by the presence of a “fast” α2-macroglobulin form (Barrett et al, 1979) on 
reducing SDS-PAGE. The ability of TviCATL to cleave the “bait” region of α2-
macroglobulin is similar to that reported for TcoCATL (Huson et al, 2009), and 
therefore, TviCATL can also be used to cleave the “bait” region which can then be 
conjugated to another high molecular weight proteases such as oligopeptidase B that 
itself is unable to cleave the “bait” region of α2-macroglobulin (Pizzo & Grøn, 2002; 
Huson et al, 2009). High antibody titres have been reported when rabbits were 
immunised with recombinant TcoCATL in complex with bovine α2-macroglobulin; and 
these antibodies were inhibitory towards TcoCATL activity, a property necessary for  
designing anti-disease vaccines against AAT (Huson et al, 2009). The ability of 
TviCATL to hydrolyse bovine α2-macroglobulin suggests that α2-macroglobulin can be 
used as a nontoxic adjuvant associated with pronounced antibody responses (Chu & 
Pizzo, 1993; Singh & O'Hagan, 2003). 
For CATL-like cysteine proteases, the P2 substrate binding site which is 
complementary to the S2 subsite of the protease, is the primary determinant of the 
substrate specificity of the protease (Turk et al, 1998). In the present study, based on 
kcat/Km values, it was found that TviCATL preferentially hydrolysed substrates with 




P1-postion is occupied by basic (Arg or Lys) residues. These findings are consistent 
with findings reported for recombinant and native TviCATL (Vather, 2010; Jackson, 
2011), TcoCATL (Mbawa et al, 1992; Pillay et al, 2010) and TbrCATL (Caffrey et al, 
2001). This subsite preference was further validated by the observed pronounced 
enzymatic inhibition when the recombinant (in the present study) and native (Jackson, 
2011) forms of TviCATL were incubated with reversible inhibitors (Z-Gly-Leu-Phe-CMK 
and H-D-Val-Leu-Phe-Lys-CMK) containing Leu or Phe in P2. These inhibition patterns 
further show that in P2, Phe and Leu residues are important for efficient substrate 
hydrolysis. Therefore, if these residues are the constituents of the P2 position of the 
inhibitor, access to the active site of the enzyme is blocked in such a way that the 
addition of the specific substrate will not reverse the inhibitor binding. An irreversible 
inhibitor, K11777 (N-methyl-piperazine-Phe-homoPhe-vinylsulfone-phenyl), which is a 
vinyl sulfone-pseudo peptide, has been classified as a potent inhibitor of TcrCATL. 
This is validated by the fact that in a mice model chemotherapeutic trials, T. cruzi 
infected mice were protected against epimastigote-infection associated pathology 
(Engel et al, 1998a). However, the kcat/Km ratio further indicated that Phe (Z-Phe-Arg-
AMC) is preferred over Leu (H-D-Ala-Leu-Lys-AMC) in P2. Recombinant TviCATL was 
further proved to be a cysteine protease since it was inhibited by thiol inhibitors: E-64, 
antipain, leupeptin, iodoacetate and iodoacetamide. Although the effect of inhibition by 
antipain and leupeptin on the parasitic lifecycle was not investigated in the present 
study, it has been reported that these inhibitors killed T. cruzi parasites through 
inhibiting the transition from the epimastigote stage to the metacyclic stage (Bonaldo et 
al, 1991). Recombinant TviCATL had no activity towards the aminopeptidase (H-Leu-
AMC) and a cathepsin B substrate (Z-Arg-Arg-AMC) nor was it inhibited by 
metalloprotease (EDTA), aminopeptidase (bestatin) and serine (TPCK and PMSF) 
protease inhibitors. 
The second objective of the present study was to raise antibodies in chickens and test 
the potential of chicken anti-TviCATL IgY antibodies and TviCATL antigen as suitable 
serodiagnostic candidates in an antibody-detection inhibition ELISA format. As an 
alternative to animal immunisation for antibody production, the Nkuku® phage display 
library was evaluated for the production of mono-specific scFvs antibodies. 
Egg-laying chickens were chosen as the hosts for antibody production due to the 
associated advantages as described by Polson et al (1980), Larsson et al (1993) and 
Tini et al (2002). Chickens were immunised with the purified recombinant TviCATL and 
chicken anti-TviCATL IgY antibodies were isolated from egg yolks using the PEG 




Coetzer (2003). These antibodies were further affinity purified by passing through a 
TviCATL affinity column. High antibody titres were obtained following immunisation of 
chickens as evidenced by measureable signals in an ELISA. This high immunogenicity 
may be attributed by the evolutionary distance between the trypanosomal antigen 
source (parasite) and the immune system of the immunised host (chicken). Though 
TviCATL and TcoCATL share high sequence identity, minimal cross-reactivity of 
chicken anti-TviCATL IgY antibodies with TcoCATL antigen was observed. On the dot 
blot for optimisation of concentration of antigen, primary and secondary antibodies, the 
prozone effect was observed. A prozone effect was also observed with the chicken 
anti-T. b. gambiense LiTat 1.3 and chicken anti-T. b. gambiense LiTat 1.5 IgY 
antibodies as reported by Mnkandla (2013). In the present study, high signals were 
obtained in the western blots, however, ECL detection kit proved to be more effective 
than a colorimetric 4-chloro-1-naphthol chromogen. The anti-TviCATL antibodies were 
also shown to inhibit the activity of TviCATL which is important in the context of an anti-
disease vaccine for T. vivax induced AAT as reported by Authié et al (2001) for 
TcoCATL for T. congolense induced AAT. 
In the present study, the next step was to use the recombinantly expressed TviCATL 
and produced chicken anti-TviCATL antibodies for the optimisation of a serodiagnostic 
test for African animal trypanosomiasis. Due to the unavailability of sera from cattle 
experimentally infected with T. vivax, sera from cattle experimentally infected with T. 
congolense were used in order to optimise the antibody detection inhibition ELISA 
format while at the same time gaining information about the extent of cross-reactivity 
between these two trypanosomal antigens. This antibody detection inhibition ELISA 
format was able to discriminate between infected and non-infected sera. Notably, the 
percentage inhibition was very low (less than 25%) suggesting that some degree of 
cross-reactivity of T. congolense serum antibodies with TviCATL antigen was 
observed. In the present study, antibody detection inhibition ELISA was chosen over 
an antibody detection indirect ELISA since the latter requires species-specific detection 
antibodies (i.e. anti-rabbit/goat/sheep/bovine IgG-HRPO conjugates) depending on the 
species being tested. An antibody detection inhibition ELISA format is cost effective 
since one detection system is used such as rabbit anti-chicken IgY-HRPO conjugate 
for testing e.g. infected cattle, goats or camels (Bossard et al, 2010). 
A broad range of recombinant trypanosomal antigens have been identified as potential 
candidates for diagnostic purposes (Boulangé et al, 2001; Boulangé et al, 2002; 
Bannai et al, 2003; Tran et al, 2008; Bossard et al, 2010; Pillay et al, 2013b; Fleming et 




antigen BiP/HSP70 from T. congolense was recombinantly expressed in a bacterial 
system and used as an antigen in an indirect ELISA and probed with T. congolense-
infected sera. It was noted that this test was more sensitive for detection of secondary 
infections than primary infections. Also, when BiP/HSP70 from T. congolense was 
probed with sera from cattle with natural or experimental T. congolense infections and 
screened in an antibody detection inhibition ELISA format, high sensitivity was also 
reported for secondary infections (Bossard et al, 2010). Recombinant invariant surface 
glycoprotein (ISG75) from T. b. gambiense has also been used for serodiagnosis of 
human trypanosomiasis. This antigen was recombinantly expressed in an E. coli 
system as a double tagged (thioredoxin reductase and glutathione oxidoreductase) 
fusion protein. Its diagnostic potential was evaluated in an indirect ELISA in which this 
antigen was probed with sera from goats experimentally infected with T. b. brucei. The 
antibodies in the sera collected post-infection resulted in maximal signals as compared 
to sera collected prior to infection (Tran et al, 2008). More recently, the proteomic 
selection method as described by Sullivan et al (2013), has been a helpful tool for the 
selection of immunodiagnostic antigens for T. vivax and T. congolense infections 
(Pillay et al, 2013b). This includes a flagellar associated-protein, GM6 antigen of T. 
vivax (TvGM6) that was recombinantly expressed in E. coli. In an indirect ELISA, 
TvGM6 was probed with sera from naturally and experimentally T. vivax infected cattle. 
High sensitivity (91.4%) was obtained for sera collected 10-days post-infection. 
However, sensitivity was reduced to ten-fold (9.1%) after an elongated infection period 
(one month post infection) (Pillay et al, 2013b). This low diagnostic sensitivity was 
thought to be attributed to the persistence of trypanosomal antibodies. This antibody 
persistence in the host might have resulted in false positive infection status of the cattle 
sera as pre-predicted by polymerase chain reaction (PCR). The persistence of 
trypanosomal antibodies in the host has been reported following 10-13 months post-
treatment of cattle with diminazine trypanocidal drug (Authié et al, 1993; Van den 
Bossche et al, 2000). Also, cross-reactivity of TvGM6 antigen with T. congolense-
infected sera was observed and was thought to be contributed by the presence of 
conserved epitopes amongst these two species (Pillay et al, 2013b).  
An invariable antigen from T. congolense (TcP46) has also been proteomatically 
identified as a diagnostic antigen (Zhou et al, 2014). This antigen was recombinantly 
expressed in E. coli as a glutathione S-transferase-tagged protein. In an indirect 
ELISA, this antigen was optimally recognised by serum antibodies collected from mice 
as early as eight days post-infection with T. congolense. No cross-reactivity was 




bigemina (Zhou et al, 2014). In another related study, an invariant surface glycoprotein 
Tc38630 was  identified as  a potential serodiagnostic antigen for detection of T. 
congolense infections (Fleming et al, 2014). In an indirect antibody ELISA, high 
sensitivity (87.2%) and specificity (97.4%) were obtained. Interestingly, it was noted 
that no signals were obtained soon after treatment with trypanosomal drugs, thus 
suggesting that there was no persistence of trypanosomal antibodies in the host soon 
after treatment and this is an important feature which will enable accurate monitoring of 
the drug treatment using an AbELISA (Fleming et al, 2014).  
 In order to find a standardised, cheap and renewable method other than animal 
immunisation for the production of mono-specific antibody against trypanosomal 
antigens, initial attempts were made to optimise a semi-synthetic chicken antibody 
library called Nkuku® phage display library (Van Wyngaardt et al, 2004). The Nkuku® 
phage display library allows for the selection of recombinant scFvs against the 
immobilised antigen of interest in vitro. Several optimisation studies have been 
reported using bluetongue (BTV) and African horse sickness virus (AHSV) antigens 
and the resultant recombinant scFvs were used for serodiagnostic purpose in an 
inhibition ELISA format (Van Wyngaardt et al, 2004; Fehrsen et al, 2005a; Rakabe et 
al, 2011; van Wyngaardt et al, 2013). In the study conducted by Van Wyngaardt et al 
(2004) in which the Nkuku® scFvs were panned against BTV and AHSV antigens, the 
analysis by ELISA of phage pools showed that the AHSV signals for 1-4 panning 
rounds were very low (less than 0.2). For BTV, the signal obtained for panning round 3 
was about 0.5 while for panning round 4, the signal was about 1.4 thus suggesting the 
enrichment of the BTV-specific phage pools with successive rounds of panning.  For 
further characterisation, the phage clones against BTV and AHSV were randomly 
picked and tested in a mono-specific phage ELISA. As a criterion for antigen-specific 
scFvs, clones with A492 nm greater than 0.2 were considered as specific binders. For 
BTV, 76% phage clones were specific binders while for AHSV, 61% phage clones 
were specific binders. No cross-reactivity was observed for enriched scFvs, i.e. BTV-
specific scFvs did not recognise other antigens such as the keyhole limpet 
haemocyanin. 
The antigen VP7, a major structural protein conserved in all 24 serotypes of BTV, is 
highly immunogenic and thus a suitable antigen for diagnosis of all serotypes in the 
competitive ELISA (Eaton et al, 1991; Martyn et al, 1991). Therefore, in the study 
conducted by Rakabe et al (2011) it was necessary to screen for VP7-specifc scFvs for 
serodiagnostic purpose. Nkuku® phage display scFvs were panned against VP7 




coated-plates. The phage pools enriched against panning on VP7 coated on Polysorp 
plates were eluted with triethylamine at pH 9.5 while the phage pools enriched by 
panning against VP7 immobilised in Ni2+ chelate coated-plates were eluted by 
competition with anti-VP7 hyper immune rabbit and guinea pig sera in an attempt to 
enrich for the phage pools with serodiagnostic potential. After four rounds of panning, 
enriched phage pools and negative control (pre-panned Nkuku® library) were analysed 
by ELISA. The ELISA signal for the pre-panned library was less than 0.3 and the signal 
was 1.2 for phage pools eluted with immune sera. The phage pools enriched against 
VP7 coated on Ni2+ chelate-coated plates gave ELISA signals at 3.6 and 2.5, 
respectively. For further characterisation of enriched phage clones, single phage 
clones were randomly picked and screened by EISA for soluble VP7-specific scFv 
binders. The negative controls i.e. E. coli Origami™ proteins and milk binders were 
included. The signals for soluble VP7-specific scFvs enriched on VP7 immobilised on 
Ni2+ chelate coated-plates were greater than those enriched on VP7 directly 
immobilised on plastic Polysorp plates. This suggested that VP7 epitopes on  Ni2+ 
chelate coated-plates were highly accessible as compared to those on plastic Polysorp 
plates at which protein conformational changes are very likely (Butler et al, 1997). 
In the present study, mono-specific scFvs were selected against TviCATL antigen 
(directly coated on plastic immunotubes) through four successive rounds of panning as 
illustrated in Figure 3.2. The phage pools were enriched during panning round three as 
evidenced by moderate signals in the first phage pools ELISA. Then, it was necessary 
to screen for the mono-specific scFvs from the precipitated phage pools in order to 
further select for TviCATL-specific scFvs. For this ELISA, forty eight phage clones 
were randomly picked and tested. The signals of the mono-specific suggested that only 
one clone (with signal at 0.4) was a specific binder. The signal for this clone is very low 
as compared to those obtained by Rakabe et al (2011) for VP7 and Van Wyngaardt et 
al (2004) for BTV and AHSV. Therefore, this suggests that in order to obtain 
satisfactory ELISA signals for TviCATL-specific scFvs, it will be necessary to further 
optimise coating plates and antigen coating concentrations for panning and optimise 
the elution of the bound phages by exploiting strategies described by Rakabe et al 
(2011). 
In the present study, the initial optimisations of Nkuku® phage display were achieved. 
However, for future work, it will be necessary to further optimise initial panning 
conditions to ensure that more specific TviCATL-scFvs fusion clones are enriched, 
therefore resulting in satisfactory signals when analysed by ELISA. It will also be 




Wyngaardt et al (2004), to obtain soluble scFvs, heterologous expression was 
conducted in which the E. coli TG1 cells together with antigen-specific scFvs were 
induced with IPTG (Kramer, 2002) in order to produce large quantities of soluble 
scFvs. These soluble scFvs were then analysed using the soluble phage ELISA in 
which the detergents were omitted or used at minimal amounts. This ELISA indicated 
that only two clones (F3 and F10) sufficiently recognised BTV serotype 10. In order to 
confirm that the enriched scFvs were indeed screened from Nkuku® phage display 
library (i.e. if they were enriched from the library in which the chicken immunoglobulins 
were synthetically randomised into the heavy chain CDR3s), the DNA of randomly 
picked phage clones were sequenced and compared to the CDR sequence of the 
primers which were used for amplification of the chicken immunoglobulin genes. 
Results showed that some of the BTV and AHSV scFv clones were originating from 
this library. Therefore, once TviCATL-scFvs are enriched, sequencing will be 
necessary to confirm their identity. To test the usability of BTV-specific and AHSV-
specific phage displayed scFvs for immunodiagnostic of BTV and AHSV in rabbit or 
sheep sera, sandwich ELISAs were performed and moderate signals were obtained 
(0.5). This was followed by the inhibition ELISA to further evaluate the specificity of the 
BTV-specific and AHSV-specific scFv clones. Some degree of inhibition was observed 
but depended on serum dilution and no inhibition was observed when the non-immune 
sera were used. 
In the study conducted by Fehrsen et al (2005a), the BTV-specific scFv clones (F3 and 
F10) produced in the study conducted by Van Wyngaardt et al (2004) were further 
evaluated for their diagnostic potential in an inhibition ELISA format. In this ELISA, 
BTV serotypes (1-24) were coated on Polysorp ELISA plates, probed with guinea-pig 
sera or sheep serum. This was followed by incubation with soluble scFvs (F3 and F10) 
pre-incubated with mouse monoclonal antibody (mAb) 9E10 (recognising the scFv-c-
Myc-tagged Ab). For detection, anti-mouse IgG-HRPO conjugate was added followed 
by addition of the chromogen. Results indicated that when F3-scFvs were used, 
serotype-specific inhibition was observed i.e. the signal for serotype 10 coated wells 
was lower than the signals for other serotypes. When F10-scFvs were used, serogroup 
cross-inhibition was observed i.e. signals of the other serotypes were inhibited. It was 
concluded that though F3 and F10 were both screened by panning against serotype 
10, their behaviour is different in an inhibition ELISA. F10 was stable for almost 3 
months at -20°C while F3 was unstable after one freeze-thaw cycle (Fehrsen et al, 
2005a). Therefore, once TviCATL-scFv specific clones are produced as soluble 




of AAT. To ascertain specificity of the TviCATL-scFvs specific antibodies, cross-
reactivity with other trypanosomal antigens such as TcoCATL could be tested in an 
inhibition ELISA format. 
In the present study, the cysteine protease, TviCATL from T. vivax, was successfully 
expressed in the Pichia yeast system. For future studies, it will be necessary to get 
larger quantities of ultra-pure TviCATL in order to optimise crystallisation conditions to 
resolve the crystal structure of TviCATL using the Rigaku CrystalTrak™ available in 
our department. Previous crystallisation trials for TcoCATL as optimised by Jackson 
(2011) will be helpful for this purpose. Conditions such as pH, protein, PEG 3350 and 
PEG 6000 concentrations were optimised. It was observed that broader needle-like 
crystals were obtained in PEG 6000 buffer than in PEG 3350 buffer. In order to test if 
the crystals obtained were able to diffract under X-ray beam, crystals were grown using 
the hanging drop method (in order to transfer them into sealable capillary tubes) for 
three days and the protein: crystallant ratio was 80:20. One crystal diffracted though 
diffraction was weak.  
 Enzymatic characterisation studies were conducted as a first step towards evaluating 
different inhibitors as possible drug targets for trypanosomiasis.  However, to further 
get convincing evidence that TviCATL is involved in pathogenesis, RNAi studies are 
necessary (LaCount & Donelson, 2001). This can be used to down regulate the 
expression of TviCATL in vitro in order to evaluate the resulting effect on parasite 
growth in vitro. In addition, this approach will indicate whether activation of TviCATL 
could result in modulation of T. vivax pathogenesis. When TbbCATL gene expression 
was down regulated by RNAi, i.e. parasites were eletroporated with recombinant vector 
containing TbbCATL transgenes, prolonged survival of the mice infected with the 
parasite in which TbbCATL was down regulated was observed as compared to mice 
infected with the parasite in which TbbCATL was not down regulated (Abdulla et al, 
2008). Gene down regulation of alanyl aminopetidases from T. congolense resulted in 
slight inhibition of growth of the procyclic T. congolense in vitro (Pillay et al, 2013a). 
In the present study, TviCATL and chicken anti-TviCATL IgY antibodies were tested in 
preliminary antibody detection inhibition ELISA format for their potential as a species-
specific diagnostic tool. For future work, it will be necessary to conduct antibody 
detection inhibition ELISA in parallel with an indirect antibody detection ELISA in order 
to compare the specificity, sensitivity and reproducibility of the two procedures. In 




in areas in which AAT is endemic such as Anaplasma, Babesia and Theileria as 
negative controls.  
In order to ensure accurate serodiagnosis of current infections by detecting circulating 
trypanosomal antigens in the host bloodstream, it is also necessary to develop an 
antigen detection ELISA (Nantulya & Lindqvist, 1989; Eisler et al, 1998). Chicken anti-
TviCATL IgY or alternatively TviCATL-scFv specific antibodies can be used to detect 
sera with T. vivax infections. The steps for the proposed antigen detection ELISA are: 
coat with chicken anti-TviCATL, probe with sera from cattle with T. vivax infections 
(with circulating antigen) and detect with rabbit anti-IgY-HRPO conjugate followed by 
addition of the chromogen.  
This study laid the foundation for TviCATL as a chemotherapeutic target and as 
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